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Abstract
This PhD thesis aims to examine the growth of T cells in response to cytokines 
of the common gamma chain (yc) family, in particular interleukin (IL)-2 and IL- 
15. Cell growth is commonly used to describe cells in exponential division 
however the growth of a cell is defined by its size and volume, which is directly 
related to the rate of cell metabolism and protein synthesis. Naive T cells are 
small and circulate around the body maintaining a minimal rate of metabolic 
activity and protein synthesis. During an immune response naive T cells 
undergo rapid proliferation and differentiate into effector cells. These cells 
produce and secrete large amounts of cytokines and effector molecules 
allowing them to mediate their immune function. The differentiation of antigen 
activated T cells to mature effectors takes several days and is regulated by 
cytokines. These cytokines need to maintain high rates of cell metabolism for a 
prolonged period. Thus the cytokines that regulate proliferation and 
differentiation of antigen activated T cells need to sustain cell growth.
Data presented in this thesis shows differential roles for gamma chain 
cytokines, specifically IL-2 and IL-15 in the regulation of protein synthesis and 
uptake of amino acids, whilst maintaining equal mitogenic capacity. This thesis 
highlights the possible uncoupling of the rate of cellular division and protein 
synthesis induced by cytokines and defines a unique role for common gamma 
chain cytokines in regulation of protein synthesis and ultimately the regulation of 
cellular function.
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Chapter 1
Introduction
Cells of the immune system can be subdivided into two different lineages, 
myeloid and lymphoid cells. These originate in the bone marrow and guard 
peripheral tissues by circulating around the body via the blood and the lymphatic 
system. The myeloid lineage includes monocytes/macrophages, dendritic cells 
(DCs), mast cells, granulocytes (polymorphonuclear leukocytes), neutrophils, 
basophils, and eosinophils. These cells are involved in immediate responses to 
infection and constitute the innate immune system which functions as the first 
line of defence against common bacterial and parasite infections. Lymphoid 
cells comprise two major cell types. B lymphocytes (B cells), which mature in the 
bone marrow and when activated differentiate into plasma cells that secrete 
antibodies and T lymphocytes (T cells) which mature in the thymus and control 
cellular immune responses. T and B cells mediate adaptive immune responses 
that provide a versatile system of defence acting to eliminate pathogens but also 
extending protection against subsequent re-infection with the same pathogen.
T cells function to recognise a unique antigen by means of a cell surface T cell 
receptor (TCR). The TCR is a multi subunit complex, which consists of two 
idiotypic disulphide bond linked polypeptide chains TCR a and TCR |3 in a 
complex with the invariant subunits of the CD3 antigen (CD3, s, 6, y and a
1
homodimer of £ chains). There are two types of TCR polypeptide chains; TCR 
ap expressed on T cells circulating in the peripheral blood and secondary 
lymphoid organs; TCR y8 expressed on T cells predominantly in the skin and 
gut.
TCR a, p, y and 6 subunits have both variable and constant regions and their 
structure is determined by somatic recombination of variable exons generating 
diversity. TCR a and p genes are composed of gene segments that encode 
variable (V), jointing (J) and diversity (D) regions. During thymocyte 
development, recombinase activating genes RAG-1 and RAG-2 drive random V 
(D) J recombination of these gene segments. The variability in recombination of 
the TCR a/p subunits generates diversity in the immune system and produces a 
population of T cells each expressing a receptor with unique specificity.
TCR ligands are not soluble antigenic peptides but peptides displayed by major 
histocompatability complexes (MHCs) on the surface of specialised antigen 
presenting cells such as dendritic cells (DCs). There are two main classes of T 
cells defined by the expression of CD4 and CD8 molecules, which act as co­
receptors for MHC class II and MHC class I molecules, respectively. CD4+ T 
cells are referred to as T helper cells (Th) and are triggered by foreign antigens 
displayed in the context of MHC class II molecules to initiate a program of 
cytokine secretion that regulates the function of B cells and macrophages.
CD8+ T cells recognise MHC class I bound antigenic peptides on the surface of 
cells infected with viruses or intracellular pathogens and can differentiate to 
effector killer cells that cytolytically destroy virally infected cells preventing the 
spread of an infection.
2
1.1 T cell development
T cell development takes place in the thymus and relays on an ordered 
sequence of differentiation and proliferation (Fig 1.1.1). T cell progenitors enter 
the thymus from the bone marrow proliferate and survive in response to the 
cytokines Stem Cell Factor (SCF) and interleukin 7 (IL-7). These early 
thymocyte progenitors lack expression of the major histocompatibility co­
receptors CD4 and CD8 and are termed double negatives (CD4-CD8-, DNs). 
The commitment of these progenitors to the T cell lineage occurs when genes 
are rearranged at the loci encoding for components of the T cell receptor (TCR). 
Firstly, TCR-p locus rearrangements occur in the double negative compartment. 
If successful, the TCR-p chain is expressed on the surface and associates with 
a constitutively expressed pre-Ta chain. This complex associates with co­
receptors of the CD3-complex, and is called the pre-TCR complex (1-4). The 
pre-TCR instructs cells to proliferate rapidly and express CD4 and CD8 co­
receptors. CD4+CD8+ double positive (DP) thymocytes rearrange their TCR-a 
locus, express a mature TCR a/p complex and are subject to the processes of 
positive and negative selection that generates CD4+ and CD8+ single positive 
(SP) thymocytes. For a single T cell expressing a given TCR the outcome of 
positive or negative selection is dependent of the strength of the signalling 
response triggered by interactions between the TCR and MHC molecules 
loaded with self peptides (5, 6). Insufficient signalling i.e. a failure to recognise 
self MHC results in cell death by neglect; signalling in the optimal range allows 
positive selection; signalling exceeding the optimal threshold results in negative 
selection of thymocytes avoiding export of potentially self reactive cells into the 
periphery. These processes select T cells with moderate affinity for MHC-self-
Proliferation/Survival dependant Positive/Negative
on pre-TCR mediated signals Selection
f ------------------- N S *
Proliferation/Survival TCR0 chain 
dependant rearrangement
on c-kit/IL-7 and selection
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Figure 1.1.1: T cell thymocyte development. Hematopoietic stem 
cells migrate from the bone marrow to the thymus. These stem cells undergo a 
series of differential stages, defined by the expression of CD44 and CD25. This 
compartment lacks the expression of CD4+ and CD8+ co-receptors, double 
negative (DN). In the DN compartment rearrangement at the TCRp locus occurs 
in the presence of a pre-Ta chain. If the pre-TCRap signals with an intermediate 
affinity for peptide presented by MHC molecules, present on thymic epithelium, 
the T cells progress to the double positive (DP) stage where CD4+ and CD8+ 
markers are up-regulated and T cells select for functional TC R a chains. DP go 
through positive and negative selection; low TCR affinity leads to death by 
neglect, strong binding leads to death, intermediate affinity results in survival and 
exit from the thymus.
4
peptide complexes but eliminate T cells with high or low-affinity for the complex 
(6).
1.2 Peripheral T cell differentiation
T cells exported from the thymus are resting or quiescent naive T cells that 
enter the lymphoid system and re-circulate continually through blood, bone 
marrow and lymphoid organs. Upon infection naive T cells in the peripheral 
lymphoid organs ‘see’ antigen in the context of MHC class I or II molecules 
expressed on antigen presenting cells, specifically dendritic cells (DCs), become 
activated and undergo a program of clonal expansion and differentiation. The T 
cell response is said to peak 5-7 days after infection and is followed by a 
contraction phase characterised by massive cell death of activated T cells. A 
small population of T cells can survive the contraction phase to persist as long- 
lived memory T cells that can respond very rapidly if re-exposed to the 
immunizing antigen thereby conferring protection against future re-infection.
1.2.1 CD4T cells
When CD4+ T cells encounter cognate antigen they can differentiate into two 
distinct subsets both defined by their unique cytokine profiles (reviewed in (7)). 
Subsets, T helperl (Th1) and T helper 2 (Th2) are responsible for cell-mediated 
inflammatory immunity and humoral i.e. B lymphocyte mediated responses, 
respectively. The hallmark cytokine of Th1 cells is IFN-y, but they also produce 
IL-2, TNF-cx and lymphotoxin (LT), known to mediate delayed type 
hypersensitivity (DTH) responses and macrophage activation. The signature 
cytokine of Th2 cells is interleukin 4 (IL-4), but these cells also secrete IL-5, IL-6,
IL-10 and IL-13, known to support B cell proliferation and differentiation and are 
critical for humoral-type immune responses (reviewed in (7)).
1.2.2 CD8T cells
When CD8+ T cells encounter cognate antigen in the context of MHC class I 
and co-receptor stimulation they undergo a program of rapid cell cycle 
progression, increased cell size and growth. After the initial activation by 
antigenic peptide CD8+ T cells also undergo a program of differentiation and 
generate a pool of cytotoxic effector T cells (CTL) (for reviews see (8-10)). CTLs 
are programmed to lyse virally infected or tumorigenic cells using cytotoxic 
granules and Fas/Fas ligand mediated lysis. CTL carry an arsenal of lytic 
granules stored in specialised organelles in the cytoplasm. The controlled 
secretion of these lytic granules mediates the selective induction of target cell 
death (11-13). A key lytic granule protein is perforin that is responsible for the 
formation of 15-16nm pores in the membranes of target cells (14, 15). Pore 
formation is a key step in the induction of target cell death by facilitating delivery 
of lytic enzymes known as granzymes, which are serine proteases that trigger 
apoptosis (16-21). There are two types of granzyme: granzyme B that triggers 
apoptosis by caspase-cleavage (22) and granzyme A that initiates a caspase 
independent cell death by inducing nicks in DNA strands and preventing cellular 
repair (23, 24). Although a major route for the delivery of granzymes is via 
perforin induced pores, perforin-independent granzyme uptake has been 
demonstrated (25). For example, granzymes A and B can be internalised by 
endocytosis after binding the mannose-6-phosphate receptor (MPR) (26).
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CTLs are capable of killing multiple targets in succession without harm to 
themselves (27). It is thought cytotoxic T cells protect against lytic granule 
damage by several mechanisms: 1. The expression of membrane bound 
cathepsin B, thought to cleave perforin on granule release preventing pore 
formation in the CTL membrane (28). 2. Expression of proteinase inhibitors 
called serpins thought to protect against granzyme B mediated killing (29). 3. 
Formation of the secretory synapse between target and killer T cell, thought to 
be the major determinant in maintaining CTL integrity during the killing (10, 30). 
This synapse formation is distinct from the immunological synapse known to 
occur between naive T cells and APCs in the initial stages of an immune 
response. The secretory synapse of cytotoxic T cells is only formed for short 
periods of time on contact with target cells (minutes), where naive T cell: APC 
interactions can last for hours (31, 32). Movement of secretory lysosomes 
containing cytotoxic granules is key to secretory synapse function. These 
lysosomes are known to move along microtubules towards and away from the 
microtubule organising centre (MTOC) where target cell recognition rapidly 
polarizes the MTOC towards the immunological synapse at the membrane (33- 
35). Small concentrations of lytic granules are secreted in the proximal region of 
synaptic contact, adjacent to the area where the TCR and co-receptors are 
clustered (31, 35, 36) and that the MTOC rapidly polarizes from one target to the 
next (37). Hence these synapses are made and destroyed very rapidly, 
facilitating an efficient killing process.
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1.2.3 T cell Memory
The generation of memory T cells is critical for the development of protective 
immunity against repeat encounters with pathogens. Memory T cells are 
identified as small resting cells that become reactivated by cognate antigen 
which mediates the rapid expansion and production of effector cytokines at low 
activation thresholds. A large proportion of work has focused on CD8+ memory 
T cell generation and maintenance (reviewed by (9, 38-40)).
Two different populations of memory T cells have been described ‘central 
memory’ ( T c m ) and ‘effector memory’ ( T em ) which differ in their tissue distribution 
and cytokine secretion profiles (41, 42). One hypothesis for the generation of T 
cell memory, proposes that T em  and T cm  cells exist as stages of a dynamic 
process of maturation that takes place after the clearance of infection, in an 
antigen free environment (43, 44). There seems to be two different models of 
CD8+ T cell memory generation currently being debated; one suggests that 
CD8+ T cell memory occurs via a linear process of differentiation whereby 
memory T cells are thought to be direct descendents from effector T cells, i.e. 
Memory T cells are effector CTLs that for some reason do not die during the 
contraction phase of the immune response and persist in the lymphoid system 
for extended periods of time (43, 45-47). Alternative to the linear proposal is a 
model whereby the generation of memory T cells does not require that naive T 
cells pass through an intermediate effector stage (48-52).
1.2.4 T cell Activation
Activation of T cells is initiated on engagement of the T cell antigen receptor 
(TCR) by antigenic peptides presented in the context of MHCs expressed on the
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surface of APCs such as DCs. Signals produced by a number of co-stimulatory 
or accessory molecules such as CD28 and integrins such as LFA-1 co-stimulate 
T cells and are critical for T cell activation (53). Within seconds of encountering 
cognate antigenic peptide/MHC complexes on the surface of APCs T cells form 
a tight contact with the APC via the immunological synapse (32, 54-56). The 
immunological synapse is a highly ordered structure that is characterised by the 
segregation of receptors and signalling molecules into distinct concentric zones 
known as supramolecular activation clusters or SMACs. In particular, integrins 
and adhesion molecules are segregated into a peripheral zone or pSMAC, 
whereas the T cell antigen receptor accumulates into a central zone or cSMAC 
(56-59). The formation of the immune synapse is accompanied by the 
generation of a complex array of signal transduction pathways mediated not 
only by the TCR but also by other receptors in the contact zone notably the co­
receptors CD4 or CD8 that mediate binding to MHC class II and I respectively. 
APCs also express co-stimulatory ligands, such as CD80 and CD86, which bind 
to the co-stimulatory receptors CD28 and CTLA-4 and play a key role in T cell 
activation. Adhesion molecules and integrins are also important regulators of T 
cell activation at this stage (56, 60-62). Signalling pathways initiated by antigen 
receptors and co-stimulatory molecules control transcription events that induce 
expression of cytokines and their receptors, which mediate T cell proliferation 
and differentiation culminating in lymphocyte activation or blastogenesis, central 
to adaptive immune responses.
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1.3 T cell receptor (TCR) signal transduction
The TCR consists of idiotypic disulphide bond linked polypeptide chains 
associated with the CD3 antigen (CD3, 8,6,7) ancl a homodimer of £ chains (Fig 
1.3.1). When antigenic peptide/MHC complexes trigger the TCR, signalling is 
initiated by the invariant CD3 and £ subunits of the TCR complex. These 
receptor-associated chains contain signalling motifs in their cytoplasmic tails 
termed immune receptor tyrosine-based activation motifs (ITAM). The CD3 y, 6, 
e subunits each have one ITAM and the £ chain contains three. ITAMs are 
phosphorylated by Src protein tyrosine kinases (PTKs), specifically Lck. This 
leads to the SH2 (Src homology 2) domain-mediated recruitment of ZAP-70 (£- 
associated protein, 70 kDa), which phosphorylates key adapters, like the 
transmembrane adapter protein LAT (linker for activation of T cells) and SLP76 
(SH2-domain containing leukocyte protein of 76 kDa).
One crucial protein that is recruited to LAT on TCR stimulation is phospholipase 
Cy1 (PLCyl). The activation of PLC results in the production of second 
messengers, diacylglycerol (DAG) and inositol 1,4,5-triphosphate [lns(1,4,5)P3] 
(IP3) by cleaving phosphatydylinositol 4,5 bisphosphate [Ptdlns(1,4,5)P2] at the 
plasma membrane. These second messengers are essential for T cell 
activation. DAG activates a number of proteins including serine kinases of the 
protein kinase C (PKC), PKD family and Ras guanyl-nucleotide-releasing protein 
(RasGRP) (63). Inositol 1,4,5 triphosphate (lns(1,4,5)P3 or IP3) binds to IP3 
receptors on the surface of the endoplasmic reticulum (ER) and triggers the 
release of calcium stores into the cytoplasm from the ER. This event then 
triggers the opening of calcium-release-activated Ca2+ (CRAC) channels at the 
plasma membrane, allowing the influx of extra cellular Ca2+. Elevation of
CD4/8
TCRai
PTEN
Calcineruin
Figure1.3.1: Immediate T cell receptor signal transduction.
When the T cell receptor complex is engaged antigen receptor-coupled 
tyrosine kinases Lck/Fyn and Zap-70 phosphorylate down stream adaptors 
that trigger IP3 and diacylglycerol (DAG) production via phospholipase C (PLC) 
mediated hydrolysis of Ptdlns(4,5)P2. DAG binds to down stream effector 
molecules via a conserved C1 domain including various isoforms of PKC, PKD 
and Ras-GRP (activators of the GTPase Ras). IP3 binds receptors on 
endoplasmic reticulum triggering the release of calcium. Intracellular calcium 
activates calcium/calmodulin dependent kinase (CaMK) and phosphatase 
calcineruin.
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intracellular calcium activates the calcium/calmodulin dependent phosphatase 
calcineruin (64) and also results in activation of members of the 
calcium/calmodulin-depedent protein kinase (CaMK) family including CaMKtype 
II (65-67), and CaMK type IV (68-71).
The importance of PLCyl regulation for lymphocyte activation stems from the 
fact that sustained elevation of intracellular calcium concentration ([Ca2+] i) is 
critical during the initial phases of T cell activation. In particular the regulation of 
the calcium phosphatase calcineurin, which is required for induction of cytokine 
gene expression. The importance of sustained calcium signalling in T cells is 
well established not least because a target for the powerful action of the 
immunosuppressive drugs cyclosporine A and FK506 is the calcium regulated 
serine/threonine phosphatase calcineurin. The important targets for 
calcium/calcineurin in lymphocytes are the NFAT (Nuclear Factor of Activated T 
cells) transcription factors that control antigen receptor induction of cytokine 
genes including the genes encoding IL-2, IL-4, GM-CSF, TNFa (72).
Other important signalling transduction pathway in T cells is mediated by the 
GTPase Ras (73). The guanine nucleotide binding cycle of Ras is controlled by 
guanine nucleotide exchange proteins (GEFs), which promote the transition 
from the inactive GDP-bound state to the active GTP-bound conformation, and 
GTPase activating proteins (GAPs) which stimulate the intrinsic GTPase activity 
of Ras resulting in hydrolysis of bound GTP to GDP. The nucleotide exchange 
reaction switches Ras on and the hydrolysis of GTP turns it off. p21ras rapidly 
accumulates in its active, GTP-bound form in antigen receptor activated T cells. 
Activation of Ras in T cells occurs through the recruitment of its exchange factor
Sos or RasGRP to the membrane. RasGRP contains a DAG binding C1 domain 
essential for its function. GTP-bound Ras leads to the activation of a number of 
serine/threonine kinases and dual-specificity kinases that are responsible for the 
eventual activation of the mitogen-activated protein (MAP) kinases Erk1/2.
One other key GTPase in T cell activation is the Rho family GTPase Rac (74). 
The involvement of Rac in T cell activation was initially suggested from 
biochemical studies where it was seen that the Rac GEF Vav-1 was tyrosine 
phosphorylated in response to antigen receptor ligation or engagement of the 
co-stimulatory molecule CD28 with its physiological ligands (75) Vav1 is a 
95kDa protein with src homology (SH) 2 and SH3 domains and a Dbl homology 
region, which is a characteristic marker of GEFs for Rho family GTPases. T 
lymphocytes lacking expression of Vav-1 have global defects in TCR signal 
transduction including a failure to activate PLCy signalling (76, 77). These 
defects are thought to arise from defects in cytoskeletal organisation and 
defects in cell adhesion.
TCR triggering also stimulates the production of the inositol lipid PI(3,4,5)P3 
which is produced when phosphatidylinositol-3 kinases (PI3K) phosphorylates 
PI(4,5)P2 on the D3 position of the inositol ring (78, 79). Antigen receptors are 
thought to stimulate the activity of a PI3K complex that comprises a heterodimer 
of a regulatory p85 and a catalytic p110 subunit. Four isoforms of the p110 
subunit have been described (a, (3, y, 6) and there are three mammalian genes 
that encode adapter subunits, p85a, p85(3 and p55y (80). T cells express p110y 
and p1106 and both these catalytic subunits appear to participate in lymphocyte 
signalling responses. p110S is expressed primarily in cells of the immune
system and the defects in T and B cell activation in p110 6 deficient mice are 
consistent with a role for this particular PI3K isoform in antigen receptor signal 
transduction (81).
Models for PI3K activation invoke p85 binding to adapters which recruit the 
enzyme to the plasma membrane; constitutive membrane targeting of p110 
catalytic subunits of PI3K creates a constitutively active enzyme that generates 
PI(3,4,5)P3 and PI(3,4)P2 when expressed in cells (82, 83). The candidate 
adapters for recruiting PI3K to the membrane in TCR activated cells are LAT or 
TRIM (TCR-interacting molecule) (84). The downstream targets of PI(3,4,5)P3 
and the signalling pathways regulated via PI3Ks will be discussed below (see 
section 1.5.4).
1.4 Gamma chain cytokines and their role in the 
immune system
Common gamma (yc) cytokines have been shown to play a central role in the 
development and differentiation of T cells (Fig 1.4.1). The crucial role of these 
cytokines in the immune system is illustrated by the development of X-linked 
severe combined immunodeficiency (X-SCID), in mice or humans with mutations 
in yc (85, 86).
1.4.1 X-Linked SCID
Severe combined immunodeficiency diseases (SCIDs) represent a spectrum of 
illnesses with similar clinical manifestations (87, 88)). Affected individuals have 
defects in both T and B cell compartments and without treatment die of
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Figure1.4.1: Cytokines play a role in T cell differentiation in
vitro and in vivo. T cell responses are initiated in the presence of pathogen 
by peptide:MHC complexes on dendritic cells (DC) interacting with T cell 
receptors (TCR). Activated T cells start to rapidly expand as they begin to 
secrete IL-2 and up regulate the IL-2 receptor (IL-2Ra). Activated T cells can exit 
lymphoid organs and migrate to sites of infection but eventually die resulting in 
the contraction phase of the response. Cytokines thought to influence T cell 
clonal expansion and differentiation in vivo and in vitro include IL-2, IL-15 and IL- 
7. IL-2 is a potent T cell mitogen and growth factor secreted by activated T cells. 
However, it is not clear if IL-2 solely drives T cell expansion in vivo as it does in 
vitro. IL-15 and IL-7 are secreted by bone marrow stromal cells. Cytokine 
gradients are thought to support T cell proliferation, differentiation and survival 
(IL-2 promotes cytotoxic T cell differentiation; IL-15/IL-7 the generation and 
survival of long lived memory T cells).
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opportunistic infection within one year of life. SCID can be cured with a bone 
marrow transplant in most cases (89). Additionally there is active work on gene 
therapy for X-linked SCID, the most common form, although safety issues have 
arisen with this approach ((90-92). X-SCID is the most common form of SCID, 
accounting for approximately half of all cases, and is known as the bubble boy 
disease (87, 88). X-SCID is the main form of T, B and natural killer (NK) cell 
SCID, where T and NK cells are absent or diminished in number and B cell 
numbers are normal but function is ablated. The genetic cause of X-SCID was 
mapped to the gene locus encoding the common gamma chain cytokine 
receptor subunit (yc) of the IL-2R complex (93, 94). Moreover, X-SCID patients 
were found to have mutated yc subunits and experiments where the yc subunit 
was deleted in mice confirmed that the X-SCID phenotype results from 
mutations in the common cytokine receptor y chain (95-97).
The yc was first identified as a subunit of the IL-2 receptor but it was quickly 
recognised that mice and humans deficient for IL-2 had a less severe phenotype 
when compared to that caused by yc mutation. Thus it was proposed that the IL- 
2 receptor y chain was a component of additional cytokine receptors. 
Subsequently this receptor subunit (now named the common cytokine y chain) 
has been shown to be a component of many cytokine receptors including; IL-4 
(98, 99), IL-7 (100) (101), IL-9 (102, 103), IL-15 (104) and IL-21 (105). The 
function of these cytokines has been shown to be very important for T and B cell 
compartments, as well as mast and NK cell functions (Fig 1.4.2).
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Figure 1.4.2: Actions of common y  chain family of cytokine
receptors. yc is a component of the receptors (R) for interleukin (IL)-2, IL- 
15, IL-7, IL-4, IL-9 and IL-21. yc can exist independently of other chains and is 
recruited into cytokine receptor complexes by cytokine binding to high affinity 
unique a  chains, or unique a  and common p chain in the case of IL-2 and IL- 
15. Known functions of these cytokines are shown above where mutation of 
the common cytokine receptor yc results in X-linked severe combined 
immunodeficiency disease (X-SCID). AICD; activation induced cell death, NK; 
natural killer, TH2 T helper 2, Ig; immunoglobulin.
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Interleukin 2 (IL-2) is a four-bundle alpha-helical cytokine, which exerts its 
biological activity by binding the high affinity IL-2 receptor (IL-2R). The 
production of IL-2 and expression of the IL-2 receptor is initially triggered by 
immune stimulation of naive T cells (106). It has also been described recently 
that dendritic cells can make IL-2 and express the IL-2 receptor when primed by 
a microbial infection (107-109). The IL-2 receptor is made up of three subunits, 
IL-2 Rye (CD132) (110), IL-2Ra (CD25) (111-114) and IL-2R0 (CD122) (HS­
US). IL-2Ra alone binds IL-2 with low affinity (Kd = 10‘8 M) but cannot 
transduce signals (87, 119, 120). The IL-2Rp and yc together form intermediate 
affinity IL-2 receptors (Kd = 10'9 M) and can signal in the presence of high 
concentrations of IL-2. The high affinity IL-2 receptors (Kd = 10'11 M) comprise of 
all three chains, IL-2Ra/ IL-2R|3/ IL-2Ryc, which can aggregate in response to 
very low gradients of IL-2.
Interleukin 2 (IL-2) was discovered in the late 1970’s as the first T cell mitogen 
and was one of the first cytokines whose gene was cloned and sequences (121- 
123). IL-2 is an extremely potent mitogen in vitro and can be used to clonally 
expand antigen primed T cells. Indeed the discovery of IL-2 made it possible to 
produce large quantities of T cell clones in vitro and opened up many new 
avenues of research.
In T cells, expression of high affinity IL-2 receptors is not constitutive but is 
restricted to activated cells and is transient once T cells are deprived of immune 
stimulation (106, 124). in vitro activated T cell entry into cell cycle requires a 
critical threshold of IL-2/IL-2 receptor interactions and is thus limited by IL-2
concentration, cellular IL-2 receptor density and the length of exposure to IL-2 
(106, 125). IL-2 was and is a very important mitogen for T cell cultures in vitro 
and has also been used in the clinic for immune therapy in cancer treatment and 
to treat HIV induced lymphopenia (126). It was thus a surprise that loss of IL-2 in 
vivo did not cause a major problem with T cell proliferation. IL-2 deficient mice 
develop a relatively normal lymphoid compartment, although, they did show 
elevated serum levels of lgG1 and IgE and suboptimal response when T cells 
were stimulated to proliferate in vitro (97). Never the less, initial studies showed 
the in vivo response to vaccinia and lymphocytic choriomeningitis virus (LCMV) 
was not impaired (127). The mitogenic role of IL-2 can thus be supplanted by 
other yc cytokines (128). However, the in vivo immune responses of IL-2 
deficient mice are not completely normal and IL-2 has essential non redundant 
functions in vivo for the efficient production of effector cytotoxic T cells, and for 
sustaining T cell expansion and induction of tolerance (129-134). Most 
interestingly, IL-2-/- mice manifested autoimmune symptoms including 
autoimmune haemolytic anaemia and inflammatory bowel disease when allowed 
to age (135, 136). These diseases were associated with lymphadenopathy and 
accumulation of activated lymphocytes ultimately leading to autoimmunity. 
Similar phenotypes are also seen in the IL-2Ra-/- mice and in IL-2Ra deficient 
patients (137, 138). Thus it was obvious the role of IL-2 as a mitogen is 
redundant but that IL-2 plays a critical and non-redundant role in the 
maintenance of peripheral tolerance in vivo.
The mechanism by which IL-2 controls T cell homeostasis and maintains 
peripheral tolerance is not fully understood, but IL-2 is thought to elicit two
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mechanisms in T cells that may play a pivotal role in tolerance; activation 
induced cell death (AICD), and homeostatic maintenance of CD4+CD25+ 
regulatory T cells (139-142). AICD is thought to be one of the processes 
contributing to cell death associated with the contraction phase of the immune 
response responsible for pathogen clearance. This massive cell death is thought 
to aid in eliminating activated T cells that may persist and mediate autoimmunity 
or malignancy. In vitro AICD is described as a sensitivity to cell death after 
exposure to primary activation signals, thus activated T cells will die rapidly if 
stimulated through the TCR multiple times.
AICD is mediated by the signalling events down stream of death receptors 
expressed on activated T cells. Death receptors associated with AICD are the 
tumour necrosis factor (TNF) receptor members, Fas and TNFR. Fas binds it’s 
ligand, FasL, resulting in oligomerisation and recruitment of adapter molecule 
Fas-associated death domain protein (FADD), via binding of death domains 
(DDs) (143-145) FADD also contains a DD that interacts with the DDs on 
procaspase 8, which allows for the formation of a complex known as the death- 
inducing signalling complex (DISC) (146). Subsequent events downstream of a 
FasL induced DISC formation results in the activation of large amounts of 
caspase 8 (147), which then signals downstream to effector caspases 3 and 7, 
and leads to apoptosis. Caspase 3 has been shown to be important in AICD 
mediated apoptosis as T cells from caspase 3-deficient mice show a significant 
resistance to AICD and an improved survival after responding to superantigen, 
anti-CD3, anti-Fas antibody stimulation (148). Alternative apoptotic pathways 
initiated by DISC formation exist and are mediated by the pro-apoptotic Bcl-2
family member Bid (149). It is not clear how this pathway functions although it is 
thought that Bid interacts with pro-apoptotic proteins Bak, and Bax, to form 
pores in the outer mitochondrial membrane (150), releasing pro-apoptotic 
factors stored in the mitochondria, including cytochrome c (151-153).
Unstimulated naive T cells are relatively resistant to AICD, as they express little 
to no FasL/Fas receptor. However, FasL has been shown to up regulate 
following TCR activation of naive T cells, sensitising these cells to AICD. IL-2 
has also been shown to up regulate FasL and promote apoptosis over 
proliferation in activated T cells (154). The importance of IL-2 for the induction of 
AICD is illustrated in IL-2 and IL-2Ra knockout mice that develop wide spread 
autoimmune disease, splenomegaly and lymphoproliferation, a result of 
unrestricted T cell proliferation (135, 155, 156). When IL-2 signalling was 
reinstated in IL-2/IL-2R knockout mice T cell susceptibility to AICD returned 
(157). It is thus proposed that IL-2 plays a role in sensitising T cells to AICD 
through the regulation of the Fas/FasL death pathway (156, 158).
One other critical role of IL-2 in immune homeostasis is its role in the growth and 
maintenance of CD4+CD25+ regulatory T cells (T regs) (131). Evidence has 
been mounting over the past few years in support of CD4+CD25+ regulatory T 
cell suppressive function (159, 160). It is now known that T regs are a subset of 
cells that develop in the thymus and migrate to the periphery where their main 
role is to suppress auto reactive T cells that have escaped negative selection in 
the thymus (141, 161, 162). T regs not only suppress autoimmunity but also 
control broad range of T cell dependent immune responses in vivo. For
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example, transplant rejection, prevention of anti-tumour immunity and regulate 
the immune systems responses to infection (163). Although little is known about 
T reg generation, homeostasis, and inhibitory activity there is increasing 
evidence that IL-2/IL-2R signalling is central to these processes.
For example, transgenic mice deficient in IL-2, IL-2Ra, IL-2R(3 or the IL-2 
activated transcription factor Stat5a/b are either missing or have decreased 
numbers of T reg’s (164-169). It has also been noted that thymus restricted 
expression of IL-2Rp restores functional T reg’s in IL-2RP null mice suggesting 
that IL-2 signalling in the thymus is critical for the development of these cells 
(167). It has also been shown that when IL-2-/- mice are injected with a cellular 
source of IL-2 there is an increase in T reg numbers (165).
1.4.3 IL-9
IL-9 was initially identified as a late acting T cell growth factor and mast cell 
growth factor. IL-9 is a multifunctional cytokine secreted by Th2 lymphocytes, 
where it has been implicated in mast cell, eosinophil and T cell mediated 
pathologies, such as asthma (170-172). IL-9 deficient mice develop a normal 
lymphoid compartment but exhibit excessive mucus production and mast cell 
proliferation (173). IL-9 has growth factor and anti-apoptotic activities on multiple 
transformed cells suggesting a potential role in tumorigenesis. Indeed, it has 
been shown that IL-9 transgenic mice develop thymic lymphomas, consistent 
with the presence of IL-9 receptors in the thymus (174). Also, IL-9 is produced 
by Hodgkin disease and HTLV-I transformed T cells in humans (175-177). The 
IL-9R and common yc chains associate with JAK1 and JAK3, respectively, 
triggering STAT1, 3, 5, IRS and RAS-MAPK pathways. In vitro, a deregulated IL-
9 response can lead to autonomous cell growth and malignant transformation of 
lymphoid cells associated with constitutive activation of the Jak/STAT pathway.
1.4.4 IL-4
IL-4 has a key role in the immune system because it controls the development 
of T helper 2 cells. CD4+ T cells can be divided into T helperl and T helper 2 
(Th1/Th2) lymphocyte subsets based on their cytokine production profiles (178- 
182). CD4+ Th1 cells produce IFNy, whereas CD4+ Th2 cells produce IL-4, IL-5, 
IL-9, IL-6 and IL-13. Cytokine production by CD4+ Th1/Th2 populations mediate 
the functional role for these cells in vivo, where CD4+ Th1 cells mediate immune 
responses against intracellular pathogens such as toxoplasma gondii and 
Leishmania and CD4+ Th2 cells are involved in antibody responses and 
protection against parasites such as intestinal helminths. IL-4 is crucial for Th2 
polarisation of CD4+ T cells. For example, when IL-4, IL4R or Stat6 (the major 
Stat protein activated by IL-4) were deleted in transgenic mice, CD4+ Th2 
differentiation was severely compromised (183-187).
1.4.5 IL-21
IL-21 R is expressed in lymphoid tissues including spleen, thymus and resting 
peripheral blood cells like B, T, NK and dendritic cells (188-191). Both CD4+ and 
CD8+ T cells up regulate IL-21 R on TCR activation (190, 192). Hence, the broad 
tissue distribution of IL-21 R indicates a role for IL-21 signalling in both adaptive 
and innate immune systems. However, the expression of the cytokine IL-21 is 
not easily detected but is induced by phorbol myristate acetate (PMA) and 
ionomycin or anti-CD3/CD28 activated CD4+ T cells, and not in CD8+ (188).
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Further analysis saw that only Th2 CD4+ T cells expressed IL-21 mRNA, in vitro 
and in vivo (193) and most of the data suggests this population of cells to be the 
primary source of IL-21, although others may yet be uncovered. Thus, because 
of this expression pattern, it has been suggested that IL-21 may play a role in 
the early differentiation of CD4+Th2 T cells.
Originally the IL-21 receptor (IL-21 R) was identified by it’s significant homology 
to the IL2Rp subunit and the IL-21 protein cloned using a functional approaches 
(188, 189). IL-21 R is expressed on T, B and NK cells and the cytokine (IL-21) is 
thought to regulate NK cell cytotoxicity/differentiation, B and T cell proliferation. 
Recent data shows that IL-21 acts synergistically with IL-15 in supporting 
proliferation of memory (CD44H|) and naive (CD44Low) CD8+ T cells and 
augments INFy production in vitro (194). IL-21 R-/- mice have normal T, B and 
NK cell numbers (195, 196), but were found to have diminished lgG1 production 
and elevated IgE.
The effect of IL-21 on T helper cell differentiation is still unclear. It has been 
reported that IL-21 is a Th2 cytokine (193) however it has also been seen to 
induce expression of Th1 related cytokines (197) and inhibit Th1 differentiation 
(193).
1.4.6 IL-15
Two independent groups originally identified IL-15 as a T cell mitogen, equal to 
IL-2, and able to induce T cell proliferation in the presence of IL-2 blocking 
antibodies (198, 199). The IL-15R consists of three chains: IL-15Ra, IL-2Rp, 
and IL-2Ryc (200-202). IL-15 is the only member of the yc cytokine family that is 
known to signal through a receptor that shares two common subunits with that
of the IL-2 receptor. However, both IL-2 and IL-15 receptors are defined by the 
expression of a unique receptor-a subunit, IL-2Ra and IL-15Ra. The IL-2Ra 
subunit (CD25) is expressed on subsets of pre-B cells, thymocytes and subsets 
of activated mature B and activated T lymphocytes. IL-15Ra chain expression is 
far more ubiquitous, seen in lymphoid and myeloid cells, as well as non- 
haematopoietic cells (201). Both a-chains confer specific binding of IL-2 or IL-15 
to trimeric receptors however there is no current biochemical evidence to show 
that the IL-2Ra and IL-15Ra subunits have signalling functions of their own. It is 
known that IL-15 is the only cytokine that binds to the IL-15Ra subunit with high 
affinity (Ka=1x1011 M"1) in the absence of any other receptor chains. In addition 
IL-15 can also bind to IL-2RP and yc complexes with intermediate affinity 
(Ka=1x109 M'1) (203) allowing signals to be transduced via the IL-2Rp/yc 
complex alone (104). IL-15 has also been found to bind to a unique receptor, IL- 
15RX, only expressed on mast cells (204). Because of the similarities between 
the IL-2 and IL-15 receptors and the fact they share common biological 
functions, it was always thought these two cytokines would also induce common 
biochemical and transcriptional programs. This view was supported by gene 
profiling experiments of yc cytokine stimulated peripheral blood T cells over 
short time courses. They found that IL-2, IL-15 and IL-7 regulated a very similar 
pattern of gene transcription (205). As well O’Shea and colleges showed that IL- 
2 and IL-15 induced a very similar pattern of tyrosine phosphorylation in T cells. 
For example both induced tyrosine phosphroylation of Jak1, Jak3, STAT5, and 
the IL-2RP chain (206).
One difference between IL-2 and IL-15 is that IL-2 is thought to function as a 
secreted soluble ligand whereas IL-15 signalling is proposed to occur as a trans
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binding event whereby soluble IL-15 secreted by cells responding to 
inflammatory cytokines, binds to high affinity IL-15Ra subunits expressed on 
these cells and is presented in trans to IL-2p/yc complexes on recipient cells 
(207-212).
IL-15 is expressed in multiple tissues including placenta, skeletal muscle, 
kidney, heart, monocyte/macrophages and bone marrow stromal cells (199).
The first cell types to be implicated as functionally relevant sources of IL-15 in 
the context of the immune system were members of the monocyte/macrophage 
lineage (213, 214). Blood derived dendritic cells have also been shown to 
produce IL-15 (215, 216).
IL-15 is a T cell mitogen in vitro, and can stimulate the proliferation of natural 
killer (NK) cells as well as supporting NK cell cytotoxicity. However, important in 
vivo differences in the action of these two cytokines have emerged particularly in 
regard to NK cell development and CD8+T cell homeostasis (202). As 
discussed, mice deficient for IL-2 and IL-2Ra show abnormal peripheral immune 
responses associated with lymphoproliferative disorders and the development of 
autoimmunity but have generally normal y/S T cell and NK cell development. 
However, mice lacking expression of the IL-2RP have an additional problem: 
profoundly decreased numbers of NK cells and y/6 T cells. These data suggest 
that IL-15 and not IL-2 has a profound role in the development and 
differentiation of these cells (217).
Furthermore, mice lacking expression of either IL-15 or IL-15Ra do not have the 
autoimmune phenotype of IL-2 and IL-2Ra deficient mice but they lack the NK 
cell compartment, confirming a distinct role for IL-15 in NK cell development
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(218, 219). IL15 or IL-15Ra mice also have decreased numbers of CD8+ T cells 
and almost a total lack of memory phenotype CD8+ cells, suggesting that IL-15 
is critical for the homeostasis of naive and memory CD8+ T cells (218, 219). 
Virus infection models concur with this showing that IL-15 is important for the 
generation and expansion of virus-specific effector CD8+ T cell clones (220,
221). The findings from IL-15 and IL-15Ra knockout animals are supported by 
the transgenic models, showing a role for IL-15 in the generation and 
proliferation of CD8+ T cell numbers (222), and over expression of a modified 
stable form of IL-15 mRNA causes CD8+ T cell lymphomas (223). IL-15 also 
plays a crucial role in the differentiation and maintenance of CD8+ T cells 
memory and is thought to be useful as a vaccine adjuvant for efficient 
generation of a memory T cell pool (218, 224) (208, 219, 220, 225-229).
Most T cell work with IL-15 has focused on its role in CD8+ T cell function but 
Geginat et al have suggested that IL-15 is a potent mitogen for different stages 
in CD4+ memory T cell differentiation (227, 230, 231). Congruently, although not 
as pronounced as the decrease in CD8+ T cell numbers, IL-15Ra/IL-15 -/- mice 
also showed a decrease in CD4+ T cell numbers. The importance of IL-15 for 
naive and memory CD4+ T cell maintenance and development has not been 
fully worked out although it seems likely to contribute in some way (232, 233).
1.4.7 IL-7
IL-7 has effects on both T and B cell biology (234-236). The critical role IL-7 in T 
and B cell development was initially studied by injecting mice with antibodies to 
IL-7 and IL-7Ra (237), and then by studies of lymphoid development in mice 
deficient in IL-7Ra and IL-7 (238, 239), where T and B cell development was
abrogated in both cases. Patients with defective IL-7Ra expression have 
defective T and NK cell but normal B cell development (240), highlighting the 
non-redundant role of human IL-7Ra in T cell but not B cell development.
IL-7 is produced by thymic and bone marrow stromal cells (241-243). In the 
thymus, IL-7 dependent signals are critical at the double negative stage of T cell 
selection, as development is blocked at this stage in IL-7 and IL-7Ra deficient 
mice suggesting IL-7 dependent signals are required for normal cell division of 
DN and DP thymocytes.
IL-7 and IL7R null mice are also characterised by their reduced T cell numbers, 
in the thymus and periphery, and abnormal T cell response to polyclonal stimuli. 
Thus it is thought that IL-7 provides distinct signals that influence T cell survival 
and proliferation (234-236, 244, 245). In addition to mitogenic signals, the 
induction of the anti-apoptotic molecule Bcl-2 is induced by IL-7 (40). The 
earliest T lineage-committed cells thus depend on IL-7 for Bcl-2 expression 
survival and normal cell cycle progression (246). However, IL-7 signalling is not 
limited to Bcl-2 induction and is also thought to regulate TCR gene 
rearrangements (247) (248-250) (251).
The B cell defect in IL-7 and IL-7Ra deficient mice appears early in development 
(238, 239). Transgenic expression or injection of IL-7 augments the expansions 
of early B cells in vivo (252-254). The defects in B cell development seen in IL- 
7/IL-7R transgenic mice are thought to be due to a combination of effects on 
early B cell proliferation, survival and Ig gene rearrangement (236, 255).
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A large body of evidence shows that IL-7 plays an important role in peripheral T 
cell homeostasis (40, 256-258). Homeostatic proliferation of naive T cells is 
driven by the presence of ‘space’ (lymphopenia) in the host animal, such as that 
occurring in neonates (259, 260). This proliferation is also driven by the 
presence of low avidity self antigen: MHC (major histocompatability complex) 
interactions (261). Data strongly indicates that IL-7 plays a vital role in naive T 
cell homeostatic proliferation. Hence naive T cells in IL-7 deficient hosts have a 
reduced proliferative rate but their proliferation is increased when IL-7 is over 
expressed in mice (262-264). IL-7 has also been implicated in the expansion, 
survival and homeostatic proliferation of CD8+ memory T cells (39, 258, 262, 
265). Indeed, IL-7 receptor expression is thought to flag effector CD8+ T cells 
with the potential of becoming memory cells (266, 267). IL-7 has also been 
implicated in the formation and maintenance of CD4+ memory T cells (263, 
268). However, it is not thought that IL-7 is the sole survival factor for memory 
CD8+ T cells as a large body of evidence implicates a vital role for IL-15 (200, 
269, 270).
1.5 Cytokine receptor signal transduction
The yc cytokine receptors have no intrinsic catalytic activity yet studies showed 
that cytokine binding induced immediate tyrosine phosphorylation of cellular 
proteins and receptor subunits (Fig 1.5.1). The key tyrosine kinases for the yc 
cytokine receptor family are the Janus kinases Jak1 and Jak3. The isolation and 
cloning of the Jak tyrosine kinases was first established in the context of 
Interferon signal transduction (reviewed in (271-273)). There are four different 
Jaks: Jak1, Jak2, Jak3 and Tyk2. Jak1, Jak2 and Tyk2 are ubiquitously and
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Figure 1.5.1: Signal transduction down stream of IL-2 receptor 
binding. Cognate cytokine binding brings together receptor subunits, resulting 
in activation of tyrosine kinase activity, association of Jak’s, dimerisation of STAT 
proteins and transcription of target genes in the nucleus. PI3K associates with IL- 
2Rp via phospho-tyrosine residues, triggering PIP3 production and activation of 
down stream pathways involving Akt (PKB) which feeds into metabolically active 
pathways such as glycolysis (GSK3), protein synthesis and cell growth (mTOR). 
The MAP Kinase pathway has also shown to be activated down stream of IL-2 
binding via a Ras mediated pathway. Y: phosphorylated tyrosine residue
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constitutively expressed, although Jak3 expression is restricted to 
haematopoietic cells (273, 274). All yc containing cytokine receptor complexes 
function by activating both Jak1 and Jak3. The common y-chain associates with 
Jak3 and the IL-2Rp chain whereas IL-4Ra, IL-9R, IL-7Ra and IL-21 R associate 
with Jak1 (102, 204, 275, 276). The analysis of the human Jak3 gene has 
revealed its linkage to a SCID immunodeficiency (85) (275, 277, 278).
The autosomal SCID immunodeficiency’s associated with Jak3 mutations cause 
identical phenotypes to those seen in patients with the yc subunit mutation or X- 
linked immunodeficiency SCID (87, 102, 279).
Indeed, Jak3-/- mice phenocopy IL-2Ry-/- mice (280-282). This similarity occurs 
because yc recruits Jak3 to the cytokine receptor complex.
The central role of Jaks in cytokine signalling makes them important therapeutic 
targets. Jak3 is the most recent focus for generating a new class of inhibitors 
with immunosuppressive, anti-inflammatory, anti-allergic, anti-thrombotic and 
anti-leukaemic properties and is in preclinical studies (283).
1.5.1 Signalling downstream of Jak kinases
Substrates down stream of Jak1 and Jak3 have not been fully characterized, but 
are known to include tyrosine residues in the specific chains of cytokine 
receptors. For example, IL-2 activation of the Jaks results in phosphorylation of 
three tyrosine residues on the IL-2Rp chain, which are vital for signal 
transduction: Tyr338, Tyr392 and Tyr510 (273). Activation of Jaks also results in 
tyrosine phosphorylation of adapter molecules such as Gab2, She, IRS-1, Grb2, 
SHP-2, Vav and STAM (206, 284-289). These tyrosine phosphorylation events
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induced by yc cytokines activate at least three known signalling pathways 
involving Ras/MAP Kinases, signal transducers and activators of transcription 
(STATs) and PI3K (290).
1.5.2 Ras proteins are activated by a subset of yc dependent 
cytokines.
Immunological interest in GTPases stems from observations in the early 1990’s 
that the GTPase Ras accumulates in the active GTP bound state in response to 
antigen receptor ligation or in response to yc cytokines such as IL-2. Two main 
classes of regulatory proteins control Ras activity: guanine nucleotide exchange 
proteins (GEFs) that promote the transition from the inactive GDP-bound to the 
active GTP-bound conformation and GTPase activating proteins (GAPs) that 
stimulate GTPase inactivation. In IL-2 signalling it has been shown that 
phospho-Tyr388 recruits an adapter molecule She. The best-defined role for 
She is the activation of the guanine nucleotide binding protein Ras (291). In 
response to IL-2, She binds to phospho-Tyr338 of the IL-2R|3 chain and 
becomes tyrosine phosphorylated (292, 293). Tyrosine phosphorylated She then 
is able to bind to the SH2 domain of a second adapter Grb2. The Ras guanine 
nucleotide exchange protein Sos, mammalian homologue of the Drosophila ‘Son 
of Sevenless’ protein, associates constitutively with the sre homology (SH3) 
domains of Grb2. The Shc/Grb2 complex formed in IL-2 activated cells results in 
the membrane re-localisation of Sos enabling the catalytic activity of Sos to elicit 
Ras activation.
Interactions between Ras GAP and tyrosine phosphorylated SOCS3 proteins 
have also been described in the context of IL-2 signal transduction. The
formation of these protein complexes might either allosterically inhibit GAP 
functions or sequester this negative regulator and physically prevent interaction 
with Ras proteins thereby promoting activation of Ras (294).
Once Ras is activated it is able to regulate diverse cellular processes by 
coupling to multiple biochemical effector signalling pathways including the Raf- 
1/MEK/Erk1, 2 kinases (295, 296). The activation of this pathway is needed for 
yc cytokine induction of cell cycle progression (297), however, the role of Ras as 
a mediator of cytokine signalling in the context of T cell differentiation has not 
been explored. Interestingly, not all yc cytokines activate Ras. The activation of 
the SHP and Ras/MAP kinase pathway is common to IL-2 and IL-15 (206, 298). 
In contrast, IL-7 does not induce She tyrosine phosphorylation or Erk activation 
(297, 299), and IL-4 does not induce Ras activation (298, 300, 301).
1.5.3 STAT proteins are activated by yc dependent cytokines
Key transcription factors that mediate cytokine responses are known as signal 
transducers and activators of transcription (STATs). Seven mammalian STAT 
proteins are known, Statl, Stat2, Stat3, Stat4, Stat5a, Stat5b, and Stat6. 
Biochemical and molecular analysis revealed Stats are direct substrates of Jak 
kinases and are tyrosine phosphorylated in cytokine-activated cells (274, 302). 
All STAT proteins have a conserved COOH SH2 domain and a COOH tyrosine 
phosphorylation site. Following Jak mediated tyrosine phosphorylation; STATs 
became dimerised through phosphotyrosine-SH2 domain interactions. STATs 
can form homodimers as well as heterodimers. Latent STAT proteins are 
predominantly cytoplasmically localised. An immediate consequence of receptor 
triggering is JAK activation and tyrosine phosphorylation of the cytoplasmic
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domain of the receptor subunits. In the prototypic model, STAT activation is 
initiated by the recruitment of STATs to tyrosine-phosphorylated sites within the 
activated receptor subunits. JAK mediated tyrosine phosphorylation then occurs 
which allows for SH2 mediated STAT dimerisation. Active dimerised STATs 
translocate into the nucleus where they bind to high affinity DNA motifs 
containing the consensus palindromic inverted repeat sequence TTC(N3^ )GAA. 
Each individual STAT has particular DNA binding affinity for specific sequences. 
This depends not only on the STAT DNA binding domain itself but also on the 
different homo and heterodimer combinations that it forms. STAT dimers can 
also polymerise through mutual N-terminal interactions to bind DNA co­
operatively, enabling the recognition of variations of the consensus site .The 
conserved COOH terminus domain acts as a transactivation domain (TAD).
The immediate biochemical consequences of triggering T cells with many 
different yc cytokine results in a common response: activation of the cytosolic 
tyrosine kinases, the Janus kinases Jak1 and Jak3. However, differences in the 
cytosolic domains of cytokine receptor subunits, which act as intracellular 
adapters for recruitment of signalling molecules, can thereafter allow immediate 
divergence of signal transduction pathways. For example yc cytokines IL-2, IL-7 
and IL-15 activate a common transcription factor STAT5 whereas IL-4 activates 
STAT6. This difference occurs because the IL-2Rp subunit and the IL-7Ra 
subunit contain tyrosine residues Tyr392, Tyr510 and Tyr449 respectively (303, 
304) that act as docking sites for STAT5 whereas tyrosines in the IL-4 receptor 
subunit act as docking sites for STAT6 (305).
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1.5.3 The importance of the STATs for cytokine signal 
transduction.
Mice deficient in expression of the various STATs have been made and studies 
of these mice have revealed that the STATs are important regulators of 
haematopoietic cells and play a role in regulating the immune system. For 
example, STAT6 appears to be crucial for the function of the yc cytokines IL-4 
and IL-13. Stat6-deficient mice thus have a similar phenotype to IL-4 or IL-4Ra - 
/- mice, displaying defective Th2 lineage T cell differentiation and defective B 
cell Ig class-switching (183-186). Stat3 and Statl are also activated by yc 
dependent cytokines: STAT3 is activated by IL-2, -7, -15, -9 and -21 (105, 304, 
306, 307) (308). STAT1 can be activated by cytokines IL-2, IL-7, IL-15, IL-12 
and IL-6 (309, 310); however, STAT1 was initially discovered as a result of 
interferon signal transduction (311, 312).
STAT3 deficiency is embryonic lethal, resulting from defects in cytokine 
signalling outside the haematopoietic system (313). T cell specific knockouts of 
STAT3 develop normally and have normal IL-7 mediated T cell proliferation, but 
are partially defective in IL-2 induced proliferation arguing that STAT3 may be 
involved in IL-2 signal transduction (314). STAT1 deficient mice have an 
impaired response to IFN a/p/y, poor anti-viral responses, and develop 
spontaneous and chemically induced tumours more rapidly than wild type mice. 
Suggesting that STAT 1 may not be a crucial transactivator for yc dependent 
cytokine signalling (315) (316).
The predominant STATs activated by yc cytokines are STAT5a and STAT5b but 
these STATs are also activated by other cytokines important for haematopoiesis
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and indeed Stat5 was originally identified as a transcription factor that regulates 
the p-casein gene in response to prolactin (317).
Mice deficient in Stat5a and/or Stat5b thus have a complex phenotype reflecting 
the involvement of these transcription factors in signalling pathways regulated 
by a diverse set of cytokines and growth factors in different cell types (318). 
Hence it is difficult to correlate the significance of STAT5 activation to one 
particular T cell function or defect in yc cytokine signal. However, even though 
mice lacking Stat5a have a small but significant decrease in splenocyte 
numbers and normal lymphoid development, it has been reported that T cells in 
these mice express less IL-2Ra (CD25) chain after in vivo antigenic stimuli with 
staphylococcal enterotoxin B (SEB) (319). These cells were also shown to have 
impaired IL-2 induced proliferation (at low concentrations of IL-2) and a sub- 
maximal response in vivo antigenic stimuli, in part reflecting that STAT5a seems 
to be required for maximal expression of CD25 and thus T cell proliferation 
(319). The immunological phenotype of Stat5b-/- mice is more severe than that 
of Stat5a-/- mice, where thymocyte numbers are slightly reduced, peripheral T 
cell numbers are more reduced than Stat5a-/- mice, NK cell numbers and IL-2 
induced cytotoxicity are reduced (320). These data argue that Stat5b maybe 
functionally more important than Stat5a for T and NK cell function (319, 320). As 
expected, Stat5a/b double knockout mice show a more severe phenotype than 
either of the single knockout mice. Where T cells respond poorly to antigen 
stimulation, even in the presence of high IL-2, develop splenomegaly and have 
T cells with an activated phenotype, in part suggesting defective IL-2 signalling. 
These mice also lack NK cells, which is consistent with defective IL-15 signalling
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although taken together the phenotype recapitulates some of the symptoms 
seen in IL-2R|3 deficient mice.
There is also evidence that STAT5 is necessary for IL-7 mediated responses 
during both B and T cell development. For example, peripheral blood B cells of 
Stat5a/b deficient mice are significantly reduced, and pre and pro-B cells were 
found to have a reduced response to IL-7 (321, 322). As well, Pallard et al 
showed that a dominant negative STAT5 mutant blocked thymocyte 
differentiation in foetal thymic organ cultures (FTOC) (323).
In vitro and in vivo data from cell lines and mice models also indicate that Stat5 
is important for IL-2 dependent T cell proliferation (293, 322, 324). Moreover, 
constitutive expression of Stat5 in cell lines results in T cell proliferation and 
constitutively active STAT5 has been isolated from HTLV-1 transformed T cells, 
B and T cell lymphomas (304, 325-328). Indeed, data suggests that expressing 
constitutively active STAT5a in naive CD4+ T cells can independently drive Th2 
differentiation of CD4+ T cells in the absence of IL-2, STAT6 and IL-4Ra, 
suggesting that STAT5a plays an important role in CD4+ differentiation (329).
The direct gene targets for STATs down stream of yc dependent cytokine 
receptor signals, has not been well studied. There has been recent data 
suggesting STAT5 proteins control pro-mitogenic and oncogenic genes 
including IL-2Ra, Pim1 and the D type cyclins (D1 and D2) (330-336). However, 
much more work is needed in this area to understand the role of identified and 
unknown targets in yc dependent cytokine signalling.
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1.5.4 yc dependent cytokine activation of PI3K
A major route for inositol lipid metabolism initiated by yc dependent cytokines is 
mediated by phosphoinositide-3 kinases (PI3K) The role of PI3K is to 
phosphorylate PI(4,5)P2 at the D3 position of the inositol ring of inositol 
phospholipids producing PI(3,4,5)P3(337).
There are multiple isoforms of PI3Ks in mammalian cells (see (338-340) for 
reviews). The forms linked to yc dependent cytokine are the Class I PI3Ks, 
comprising a heterodimer of a catalytic subunit p110 and a regulatory/adapter 
subunit p85.
The initial model for PI3K activation by yc cytokines was patterned on the 
prototypical model worked out for growth factors in the context of receptor 
tyrosine kinases in fibroblasts. In this model receptor tyrosine kinases 
phosphorylate stimulated receptor subunits. The PI3K p110 catalytic subunit is 
recruited to the receptor via high affinity binding between the Src homology (SH) 
2 domain of the p85 adapter subunit and specific phosphorylated sequences 
within the cytoplasmic tail of the receptor (341, 342). This process recruits the 
p110 catalytic subunit of PI3K to the plasma membrane where it can 
phosphorylate its main substrate PI(4,5)P2 to generate PI(3,4,5)P3. The ability of 
p85 to bring the catalytic subunit to the plasma membrane is a crucial role for 
this adapter; constitutive membrane targeting of p110 catalytic subunits of PI3K 
creates an enzyme that constitutively generates PI(3,4,5)P3 and PI(3,4)P2 when 
expressed in cells (82). PI3K signalling in response to yc cytokines initially 
seemed to fit a simple model whereby Jaks mediated tyrosine phosphorylation 
of receptor subunits (Tyr392 in the IL-2Rp chain, Ty449 in the IL-7 receptor 
subunit orTyr731 in the IL-4 receptor) initiating p85 mediated recruitment to the
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plasma membrane (343-345). However, PI3K recruitment to the plasma 
membrane is not necessarily mediated by direct receptor binding, there are a 
number of reports of interactions between p85 and other adapters that could 
bring p110 to the plasma membrane in T cells. For example, a complicated 
signalling scaffold formed by three adapters, She, Grb2 and Gab2 recruits PI3K 
to the plasma membrane in cells activated by haematopoietic cytokines such as 
IL-2 and IL-3 (206, 346).
As discussed, multiple isoforms of PI3K exist and are co-expressed in T cells. It 
is not yet known which PI3K isoforms are regulated by yc cytokines in T cells 
although the in vivo biological role of different PI3K isoforms has begun to be 
elucidated through the generation of knockout mice models by gene targeting 
methods. A full discussion of the phenotype of mice lacking the different PI3K 
subunits is beyond the scope of the present report and has been extensively 
reviewed (80, 347). It should be emphasised that work involving lymphocyte 
function in PI3K knock out models has focused on TCR/CD28 mediated signals, 
development, proliferation and migration and virtually no work has looked 
directly at the impact of losing PI3K isoforms on signalling down stream of IL-2 
receptors and other yc cytokines IL-7, IL-4, IL-15, IL-9 and IL-21.
It is however worth discussing the phenotype of mice deficient in expression of 
p1106, which is selectively, expressed by haematopoietic cells. Here 
Okkenhaug and colleagues generated mice expressing a catalytically inactive 
form of the p110S subunit (p1105D910A/D910A) referred to as p110S knock-in mice 
(81). These mice were fertile and healthy. T cells in the thymus appeared 
normal although T cell numbers in the spleen were reduced. Peripheral T cells
expressed higher than normal levels of naive markers CD44 and CD62L, 
seeming more ‘naive’ than controls, and had a reduced signalling capacity and 
IL-2 production when responding to antigen presented by B cells. Hence, it is 
suggested that T cells develop normally in these mice although peripheral 
maturation and survival is disrupted. Overtime p1106D910A/D910A mjce developed 
inflammatory bowel disease, a complex autoimmune response, thought to be 
mediated by dysfunctional regulatory T cells. The deregulation of immune 
tolerance in these mice may suggest impaired yc cytokine signalling as 
uncontrolled proliferation and autoimmunity has been seen in IL-2/IL-2R-/- mice. 
The B cell defect in these p1106 D910A/D910A mjce very severe, where B cell 
numbers are largely reduced, proliferation inhibited and apoptosis accelerated. 
This B cell phenotype is similar to P1106-/- mice created by Clayton et al (348) 
using a gene deletion protocol. These results have been interpreted as evidence 
that P1106 maybe important for PI3K signalling down stream of the B cell 
receptor (BCR) (348, 349) (350, 351).
There is evidence that PI(3,4,5)P3 functions in yc signal transduction. Firstly, 
experiments in vitro with PI3K inhibitors such as LY294002 or wortmanin have 
shown a role for PI3K in yc cytokine mediated cell cycle progression, T cell 
differentiation and anti-apoptotic function (352-360) (323, 361-367). Conversely, 
elevation of cellular levels of PI(3,4,5)P3 in T cells lines in vitro by expression of 
constitutively active membrane targeted PI3K can substitute for yc cytokines in 
the regulation of the E2F family of transcription factors (357). Studies of 
phospholipid phosphatases in vivo have also highlighted the importance of 
Pl(3,4,5)P3signalling in yc cytokine signalling. Hence, PI(3,4,5)P3 is normally
destroyed by a 3 ’ inositol lipid phosphatase PTEN (phophatase and tensin 
homologue deleted on chromosome 10) (368) which mediates the conversion of 
Pl(3, 4, 5)P3 to Pl(4, 5)P2. Deletion of PTEN results in constitutive accumulation 
of Pl(3, 4, 5)P3 with severe consequences. Complete gene inactivation of PTEN 
in mice is embryonic lethal (369). PTEN is also tumour suppressor gene in 
humans and is located in a region of the chromosome that suffers loss of 
heterozygosity in many human cancers. In this respect, mice that have lost a 
single PTEN allele have complicated phenotypes associated with increased 
tumorigenesis and the development of polyclonal autoimmune disease (370). 
Recently, T cell specific knockouts of PTEN in mice have shown that PI(3,4,5)P3 
concentrations play a pivotal role in thymocyte proliferation and development. In 
particular, the thymocyte developmental defects seen in IL-2Ryc-/- mice can be 
rescued when by simultaneous deletion of a single allele of PTEN in pre-T cells 
i.e. the role of yc cytokines in the thymus can be fully substituted by elevating 
Pl(3,4,5)P3 cellular concentrations (371). There is one caveat about interpreting 
the PTEN rescue experiments namely that there is evidence that in certain 
circumstances PTEN has protein kinase activity (372).
1.6 Downstream of PI3K in T cells
PI(3,4,5)P3 and PI(3,4)P2bind to pleckstrin homology (PH) domains of proteins 
(373). This allows for allosteric modification of activity or re-localization of the 
protein to defined areas of the plasma membrane for further signal transduction. 
Three major classes of signalling molecule are regulated by D3 
phosphoinositide binding to PH domains: guanine nucleotide exchange proteins 
for Rho family GTPases, the TEC family tyrosine kinases such as Btk and Itk in
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B and T lymphocytes respectively and the AGC super family of serine/threonine 
protein kinases (Fig 1.6.1).
1.6.1 PI3K regulation of guanine nucleotide binding proteins
Guanine nucleotide binding proteins cycle between a guanosine diphosphate 
(GDP)-bound or guanosine triphosphate (GTP)-bound state. These proteins 
function as binary switches controlling activation in response to environmental 
cues. GTPases exist in two different conformations when bound to GTP or GDP. 
The GTP-bound state is the active form allowing GTPases to interact with a 
down stream signalling cascades and mediating biological outcomes. Members 
of the Ras family of GTPases, Ras, Rap1 A and the Rho family of GTPases 
Cdc42, Rac1, Rac2 and RhoA are important molecules for T cell signal 
transduction (74). Activation of Rac and Rho is stimulated by guanine nucleotide 
exchange proteins (GEFs) which characteristically comprise a catalytic Dbl 
homology domain flanked by a PH domain that is critical for GEF function, for 
review see (374). In particular, GEFs involved in activation of the GTPase Rac-1 
have a PH domain that can bind PI(3,4,5)P3 with high affinity (375). Rac is now 
known to mediate signals from PI3K down stream of IL-2 receptor signals (361): 
IL-2 regulates T cell shape and motility, along with T cell proliferation, and is 
thought to provoke membrane ruffling via a PI3K/Rac pathway (361).
1.6.2 PI3K and tyrosine kinases
The TEC family of tyrosine kinases, Itk, Tec and Btk are activated via a 
phosphorylation event within their activation loop by src kinases (376, 377).
Most TEC kinases contain a plextrin homology (PH) domain that binds
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Figure1.6.1: PI3K signaling and protein translation initiated 
by IL-2/IL-2 receptor binding. Receptor dimerisation and association of 
PI3K p85 subunit catalyses PI(3,4,5)P3 production. PIP3 brings PKB to the 
membrane leading to activation by PDK1. Active PKB is known to regulate 
glucose metabolism and protein synthesis machinery through GSK3 and 
m TOR/p70S6K respectively. mTOR promotes p70S6K activation of ribosomal 
protein S6  and de-represses 4EBP-1 binding to translation initiation factor 
elF4E promoting mRNA association with polysomes and thus protein 
synthesis. It is now thought that protein synthesis is regulated through 
rapamycin sensitive (mTOR/Raptor) or insensitive (mTOR/Rictor) pathways.
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PI(3,4,5)P3 and translocates the TEC kinases to the plasma membrane for close 
proximity to Src kinases for activation (378, 379). The importance of the PH 
domains of these kinases for their activation is illustrated in the context of BTK, 
where mutations in the BTK PH domain cause of X-linked 
agammaglobulinaemia in humans and a similar x-linked immunodeficiency in 
mice (380-383). BTK kinases are activated in response to cytokine receptors.
Not much is known about Tec kinases in yc cytokine signalling although it has 
been shown that IL-2 regulates the activity of the tyrosine kinases Itk and Tec 
via activation of PI3K (384).
1.6.3 PI3K and serine/threonine kinases
A serine/threonine kinase that mediates PI3K action is protein kinase B (PKB) or 
Akt (385, 386). PKB has a PH domain that can bind PI(3,4,)P2and PI(3,4,5)P3 in 
vitro. However it is thought that PKB preferentially binds PI(3,4,5)P3 in vivo, 
because reduction of PI(3,4,5)P3 levels by inositol phosphatase SHIP, and a 
concomitant increase in PI(3,4,)P2, does not favour PKB activation (387, 388). 
The elevation of PI(3,4,5)P3 levels in T cells seems sufficient to activate PKB.
For example membrane targeting of the PI3K p110 catalytic subunit, which 
results in constitutive production of P!(3,4,5)P3, is sufficient to trigger PKB 
activation (388, 389). Similarly, elevation of PI(3,4,5)P3 levels in PTEN null cells 
results in constitutive activation of PKB and an uncoupling of PKB activation 
from mitogenic stimuli (368, 390).
PKB activation is regulated by the upstream kinase PDK1 (phosphoinositide- 
dependent protein kinase 1) that acts down stream of PI3K/PI(3,4,5)P3 and
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phosphorylates PKB on Thr308 in the kinase activation loop. Thr308 
phosphorylation is thought to relieve auto inhibition of the PKB catalytic domain 
and is considered to be a key step in PKB activation (391-397).
PKB is also phosphorylated on Ser473 in a hydrophobic motif at the enzymes 
carboxyl terminus by a kinase known as PDK2 (398, 399). Recent data 
suggests that PDK2 is the target of rapamycin kinase (TOR) and its associated 
protein Rictor (400).
The importance of PDK1 for PI3K action was first established in the context of 
PKB: but it is now recognised that PDK1 is constitutively active and 
phosphorylates key residues in the activation loop o r ‘T loop’ of probably all 
serine/threonine kinases of the AGC superfamily including all Protein Kinase C 
isoforms (401, 402), the ribosomal S6 Kinase, S6K1 (p70S6 kinase) (396, 403) 
and p90Rsk (395). PDK1 has an N-terminal catalytic domain and a C-terminal 
PH domain that binds PI(3,4,5)P3 with high affinity. The role of D3 
phosphoinositides in controlling PDK1 activity and subcellular localisation is very 
controversial (404, 405) (For review see (403, 406)). One view is that PDK1 
specificity is regulated primarily by substrate conformation (403, 407) whereby, 
the D3 phosphoinosotides act to change the structure of PDK1 substrates at the 
membrane facilitating PDK1 mediated activation, rather than directly stimulating 
PDK1 (408). It has also been suggested that D3 phospholipids initiate PH 
domain dependent re-localisation of PDK1 from the cytosol to the plasma 
membrane (404, 408). Initial work in mouse embryonic stem cells lacking both 
copies of the PDK1 gene has allowed for the analysis of down stream pathways 
of PDK1. From this data it was clear that PDK1 interacted with multiple
45
members of the AGC kinase family in different ways, specifically PKB, were it 
was clear that multiple phosphorylation events were required for full activation in 
vivo (395).
Transgenic mice that lack PDK1 or have hypomorphic alleles, which express 
only 10% of normal levels of PDK1, have been produced. PDK1-/- embryos die 
at day 9.5, however hypomorphic PDK1 mice are viable and fertile but with 40- 
50% smaller body size than controls. One important observation was that cell 
numbers in these mice remained the same but organ size was smaller, hence 
the volume of cells lacking PDK1 was reduced 35-60% of normal suggesting 
PDK1 plays a pivotal role in regulating cell size independently of proliferation 
(409).
Recent data from Hinton et al shows that PDK1 is an essential kinase for T cell 
development as the loss of PDK1 in T cells blocks T cell differentiation in the 
thymus (410). Hence analysis of the PDK1 hypomorphic mice and mice with a T 
cell specific knockout of PDK1 genes indicated that complete loss of PDK1 in T 
cells blocked T cell differentiation in the thymus and reduced PDK1 expression 
allowed T cell differentiation but blocked proliferation (410).
1.7 PKB function in lymphocytes
1.7.1 Glycogen Synthase Kinase 3 (GSK3)
The first known substrate for PKB was Ser21 in GSK-3a and Ser9 in GSK3p 
(411, 412). These phosphorylation events have been shown to occur in 
lymphocytes responding to TCR activation and IL-2 stimulation (78, 413) and 
are associated with inactivating GSK3.
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GSK-3 was initially identified as a regulator of glycogen metabolism but may 
have a much broader range of functions. Including phosphorylation of 
transcription factor Nuclear Factor of Activated T cells (NFAT) in T cells.
NFAT is controlled by a phosphorylation/de-phosphorylation cycle: 
phosphorylated NFAT are mainly cytoplasmic and de-phosphorylated forms 
accumulate in the nucleus (414-416). NFAT de-phosphorylation is mediated by 
calcium phosphatase calcineurin, promoting NFAT nuclear import and 
transcription of early immune response genes, including cytokines (414, 417). In 
contrast the phosphorylation of NFAT by kinases including GSK-3 drives nuclear 
export (413). Thus PKB phosphorylation of GSK-3 inactivates the kinase limiting 
re-phosphorylation of NFAT and promoting de-phosphorylated NFAT nuclear 
retention. Gene targets of NFAT include TNFa, IL-2 and IL-4 suggesting a role 
for PKB in regulating immune responses (415). Although the role of PKB in 
NFAT regulation has not been directly been looked at there is evidence that 
expression of an active mutant of PKB in T cells of transgenic mice promotes T 
cell mediated inflammatory immune responses (418). Additionally PKB can 
substitute for CD28 co-stimulation of IL-2 and IFNy gene transcription although 
the later response may rely on PKB-NFicB/Rel family transcription factors and 
not NFAT (419, 420). PKB does not mediate all CD28 functions but NFkB 
control of IL-2 and IFNy genes by antigen receptors and CD28 is controlled 
synergistically by PKB and PKCs (420, 421). The actual substrates for PKB in 
NFkB regulation in lymphocytes are not known.
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1.7.2 Forkhead transcription factors
PKB phosphorylation and regulation of the FOXO transcription factors is an 
evolutionarily conserved pathway. The FOXO family of transcription factors 
includes: FOXOIa (FKHR), F0X03a (FKHR.L1) and F0X04 (AFX) (422, 423). 
PKB phosphorylation of FKHR, FKHRL and AFX promotes their export from the 
nucleus to the cytoplasm where they can form a complex with 14-3-3 proteins, 
which retains them in the cytoplasm away from target gene promoters. Thus the 
model for PKB/FOXO regulation of gene expression is that in quiescent cells 
FOXO proteins are in the nucleus where they induce transcription of genes 
encoding pro-apoptotic proteins such as the Bcl-2 family member Bim and Fas 
ligand. FOXO proteins also induce transcription of cell cycle inhibitors such as 
p27Kip1 (424) (422, 425) PKB mediated nuclear export of FOXO transcription 
factors prevents their transcriptional activity and is associated with increased cell 
survival and cell cycle progression (424).
Recent insights about the importance of FOXO transcription factors for 
lymphocytes has come from studies of mice lacking F0X03a (FKHRL1), the 
predominant forkhead protein expressed in peripheral lymphoid organs. These 
mice develop spontaneous lymphoproliferation and a complex organ 
inflammation disease that correlates with deregulated apoptosis in T cells. The 
result is hyper activated helper T cells, which proliferate rapidly and produce 
excess Th1 and Th2 cytokines (426).
1.7.3 PKB and cell survival
One of the most highly publicised functions of PKB is in cell survival (427-430). 
Most of the work ascribing the anti-apoptotic function to PKB has been in
48
fibroblasts and epithelial cells. In these cells PKB mediated prevention of cell 
death has been linked to the phosphorylation and inactivation of proapopotic 
protein Bad. PKB has also been linked to suppression of Fas-mediated cell 
death (431). Most of the work defining PKB as a survival factor has been worked 
out in epithelial cells although Craig Thompson’s lab has shown that IL-3 
induction of PKB activity is linked to survival in pre-B cells (432). In the pre B cell 
model PKB regulation of glucose metabolism via regulation of glucose 
transporters is a key survival signal (433).
There is thus a model whereby the ability of PI3K/PKB to control lymphocyte 
survival is mediated by PKB control of glucose metabolism (434-436).
A role for PKB in regulating glucose metabolism in T cells has also been 
proposed in the context of CD28 signal transduction (437). There is some 
evidence that T cells from transgenic mice expressing constitutively active PKB 
under control of a T cell specific promoter show enhanced survival and have 
enhanced rates of glycolysis (436, 438). However, PI3K inhibitors preventing 
PKB activity cause T cells to arrest in GO/early G1 of the cell cycle without 
apparent loss of cell viability (357). Similarly other studies do not see a 
correlation between PKB activation and cell survival in haematopoietic cells 
(439) (440). Thus, it would seem that Akt/PKB is not an essential regulator of 
cell survival in T cells. Moreover it is likely that Pl(3,4,5)P3 binding to proteins 
other than PKB is important in T cells. For example active PKB mutants cannot 
substitute for yc cytokine signalling during thymocyte development whereas loss 
of the inositol phosphatase PTEN which causes accumulation of PI(3,4,5)P3 
does rescue thymic developmental defects in yc null mice (371).
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The mechanism by which yc cytokines regulate cell survival not fully been 
worked out. It has been shown that IL-2 inhibits expression of the pro-apoptotic 
molecule BAD but induces expression of anti-apoptotic molecules Bcl-2 and Bcl- 
XL (428, 441-444) but PKB may not be the sole regulator of these responses.
1.7.4 PKB substrate TSC: a link to protein synthesis and 
nutrient sensing
Tuberous sclerosis factors TSC1 (harmartin) and TSC2 (tuberin) form an 
inhibitory heterodimer complex known to be instrumental in regulating cell size 
and proliferation (445-448). These proteins form an evolutionarily conserved link 
between PKB and the nutrient-sensitive (mammalian target of rapamycin) 
mTOR pathway (reviewed in (449)). Akt/PKB phosphorylates TSC2 on Ser939 
and Thr1462; additional phosphorylation sites include Ser981, Thr993, Ser1130, 
Ser1132, and Thr1162 (450-453). Growth factor induced TSC2 phosphorylation 
is sensitive to PI3K inhibitors wortmannin and LY294002 (450, 451, 453) and 
can be induced by expression of constitutively active PI3K or Akt/PKB (451,
454). TSC2 phosphorylation by PKB is functionally important for the activation of 
the ribosomal S6 kinase 1 (S6K1) by mTOR kinases (see below for further 
discussion (450)).
1.8 mTOR
Signal transduction by PKB is linked to the TOR kinases (also known as FRAP,
RAFT, or RAPT). These are large, evolutionarily conserved serine/threonine
kinases, related to PI3Ks, that play a central role in integrating signals from
nutrients (amino acids and energy) and growth factors (in higher eukaryotes) to
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regulate cell growth and cell cycle progression (reviewed in (455)). mTOR 
stands for mammalian target of rapamycin, as the TOR kinases were discovered 
from studies of the mechanism of action of the immunosuppressant rapamycin. 
Rapamycin is a natural compound used in the clinic as an immunosuppressant 
for organ transplant patients and was first described as an immunosuppressive 
drug that blocked IL-2 induced proliferation. Rapamycin binds to cellular peptidyl 
propyl cis/trans isomerases, known as FK506-binding proteins (FKBPs)(456- 
461). Rapamycin binds to FKBP12 forming the active drug-protein complex 
necessary for the immunosuppressive effect of rapamycin in T cells (462-464).
In mammalian cells mTOR phosphorylates and regulates two proteins, the 
ribosomal S6 Kinases that control ribosome biogenesis and 4E-BP1 (also 
known as PHAS-1) a repressor of translation initiation factor elF4E. Non- 
phosphorylated 4E-BP1 binds and inhibits elF4E. When 4E-BP1 is activated by 
mTOR/PI3K mediated phosphorylation it disassociates from elF4E and allows it 
to bind other initiation complex proteins promoting translation initiation (465- 
467).
The 40s ribosomal S6 kinases (S6Ks) are the most well defined substrates of 
mTOR and were the first identified cellular targets for inhibition by rapamycin 
(456, 461, 468-472). The function of S6Ks was initially discovered by 
experiments showing that rapamycin suppressed the serum induced 
translational up regulation of a family of mRNAs containing a polypyrimidine 
tract at the 5’ end (5’-terminal oligopyrimidine [5’ TOP] mRNAs) (473-475). 
These mRNAs code for transcriptional apparatus such as ribosomal proteins 
and elongation factors (476) (reviewed in (477)). In mammals two S6K isoforms 
have been identified, S6K1 and S6K2. The role of S6K1 as a regulator of
cellular growth has been clearly illustrated by gene deletion studies in mice 
where the deletion of S6K1 is not lethal but results in mice with a 20% smaller 
body size at birth (478). S6K1-/-S6K2-/- mice are perinatally lethal (479). The 
regulation of S6K1 is complex involving multiple phosphorylation events (399, 
480-482) and reviewed in (483). Crucial events include PDK1 mediated 
phosphorylation of threonine 229, which lies in the activation loop of the kinase 
domain (399, 484) and TOR phosphorylation of Thr229, Thr389 (485). The 
precise sequence of these phosphorylations is not known but the ability of TOR 
to phosphorylate S6Ks is regulated by cellular amino acid concentration (486- 
488). It is not known how mTOR senses amino acid levels but several models 
have been proposed: mTOR may sense charging or aminoacylated tRNA (486) 
or are regulated directly by amino acids, their metabolites or amino acid 
activated second messengers (489). Other key facts about the activation of 
S6Ks are that it requires activation of PI3K/PKB. Moreover, the effects of PKB 
on S6K are mediated by TSC2 (452, 490) and involve the GTPase Rheb. TSC2 
acts as a GTPase-activating protein (GAP) towards Rheb and stimulates 
conversion of this GTPase from an active GTP-bound form to an inactive GDP- 
bound state. TSC2 inactivates Rheb, which results in the down regulation of 
TOR (491-494). PKB phosphorylation of TSC2 blocks its action as a Rheb GAP 
and promotes the accumulation of active GTP loaded Rheb which then activates 
mTOR.
1.8.1 Two mTOR pathways: Raptor and Rictor
The nutrient-sensitive mTOR complex required for downstream signalling is a 
complex of TOR and an adapter known as raptor although the mechanism is still
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under debate (495, 496)(reviewed in (468)). GpL is thought to bind and stimulate 
the ability of mTOR to auto-phosphorylate (497-501). However, it has recently 
been shown that mTOR is also part of a distinct complex defined by the novel 
protein rictor (rapamycin-insensitive companion of TOR).
Rictor was identified through homology to yeast proteins known to be part of a 
rapamycin-insensitive TOR complex that does not contain raptor and signals in 
yeast to the actin cytoskeleton through Protein Kinase C 1 (PKC1) (502). 
Congruently, the rictor-containing mTOR complex contains GpL not raptor. This 
complex doesn’t regulate S6K1 phosphorylation nor does it bind to FKBP12- 
rapamycin rather the rictor-mTOR complex modulates the phosphorylation of 
the actin cytoskeleton (503). For example HeLa cells deficient or knocked down 
for rictor display a perturbed morphology with actin formations differential to 
those seen in control cells (503). The rictor-mTOR complex is not sensitive to 
rapamycin but the PI3K inhibitor LY294002 seems to effect rictor-mTOR 
function suggesting this complex mediates functions assigned to PI3K.
The function of rictor-mTOR complexes in T cells is totally unexplored although 
recent data from David Sabatini’s lab has shown that rictor-mTOR is necessary 
for the phosphorylation of Ser473 on Akt/PKB in an LY294002 and wortmannin 
sensitive manor (400), and facilitates PDK1 phosphorylation of Thr308. Hence 
yc cytokines may regulate PKB via the rictor-mTOR complex.
The importance of the raptor/TOR complex T cells can be inferred from the 
immunosuppressive effects of rapamycin which can inhibit the ability of IL-2 to 
regulate T cell size and cell cycle progression (357, 360, 389, 504). There are 
conflicting reports on how T cells respond to rapamycin. For example Breslin et
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al suggest that IL-2 regulated expression of D type cyclins is sensitive to 
rapamycin and PI3K inhibitor LY294002 (352, 505). In contrast, Terada et al 
suggest that rapamycin down regulates S6K1 but does not inhibit T cell cycle 
progression in T cells already cycling as a result of IL-2 stimulation (506). It has 
also been reported that different yc cytokines show differential sensitivity to 
rapamycin e.g. IL-15 induced T cell proliferation is also more sensitive to 
inhibition of mTOR function by rapamycin than IL-2 responses (507).
One explanation for reported discrepancies in the sensitivity of T cell responses 
to rapamycin has recently been reported by Craig Thompson’s lab who 
identified the Pirn kinases as being able to substitute for rapamycin sensitive 
signalling pathways to control lymphocyte growth and survival. Pirn kinases are 
a family of proto-oncogenes encoding a distinct class of serine/threonine 
kinases consisting of Pim1, Pim2 and Pim3.
It is known that IL-2 induces expression of Pirn 1 (205). Mice deficient in Pirn 1,
2 and 3 mice are viable and fertile but show a dramatic loss in body size and 
have severely impaired responses to growth factors in haematopoietic cell 
populations (508). Thus it is clear that Pirn kinases are important to growth 
factor signalling. The relevance of Pim1 for yc signalling is demonstrated by 
studies of Pim1 transgenic mice (509-511). Where ectopic expression of Pim1 
as a transgene can rescue the thymocyte developmental defects seen in IL-7-/- 
or yc-/- deficient mice (511).
Thompson and colleagues have recently probed cytokine signalling in Pim1/2 
deficient mice and observed that T cell survival is rapamycin sensitive in their 
absence but rapamycin resistant when they are present. Pirn kinases thus seem
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to compensate for rapamycin independent regulation of T cell functions (512, 
513).
1.8.2 Regulation of T cell growth
Analysis of the mechanism of action of rapamycin and work on Pirn kinases has 
revealed the importance of changes in T cell metabolism for immune responses 
(434, 514-516). During an immune response, small metabolically inactive naive 
T cells must rapidly increase basal glucose metabolism and rates of protein 
synthesis to satisfy the biosynthetic demands associated with execution of 
effector function (434, 517). Accordingly, the transcriptional response of effector 
T cells includes up regulation of genes encoding ribosomal components so that 
there is a coordinate and matched increase in cytokine gene expression and 
protein synthesis capacity (518). Reinforcement of the idea that immune 
responses are dependent on the ability of T cells to modulate their metabolism 
stems from work on the co-stimulatory molecule CD28 that regulates glucose 
metabolism during the primary response of T cells to antigen (437). It has also 
been recognised that the importance of Rel/NFicB transcription factors for T cell 
immune responses in part reflects their role in the regulation of T cell size (519).
The differentiation of antigen activated T cells to mature effectors takes several 
days and, as discussed, yc cytokines play a key role. These cytokines, 
presumably, need to maintain high rates of cell metabolism for a prolonged 
period to sustain the T cell differentiation process. Different yc cytokines all 
control distinct aspects of T cell differentiation, suggesting that they may differ in 
molecular responses induced within T cells (129, 133, 200, 227, 520-524).
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However, analysis of cytokine signalling has focused on immediate biochemical 
and transcriptional programs where there is a commonality in the responses 
induced by yc cytokines and does not explain their unique functions (205, 206,
525).
One unexplored area of yc cytokine signal transduction is how cytokines 
compare in their effects on basic processes of cell growth. The question of how 
T cell cytokines regulate T cell growth is important because even if different 
cytokines can induce a common genetic program, differences in how they 
modify protein synthesis and cellular energy metabolism will influence how this 
genetic program is executed. Hence the term mitogen or growth factor, are 
frequently used interchangeably to describe yc cytokines but they are not 
synonymous. A growth factor is a molecule that regulates cell metabolism, 
protein synthesis and cell mass, whereas a mitogen controls cell division and 
proliferation. These are not the same processes nor are growth and cell division 
necessarily directly coordinated in eukaryotic cells (526-528). There is some 
information about how cytokines act as metabolic regulators for T cells; IL-7 
regulates glucose metabolism in naive T cells (435). Moreover, IL-2, the first 
cytokine shown to drive mitosis in activated T cells, was originally called T cell 
growth factor because of its ability to simultaneously induce cell cycle 
progression and induce an increase in cell size (529). As discussed, the 
mitogenic role of IL-2 can be supplanted by other yc cytokines (128) but IL-2 has
essential non redundant functions in vivo for the efficient production of effector 
cytotoxic T cells, for sustaining T cell expansion and induction of tolerance (129- 
134).
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The molecular basis for this unique signalling capacity of IL-2 is not known but 
one possibility is that it is due to the actions of IL-2 as a growth factor rather 
than its role as a mitogen. Support for this hypothesis stems from reports that 
other cytokines known to control T cell proliferation may not be as potent growth 
factors as IL-2. For example, IL-7 is very important for the survival of naive 
CD8+ T cells but these survive as small cells not large lymphoblasts. Moreover, 
antigen primed T lymphoblasts cultured in IL-7 rapidly regain a small cell 
phenotype compared to large IL-2 blasts (229).
Similarly, IL-15 is equal to IL-2 in it's capacity to promote mitogenesis and clonal 
expansion of antigen primed CD8+ effector T cells in vitro but IL-15 maintained 
CD8+ T cells are decreased in cell size compared to IL-2 lymphoblasts (48, 51, 
229). IL-15 induced T cell proliferation is also more sensitive to inhibition of 
mTOR function by rapamycin than IL-2 responses (507); a further indication that 
these cytokines may not be equivalent in terms of protein synthesis. The 
possibility that yc cytokines are not equivalent growth factors for T cells affords 
the insight that understanding the biochemistry of cell growth control in 
lymphocytes will be the key to understanding the unique actions of different 
members of the yc cytokine family.
1.9 Thesis aims
The object of the present thesis was to explore the ability of yc cytokines to 
regulate T cell growth. The main focus of the present study was to compare the 
actions of IL-2 and IL-15 on protein synthesis and cell growth of antigen 
activated CD8+ T cells. The choice of this model is based on previous 
observations that IL-2 and IL-15 are equivalent mitogens for these cells in vitro
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but differentially regulate T cell size: antigen primed CD8+ T cells cultured in the 
presence of IL-2 differentiate into large cytotoxic effector T cells whereas T cells 
maintained with IL-15 do not and rather develop into small cells with a 
phenotype reminiscent of CD8+ memory T cells (48, 51). The present study 
explores the signalling pathways used by IL-2 and IL-15 to control T cell protein 
synthesis and reveals the basis for the differential size response of T cells to 
these cytokines.
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Chapter 2
Methods and Materials
2.1 P14 LCMV TCR Transgenic Mice
P14 TCR transgenic Mice (530) were bred and maintained in the Cancer 
Research UK Biological Resources Unit and the Wellcome Trust Biocentre, 
University of Dundee Transgenic animal unit in compliance with UK Home Office 
Animals (Scientific Procedures) Act 1986 guidelines.
2.1.1 LCMV specific peptide
The P14 TCR recognises LCMV gp(33-41) (KAVYNFATM) in the context of H- 
2Db (531). This peptide was synthesised and purified in the Cancer Research 
UK protein production laboratory.
2.1.2 Mice typing by flow cytometry
Tail blood from P14 TCR transgenic mice was screened by flow cytometry for T 
cell expression of TCR Vp8, Va2, T cell specific CD3 antigen and co-receptors 
CD4 and CD8. 50pil of blood was transferred into FACS tubes and the red blood 
cells lysed with 300jxl of ACK lysis buffer (see cell culture) for 10 min at room 
temperature or until the solution is clear. The cells were washed in FACS buffer 
(see flow cytometry) and stained using saturating concentrations of anti-Vp8,
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anti-Va2, anti-CD3, anti-CD4 and anti-CD8 antibodies. Expression of the 
transgenic TCR V(38:Va2 and CD4:CD8 T cell ratios were determined by 
CellQuest software (Beckton Dickinson).
2.2 Cell culture and organ preparation
2.2.1 Isolation and Preparation of Lymphoid Organs
Spleens and Lymph nodes were obtained by dissection from 1-3 month old 
mice. Tissue was disaggregated using a 2|WI mesh cell strainer to obtain a 
single cell suspension. Splenocytes were treated with ACK lysis buffer for 
erythrocyte lysis and washed thoroughly. Cell numbers were adjusted according 
to subsequent application (1-10 x 106 cells/mL).
2.2.2 In vitro T cell activation and cell culture
Murine T cell blasts were made from splenocyte and lymph node cell 
suspensions, adjusted to 5x106 cells/ml, and cultured in RPMI/DMEM, 10%FBS 
(heat inactivated), pME 50pM and penicillin/streptomycin. The cells were 
stimulated with soluble LCMV specific peptide gp33-41 (1uM) or 2C11 (1- 
5^g/ml) antibody (Cancer Research UK hybridoma unit) for 48hours, washed 
and resupsened in 20ng/mL of cytokine (IL-2, IL-15, IL-4, and IL-7), unless 
indicated differently, or medium only as a control. Where indicated the cells 
were incubated in specified concentrations of a kinase inhibitor.
To inhibit PI3K LY294002 (Promega) or wortmannin (Sigma) was added to cell 
cultures at a final concentration of 10piM and 100nM respectively.
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To inhibit mTOR rapamycin was added to cell cultures at a final concentration of 
20nM.
2.2.3 Live cell imaging for microscopy
T cell blasts were adjusted to 4x106 cells/ml in RPMI-1640, 10% FBS, 50^M 
2ME, penicillin/streptomycin and added to a glass bottomed Matex dish (Matex) 
previously coated with murine ICAM-1 5ng/ml in PBS, for one hour at 37°C. 
Cells were left to adhere in serum free medium for 30 min at 37°C and imaged 
in RPMI-1640, 10% FBS, 50^M 2ME, and penicillin/streptomycin.
Images were taken in a 37°C humidified environmental chamber provided with 
5% CO2 in balanced air. Specimens were analysed with a Carl Zeiss LSM510 
confocal imaging system (Zeiss, Jena, Germany) equipped with a 63x NA 1.4 
plan apochromat lens.
Recombinant Mouse ICAM-1/Fc Chimera (R&D Systems)
2.2.4 Cell Culture Reagents and Solutions 
Reagents
Recombinant human IL-2 (Proleukin, Chiron.B.V, Netherlands)
Recombinant Human IL-15 and IL-7, mouse IL-4 (Peprotech)
Recombinant Mouse ICAM-1 /Fc Chimera (R&D Systems) 
2-Betamercaptoethanol (p-ME) (Sigma)
LY294002 [2-(4-Morpholinyl)-8-phenyl-4/-/-1-benzopyran-4-one], use at 10|iM 
Wortmannin use at 100nM (Calbiochem)
Rapamycin 20mM (Calbiochem)
DMSO sterile (sigma)
Roswell Park Memorial Institute-1640 (RPMI 1640) (GIBCO)
Dulbecco’s modified Eagle’s medium (DMEM) (GIBCO)
Foetal Bovine Serum FBS (GIBCO) EU approved 
Penicillin/Streptomycin (Pen/Strep) (GIBCO)
Media and Solutions
RPMI-1640 + L-Glutamine (GIBCO) 10% FBS (heat Inactivated), 50^iM 2ME, 
Pen/Strep (GIBCO)
DMEM + L-Glutamine (GIBCO) 10% FBS (heat Inactivated), 50|nM 2ME, 
Pen/Strep (GIBCO)
ACK Ivsis buffer: 4.145g NH4CI, 0.5g KHCO3 and 0.018g EDTA pH 7.8
2.3 Flow Cytometry
2.3.1 Live cell staining
Antibodies were obtained conjugated to fluorescent isothiocyanate (FITC), 
phycoerythrin (PE) and Allophycocyanin (APC). Prior to staining, Fc Receptors 
were blocked with an anti-FcyRII blocking monoclonal antibody. Cells were then 
stained at 1 x106 cells per sample with previously titrated concentrations of 
antibody at 4°C for 20 minutes or 1hour in FACS buffer. Cells were washed and 
resuspended in FACS buffer prior to acquisition on a FACS Calibur (Becton 
Dickinson, San Jose, CA). Events were collected, stored ungated and data 
analysed with CellQuest (Becton Dickinson) software. Live cells were gated 
according to their forward light scatter (FSC) and side light scatter (SSC) 
profiles.
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2.3.2 Live cell cycle analysis
Cellular DNA content was assayed on live cells using 7 amino actinomycin D 
(7AAD) staining. Cells (1 x 106 cells) were incubated for 1 hr at 37°C in 7AAD 
staining solution. Data was analyzed by FACS using CellQuest software and 
doublet discrimination.
7AAD staining solution: 20 g/ml 7AAD, 25 g/ml Rnase and 0.03% saponin in 
PBS/20 mM HEPES (pH 7.4)12% heat-inactivated FBS
Cellular DNA content was assayed using the dye Ho33342 (Hoescht). 20ug/mL 
of Hoescht dye was added to 106 cells and incubated at 37°C for 50 minutes 
before being analysed by flow cytometry using the LSR (Becton Dickinson) flow 
cytometer UV laser.
2.3.3 Phospho-S6 ribosomal protein intracellular staining
After indicated treatment at 37°C, T cells were washed and fixed in 0.5% PFA 
for 15 minutes at 37°C, washed twice in PBS and followed by a preciselO 
minute incubation in 90% methanol at -20°C. Cells were washed twice in PBS 
and blocked in BSA buffer for 10 minutes at room temperature. Cells were 
incubated with 1:100 dilution of primary anti-phospho-S6 (cat # 2211; Cell 
Signalling Technologies) in BSA buffer for 30 minutes at room temperature, 
washed once with BSA buffer and incubated with 1 pig of FITC conjugated 
donkey anti-rabbit IgG (cat# 711-096-152; Jackson ImmunoResearch) for 30 
minutes at room temperature in the dark. Samples were washed in BSA buffer 
and analysed on a FACSCalibur (Becton Dickinson).
Pharmacological stimulation for 30 minutes at 37°C with 2pg/mL of the phorbol 
ester, phorbol 12.13 dibutyrate (PdBu), was used to stimulate all available S6 
protein in the cell and served as a positive control. Pharmacological inhibitor 
treatments were undertaken for 30 minutes at 37°C before fixation. (Rapamycin 
20nM, LY294002 10pM, Wortmannin 100nM) 
anti-phospho-S6 (cat #2211; Cell Signalling Technologies)
2.3.4 Flow Cytometry Reagents and Solutions 
Reagents
7aad (7 amino actinomycin D) (Sigma)
Hoechst 33342 10mg/ml, Molecular probes 
Methanol
Paraformaldehyde (Sigma)
PBS tablets (Sigma)
BSA (Sigma)
Solutions
FACS Buffer: DMEM/RPMI minus Phenol Red, 25mM Hepes (pH7.4 with HCI), 
1% FBS
0.5% PFA: 0.05q Paraformaldehyde, 10mL PBS (tablets, Sigma)
BSA Buffer: 0.5% BSA, PBS (tablets, Sigma)
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Antibodies
Directly conjugated: R-Phycoerythrin (RT-PE); Fluorescein Isothiocyanate 
(FITC); Allophycocyanin (APC) Pharmingen.
Vp8
CD3e
CD4(L3T4)
CD8a (Ly-2)
CD25 (IL-2 Receptor a chain, p55) 
CD44 (Pgp-1, Ly-24)
CD45R/B220
CD62L (L-selectin, LECAM-1, Ly-22) 
CD71 (Transferrin Receptor)
CD90.2 (Thy 1.2)
4G3 Common y chain (IL-2R, IL-4R, 
IL-7R Shared y subunit)
Va2
Directly conjugated: Tri-colour (TC) 
CD4
Clone F23.1, isotype: Mouse lgG2a, k
Clone 145-2C11, isotype: Armenian 
Hamster lgG1, k .
Clone RM4-5, isotype: Rat lgG2a, k , 
Clone GK1.5, isotype: Rat lgG2b, k .
Clone 53-6.7, isotype: Rat lgG2a, k .
Clone 3C7, isotype: Rat (lewis) lgG2b,K
Clone IM7, isotype: Rat lgG2b,K
Clone RA3-6B2, isotype: Rat lgG2a,K
Clone MEL-14, isotype: Rat (Fischer) 
lgG2a,K
Clone C2 (C2F2), isotype: Rat lgG1,K 
Clone 53-2.1, isotype: Rat lgG2a, k  
Clone 4G3, isotype 
Clone B20.1, isotype: Rat lgG2a, X
Caltag
Clone RM4-5, isotype: Rat lgG2a
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CD8a Clone 5H10, isotype: Rat lgG2b
Purified Antibodies 
CD16/CD32 ( Fey 11 I/I I Receptor)
CD98(4F2)
IL-15Ra isotype: Goat lgG1 ( R&D Systems)
Anti-phospho-S6 Rabbit antibody (cat # 2211; Cell
Signalling Technologies)
FITC conjugated Secondary Antibodies (Jackson ImmunoResearch) 
AffiniPure F(ab’)2 Fragment Donkey: Anti-Rabbit IgG (H+L)
AffiniPure Mouse: Anti-Goat IgG (H+L)
AffiniPure Goat: Anti-Rat IgG (H+L)
Monoclonal Antibody (Mouse BD Fc 
Block) clone: 2.4G2, isotype lgG2b,K
Clone H202-141, isotype: Rat lgG2a, k
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2.4 Proliferation assay
Antigen activated P14 LCMV CD8+ T cells were re-suspended in 
RPM11640/10% FBS/50pM pME, and seeded in triplicate at 5 x 104-1 x 105 
cells/well in 96 well-flat bottom microtitre plates. Cells were cultured with 
medium alone or different concentrations of cytokines. Cells were then cultured 
at 37°C in a 5% CO2 humidified incubator for the indicated time. Prior to 
harvesting 1pCi of tritiated (3H) thymidine (Amersham, UK) was added to each 
well and cells incubated for a further 2 hours. Cells were harvested using 
vacuum aspiration onto glass matrix filters. Incorporated radioactivity was 
quantified using a p-microplate scintillation counter (532).
[methyl-3 H] Thymidine (Amersham Biosciences)
2.5 Amino acid uptake into cells
The rate of amino acid uptake into antigen activated P14 LCMV CD8+ T cells in 
response to different concentrations of cytokine or medium alone was assayed 
by re-suspending antigen activated CD8+ T cells in RPMI 1640/10% FBS/50pM 
pME, and seeding in triplicate at 1 x 105 cells/well in 96 well-flat bottom 
microtitre plates. Cells were then cultured at 37°C in a 5% CO2 humidified 
incubator for the indicated time. Tritiated (3H) amino acid mix (Amersham, UK), 
2pCi/well, was added to the plates for 6 hours prior to harvesting by vacuum 
aspiration on glass matrix filters. Incorporated radioactivity was quantified using 
a p-microplate scintillation counter.
[3 H] Amino Acid mix, Amersham Biosciences
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2.6 Amino acid incorporation into cellular protein
To determine amino acid incorporation into cellular protein, antigen stimulated 
P14 LCMV CD8+ T cells were cultured in cytokine or medium alone at 5 x 106 
cells/mL and cells collected at indicated time points. Cells were pulsed for 12 
hours, prior to harvest, with 5pCi/mL tritiated (3H) amino acid mix (Amersham, 
UK). Cell pellets (5 x 106 cell/pellet) were harvested in triplicate and lysed in 1mL 
of lysis buffer (see western blotting) for 20 min at 4 °C. The resulting extract was 
centrifuged at 15,000g for 30 minutes at 4 °C and resultant supernatant 
transferred to fresh eppendorff tubes and protein was precipitated by adding an 
equal volume of 70% acetone and incubating for 1hour at 20 °C. The solution 
was then centrifuged at 15,000g for 30 minutes supernatant removed and pellet 
dissolved in water before incorporated radioactivity was quantified on a |3 
scintillation counter.
2.7 Protein Content
Cell pellets containing 1 x 106 cells were lysed at 4 °C in 1mL of lysis buffer (see 
western blotting) and cell debris removed by centrifugation at 15,000g for 30 
minutes and aliqots taken for analysis of protein concentration. Protein content 
was quantified using the BIORad protein assay dye reagent, referenced against 
a standard curve of BSA. All samples were analysed by spectrophotometry 
(Jenway 6405 UVA/is) at 595nm.
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2.8 Cytotoxic assay
The JAM test was performed to evaluate the antigen specificity of LCMV TCR 
positive effector and central memory CD8+ T cells (533). Peptide-pulsed EL4 
thymoma cells were used as target/stimulator cells. Antigen loaded and [H3] 
thymidine-labelled EL4 cells were generated by pre-incubation with 5 [iCi/mL 
[H3] Thymidine and 1-1 OpM of peptide overnight at 37°C. Peptides used in this 
assay included the LCMV gp(33-41) (KAVYNFATM) in the context of H-2Db 
(530), recognising the P14 TCR, and the control peptide, influenza np(60-68) 
(ASNENMDAM) in the context of H-2Db (534), specific for the F5 TCR. These 
peptides were synthesised and purified in the Cancer Research UK Protein 
Production Laboratory.
The T cell blasts of interest were added to a 96 flat-bottomed plate and diluted in 
a series from 1 x 106/well to 1 x 104/well and the labelled ‘target’ EL4 cells were 
added to the plate (1 x 104 cells/well or 1 x 105cells/mL). Target cells and 
effector cells were co-incubated for 2 h at 37°C, plates were harvested by 
vacuum aspiration on glass matrix filters. Incorporated radioactivity was 
quantified using a p-microplate scintillation counter (LKB Wallac 1205 
Betaplate® liquid Scintilation counter).
The percent specific lysis of target cells by CTL was calculated, E = 
Experimentally retained DNA in the presence of killers (in CPM), S = retained 
DNA in the absence of killers (spontaneous) incorporated, so % specific killing 
= [(S-E)/ S]X100.
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2.9 Western Blotting
Cell pellets containing 10 x 106 cells were harvested and lysed in 1mL lysis 
buffer for 30 min at 4°C, centrifuged at 15,000rpm for 30 min at 4 °C and 
transferred to clean eppendorff tubes. [Protein content was determined at this 
stage using the BIORad protein assay dye reagent, referenced against a 
standard curve of BSA]. Resultant supernatant was incubated with equal 
volumes of -20°C 70% acetone, to precipitate protein, for 1 hour at -20 °C and 
centrifuged at 15,000g for 30 minutes at 4 °C. Pelleted protein samples were air 
dried, boiled at 100°C in reducing sample buffer for 5 minutes and shaken 
overnight to dissolve protein. All samples were boiled for 5 minutes prior to 
being separated on 7.5% SDS-PAGE gels at a concentration of 10O^ig/sample 
for 12 hours at 50 volts. Protein was transferred by electro-blotting onto 
polyvinylidene diflouride (PVDF) membranes over 4 hours at 0.4mA (70volts) in 
10mM CAPS transfer buffer at pH 11. Efficiency of protein transfer was checked 
using ponceau S staining of the membrane and washed off with PBS-Tween20. 
Membranes were then blocked in 4% milk solution (dried fat free milk powder 
dissolved in PBS-Tween20) and incubated overnight at 4°C with primary 
antisera diluted in BSA blotting solution. Membranes were washed (3x 10 
minutes) in PBS-Tween20 and incubated with HRP linked secondary antibody 
diluted in milk blotting solution at room temperature for one hour. The 
membrane was washed (3x 10 minutes) in PBS-Tween20 and protein visualised 
using chemiluminessence detection (ECL, Amersham).
Subsequent primary antibodies were applied to membranes after stripping in 
buffer at 56°C for 30 minutes, washing in PBS-Tween20 and blocking in 4% milk 
solution.
2.9.1 Western Blotting Solutions and Reagents
Solutions
Stock 2x cell Ivsis buffer: 100mM HEPES @ pH 7.4, 300mM NaCI, 20mM NaF, 
20nM lodoacetamide (IAA)
Working cell Ivsis buffer: 5mL 2x stock lysis buffer, 10% NP40, 100mM PMSF in 
ethanol, 1 complete protease inhibitor cocktail tablet (Sigma), add water to 
10mL volume.
i.e. (Final 10mL solution; 50mM HEPES at pH 7.4, 150mM NaCI, 10mM NaF, 
10mM iodoacetamide (IAA), 1% NP-40, 1mM phenyl methyl sulphonyl fluoride 
(PMSF), 1 protease inhibitor cocktail tablet, EDTA-free (Pancreas extract 0.02, 
chymotrypsin 0.02, thermolysin 0.02, trypsin 0.02, papain 0.33: mg/ml, Roche)). 
Reducing sample buffer: (3x) 30% (w/v) glycerol, 187.5mM Tris at pH 6.8, 10% 
(v/v) 2-Betamercaptoethanol (p-ME), 9% (w/v) SDS 
Transfer buffer: 10mM CAPS buffer at pH 11.
Running buffer: 25mM Tris pH 8.3, 190mM glycine, 3.5mM SDS.
Stripping buffer: 36.5mL H2O, 10mL 10% SDS, 3.125mLTris 1M pH 6.8, 
0.347mL p-ME.
PBS-Tween: PBS, 0.05% Tween20
Membrane blocking: 4% fat free milk powder (Marvel) dissolved in PBS, 0.05% 
Tween20 (PBS-T)
Primary Antibody BSA blotting: 1% BSA, 0.05% azide in PBS-Tween20 
Secondary detection antibody milk blotting: 4% fat free milk powder (Marvel) 
dissolved in PBS-Tween20
SDS-page acrylamide protein gels
7.5%: 11.2mL 1M Tris at pH8.8, 11.2mL water, 7.5mL Protogel, 300[aL 20% 
(w/v) SDS; 100pL 10% (w/v) ammonium persulphate (APS), 20^L 
tetramethylethylenediamine (TEMED) for cross-linking acrylamide (30mL total 
volume)
4% stacking gel: 2.5mL1M Tris at pH6.8, 13.3mL water, 4mL Protogel, 200piL 
20% (w/v) SDS; 10OpiL 10% (w/v) ammonium persulphate (APS), 20^L 
tetramethylethylenediamine (TEMED) for cross-linking acrylamide (10mL total 
volume). Cast over the resolving gel to aid sample resolution.
Reagents
Ponceau S (Sigma)
BioRad Dye reagent concentrate, BioRad.
Rainbow coloured protein molecular weight markers, Amersham Biosciences 
Protease Inhibitor Cocktail Tablets Complete, Mini, EDTA-free (Pancreas 
extract, Chymotrypsin, Thermolysin (Metalloprotease) and Trypsin 0.02mg/mL, 
Papain 0.33mg/mL), Roche 
ECL (Pharmingen)
Temed (tetramethylethylenediamine) (Sigma)
Ammonium persulfate (Aps) (Sigma)
Azide (Sigma)
2-Betamercaptoethanol (|3-ME)
SDS (Sigma)
TRIS-HCI (Sigma)
Polyvinylidene diflouride (PVDF) membranes. (immobilon-P, Millipore)
3mm blotting paper
Antibodies 
Primary antibodies
2d4-perf anti-Perforin mouse antibody (Diluted 1:1000)
(A gift from Gillian Griffiths (535))
U5 monoclonal rabbit antibody against the BCR domain of
p85a (536) 1.7ug/mL
Peroxidase Conjugated Secondary Antibodies
All were diluted 1:5000
Anti-Rabbit HRP Amersham biotech
Anti-Mouse HRP Amersham biotech
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Chapter 3
IL-2 and IL-15 differentially control T cell 
differentiation in vitro.
3.1 Introduction
The initial aim of this thesis was to develop an in vitro model to compare the 
action of IL-2 and IL-15. These cytokines activate cells via a receptor that 
shares a common y chain (yc, IL2Ryc, CD132), the IL-2R|3 chain (CD122) but 
has unique a chain subunits (IL-2Ra and IL-15Ra). IL-2 and IL-15 are known to 
initially induce common transcriptional programs (205) yet ultimately induce 
different biological outcomes in vivo. To fully understand these differences, 
extensive analysis of how these two cytokines signal in T cells is needed. It is 
very difficult to isolate sufficient primary activated T cells ex wVo for biochemical 
analysis and accordingly an in vitro model in needed to generate sufficient 
numbers of pure T cells for functional studies. In this respect, it has been known 
for more than 20 years that antigen activated T cells can be clonally expanded 
in vitro in the presence of IL-2 to generate cytotoxic effector T cells. More 
recently, the laboratory of Von Andrian described a similar in vitro model for the 
generation of effector memory-like CD8+ T cells (48, 49). This model uses a 
transgenic (Tg) mouse P14 (specific for the lymphocytic choriomeningitis virus 
glycoprotein peptide gp(33-41)). This protocol involves antigen activation of
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mice splenocytes in vitro to generate a large population of antigen activated 
CD8+ T cells. These cells were then cultured in IL-2 or IL-15. The antigen 
activated T cells cultured in IL-2 differentiated into classical effector CTL. In 
contrast T cells cultured in IL-15 differentiate to cells that resemble memory T 
cells in that they are small and very inefficient cytotoxic effectors. However, 
these antigen activated T cells cultured in vitro with IL-15 could mediate rapid 
recall responses to antigen in vitro and in vivo e.g. the cells could survive for 10 
weeks in a host after adoptive transfer and were capable of mounting a 
secondary immune response in response to antigen re-challenge that was as 
potent as an in vivo stimulated endogenous memory response (48). One other 
way in which the in vitro IL-15 cultured T cells resemble memory T cells is in 
their chemotactic and homing responses. Von Adrian’s lab initially analysed 
antigen activated T cells cultured in IL-15 or IL-2 in vitro transwell assays. These 
data showed antigen activated cells cultured in IL-2 and IL-15 were able to 
migrate toward inflammatory cytokines in vitro, however cells cultured in IL-15 
were more efficient at homing towards lymph node tropic chemokines 
suggesting that both cells cultured with IL-2 or IL-15 were able to home to sites 
of infection, but only cells cultured in IL-15 were responsive to lymph node 
homing chemokines (48). This in vitro data was supported by a set of in vivo 
adoptive transfer experiments where they found that naive, cells cultured in IL- 
15 and, to a lesser extent, cells cultured in IL-2 homed to the T cells areas of the 
spleen. However, only naive and cell cultured in IL-15 homed to the lymph 
nodes and Peyer’s patches (51, 537). Again, using intravital microscopy, 
showed antigen activated T cells cultured in IL-15 not IL-2 could roll and arrest 
in high endothelial venules (HEVs) (51). Also in a peritonitis inflammation model
they were able to show that both cells cultured in IL-2 and IL-15 were efficient at 
homing to sites of inflammation when compared to naive cells, although cells 
cultured in IL-2 were significantly more efficient (51). Thus, in vitro and in vivo 
migration data confirmed that these in vitro generated antigen activated T cells 
cultured in IL-15 home avidly to lymphoid organs and moderately to sites of 
inflammation, reminiscent of central memory T cells, and cells cultured in IL-2 
accumulated in inflamed tissue but excluded from most lymphoid organs, typical 
of effector CTL (51). We considered that the system described by Von Andrian 
would be good for the comparisons of IL-2 and IL-15 signal transduction. It could 
also allow for the generation of unlimited numbers of memory CD8+ T cells and 
thus possibly open up an avenue for biochemical analysis of cytokine signalling 
in memory verse naive T cells. Accordingly an initial objective of the thesis was 
to evaluate the potential of antigen primed T cells derived from the P14 LCMV 
TCR transgenic model to be used as a system for the comparison of IL-2 and IL- 
15 signal transduction.
3.2 Results
3.2.1 IL-2 and IL-15 are potent T cell mitogens but have a
differential effect on T morphology and function.
In the present study we used primary CD8+ T cells derived from the P14 LCMV 
TCR transgenic model where peripheral CD8+ T cells express a Va2A/|38.1 
TCR specific for the immunodominant lymphocytic choriomeningitis virus 
(LCMV) glycoprotein peptide, gp33-41 (KAVYNFATM), presented in the context 
of H-2Db class I MHC molecule (538). The efficient positive selection of the P14 
TCR cause P14 mice to have an abnormal ratio of CD4:CD8 T cells were CD8 T
cells out number CD4 by 4:1, differing from a normal T cell distribution of 1:2 
(CD8:CD4).
Lymph node and spleen were taken from the P14 mice, mashed through a cell 
strainer, re-suspended vigorously for 30 seconds in ACK buffer, to lyse the 
majority of unwanted red blood cells, and washed twice in RPMI supplemented 
with 10% FBS, 2ME and penicillin/streptomycin. The cell suspension 
(comprising of T cells and antigen presenting cells) was fixed to 5 x 106cells/mL 
and treated with 1 i^M of the LCMV gp33-41 specific peptide (hereafter referred 
to as gp33 peptide) for two days, in the absence of exogenous cytokine. This 
initial stimulation specifically activates the high number of CD8+ T cells in the 
population which express the LCMV Va2A/p8.1 TCR and allowed us to generate 
a large pool of activated CD8+ T lymphoblasts. After the two-day activation 
these cells were washed free of antigen and cultured in medium alone or in the 
presence of a cytokine as indicated. The data in Fig 3.2.1a compares the effect 
of different concentrations of IL-2 or IL-15 on the ability of these antigen 
activated T cells to incorporate tritiated thymidine into newly synthesised DNA. 
Thymidine incorporation measures rates of DNA synthesis and hence allows a 
comparison of the frequency of cells in the S phase of the cell cycle. The data in 
Fig 3.2.1a show that both IL-2 and IL-15 are comparable in their ability to initiate 
DNA synthesis in antigen primed CD8+ T cells. A true comprehensive measure 
of proliferation is to count cell number increases over time in culture. The data in 
Fig 3.2.1b show cell counts taken over 10 days in culture with 20ng/mL of IL-2 
or IL-15. A parallel cell count of the same activated T cells cultured without 
exogenous growth factors was the medium only control. Antigen activated T 
cells cultured without exogenous growth factors (medium only control) do not
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Figure 3.2.1: IL-2 and IL-15 are equivalent mitogens for antigen 
primed CD8+ T cells, a) Data show representative graphs of 
tritiated (3H) thymidine incorporation into 2 day antigen activated 
P14 LCMV CD8+ T cells cultured with indicated concentration of IL- 
2 (CD8IL'2), IL-15 (CD8IL*15) or in medium alone for 24 hours, b) Cell 
numbers of antigen activated CD8+ T proliferating exponentially 
with 20ng/mL IL-2 (CD8IL'2), IL-15 (CD8IL'1S) or medium only. These 
experiments were repeated 10-15 times.
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proliferate and become apoptotic over 48-96hours and die. However, when 
antigen activated CD8+ T cells are cultured in the presence of mitogens IL-2 
and IL-15 it is obvious that both cytokines have a potent ability to drive mitosis, 
as indicated by a rapid phase of clonal expansion resulting in an approximate 
200-400 fold increase in cell number over a period of 6 days (Fig 3.2.1b). At 
later time points in the growth curve, day 6 in culture and onwards, the 
responses to the two cytokines diverge. T cells maintained in IL-2 stop 
proliferating and decline in number, due to an increase in the rate of apoptosis 
versus cell division. Although, in contrast, T cells maintained for a similar time in 
IL-15 no longer proliferate but support cell numbers in culture and are able to 
survive for prolonged periods of time (Fig 3.2.1b).
It has been described that antigen activated T cells cultured in the presence of 
IL-2 differentiate to effector cytotoxic T cells whereas cells cultured in IL-15 
resemble central memory T cells (48, 49). The morphology of effector cells 
verses memory T cells is quite different. Accordingly, we have compared the 
morphology and phenotype of the antigen activated CD8+ T cells cultured in IL- 
2 (CD8il'2) or IL-15 (CD8IL'15). In Fig 3.2.2 the cell morphology of antigen 
activated CD8+ T cells cultured in IL-2 or IL-15 was visualised using live cell 
imaging with low light video microscopy. Activated CD8+ T cells cultured in the 
presence of 20ng/mL of IL-2 or IL-15 for 5 days were allowed to spread and 
migrate over glass bottomed matex dishes, coated with 5ng/mL recombinant 
mouse ICAM-1 for 1 hour at 37°C, in a humidified chamber for 30 minutes. The 
data show representative still images of these cells and reveal that antigen
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Figure 3.2.2: Antigen primed T cells cultured in 
IL-2 are bigger than T cells cultured in IL-15.
Live cell images of antigen primed P14 CD8+ T 
cells cultured for 5 days in either 20ng/mL IL-2 
(CD8IL'2) or IL-15 (CD8IL15). Cells were allowed to 
settle on glass coated with 5ng/mL of recombinant 
mouse ICAM-1.
activated CD8+ T cells cultured in IL-2 (CD8IL'2) appear larger and more 
granular than cells cultured in IL-15 (CD8IL'15) (Fig 3.2.2).
The phenotype of CD8 IL'2 verses CD8 IL'15 cells was assessed by also flow 
cytometric analysis of cell surface markers commonly used to distinguish 
effector and memory CD8+ T cells.
Data in Fig 3.2.3 show CD8IL‘2 cells were CD25High, CD44High and CD62LLow, 
where cells maintained in IL-15 for the same time were CD25Low, CD44High and 
CD62LHigh.
Activated CD8+ T cells are defined by their role as effector or cytotoxic killer T 
cells. Analysis of cytotoxic activity associated with the two phenotypically distinct 
populations CD8IL'2 and CD8IL'15was undertaken as it has been previously noted 
that effector memory CD8+ T cells (CD811'15) loose their immediate killing 
capacity (41). Moreover, Von Andrian and colleges described CD8IL‘2 cells as 
having high cytotoxic activity and CD8IL'15 cells as having very little cytotoxic 
potential (48).
One important molecule in cytotoxic T cells is the pore forming protein perforin. 
The data in Fig 3.2.4a shows western blot analysis of perforin expression in 
CD8IL'2 verses CD8IL'15 cells. The data show that CD8IL'2 cells have high levels of 
perforin whereas CD8 IL‘15 cells have almost undetectable levels of perforin. 
These data are consistent with the described inability of IL-15 to support the 
differentiation of effector CTL. In additional experiments the cytotoxic potential of 
T cells cultured in IL-2 or IL-15 was compared using a method whereby the 
ability of T cells to kill a specific number of target cells was measured by the 
release of a radiolabel from a target cell indicating T cell lysis or death (533).
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Target cells used were a thymoma cell line, EL4, which can present antigens 
the context
CD44 CD25 CD62L
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Figure 3.2.3: Antigen primed T cells cultured in IL-2 or IL-15 
for 5 days express different surface markers when compared 
to ex vivo naive CD8+ T cells.
Representative FACS histograms indicating surface levels of 
markers: CD44, CD25 (IL-2Ra chain) and CD62L (L-Selectin), on 
2 day gp33 LCMV antigen primed P14 CD8+ T cells cultured for 
5 days in either 20ng/mL IL-2 (CD8IL‘2) or 20ng/mL IL-15 (CD8IL- 
15). Ex vivo CD8+ T cells were isolated by flow cytometric cell 
sorting. Staining profiles repeated over 10 times.
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Figure 3.2.4: IL-2 drives differentiation of effector CTL; IL-15 
does not. a) Antigen primed P14 CD8+ T cells cultured for 5 days 
in either 20ng/mL IL-2 (CD8IL2) or IL-15 (CD8,L‘15) were lysed and 
immunoblotted for perforin with antibody HuPerf-2d4. p-Acitn was 
used as a loading control, b) Cytotoxicity assay: target EL4 cells 
were labelled with 3H-thymidine. T cell lysis of target cells was 
measured by the loss of tritium.
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of H-2Db class I MHC molecules. The target cells used were cultured at 5 x 106 
cells/mL in fully complemented RPMI 1640 and incubated with 5|^Ci/mL of 
tritiated thymidine (3H-thymidine) for 12-20 hours at 37°C. This labelling process 
allows the incorporation of a maximal concentration of tritium into cellular DNA.
If effector CTL kills these cells then specific lysis will occur that is mediated via a 
caspase-mediated pathway of induced apoptosis. This causes DNA degradation 
and the associated release of tritiated thymidine by the target cell. In the 
experiment shown in Fig 3.2.4b the cytolytic activity of antigen activated P14 
CD8+ T cells cultured in the presence of IL-2 for 5 days (CD8IL'2) was compared 
to that of antigen primed T cells cultured in the presence of IL-15 for 5 days 
(CD8il'15). The target cells in this assay were loaded with the gp33 LCMV 
specific peptide. Fig 3.2.4b indicates that CD8IL'2 cells were potent cytotoxic 
killer T cells whereas cells cultured in the presence of IL-15 for 5 days (CD8IL'15) 
showed reduced capacity to specifically lyse target cells at low T cell: target 
ratios when compared to the CD8IL'2 cells. Von Andrian and colleagues 
described the IL-15 cultured cells as having very little cytotoxic potential (48). 
The present data show that although they lack detectable levels of perforin 
protein at this time point (Fig 3.2.4a) they do have some potential to kill albeit 
less efficiently that IL-2 cultured cells. This residual killing capacity could be 
mediated by Fas ligand as flow cytometric analysis revealed that EL4 target 
cells express Fas antigen (data not shown).
3.3 Discussion
The main aim of the experiments in this chapter was to assess the reliability
of system described by Manjunath et al (48) for the generation of large numbers
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of central memory-like and effector CD8+ T cells in vitro for the biochemical 
analysis of IL-2 and IL-15 signalling in murine T cells. The data confirm that IL-2 
and IL-15 are equivalent mitogens for antigen activated T cells, both able to 
drive DNA synthesis and clonal expansion at a similar rate. However, IL-2 and 
IL-15 differ in their control of antigen activated T cell morphology or 
differentiation: CD8,L'2 cells remained large, expressed activation markers and 
developed efficient CTL activity, whereas CD8IL'15 became smaller, expressed 
memory associated cell surface markers and were unable to develop an equally 
efficient CTL activity as CD8IL'2 cells. Von Andrian and colleges have suggested 
that antigen activated T cells generated in the in vitro cultures with IL-15 are 
equivalent to memory T cells (48, 51). We did not perform in vivo adoptive 
transfer experiments to compare the immune recall or homing potential of CD8IL 
2 versus CD8IL'15 cells to assess this in more detail. However, in vitro transwell 
assays indicated that CD8IL'15 T cells preferentially migrated toward lymphoid- 
tissue chemokines 6Ckine/CCL21 (SLC) and MIP-3p/CCL19 (ELC) whereas 
CD8,l'2 T cells did not (data not shown). This is consistent with the phenotype 
described by the studies of the Von Andrian group (51). Whether CD8IL'15 cells 
are a true model for memory T cells is questionable not least because it is 
based on exposing cells to a single cytokine, which will not reproduce what 
happens in vivo. As well, the concentration of exogenous cytokine added might 
not represent that encountered in vivo. Other factors to consider are the 
presence of other immune cells in vivo, inflammation status of host skewing 
normal cytokine milieu and migratory status of cells determining what tissue 
cytokine environment is encountered.
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There is also one very important factor to consider about the use of soluble IL- 
15 to study IL-15 signal transduction. In vivo studies of IL-15Ra-/- and IL-15-/- 
mouse models have indicated that IL-15 is presented in Trans by the IL-15R 
alpha chain to (3/yc complexes on T cells thus inducing a signal as an 
immobilised molecule (207). It is thought that T cells responding to IL-15 do not 
need to express the IL-15 receptor alpha chain, rather, this chain is required to 
be expressed by cells producing IL-15 (thought to be dendritic cells, 
macrophages or bone marrow stromal cells) (523). This is unlike IL-2 which is 
known to be secreted as a soluble factor and then signal when it binds to 
IL2Ra/p/yc complexes. Trans IL-15 signalling means that cells producing IL-15 
in response to inflammatory cytokines such as IFN-y secrete the soluble form of 
the cytokine which then associates with the high affinity IL-15Ra chain, 
signalling is said to occur when the IL-15 presenting cell meets the IL2/15(3:IL- 
2/15yc complex, on an antigen activated T cell (207-209) (210, 212). This theory 
of Trans presentation has been eluded to by Singer and colleges where they 
propose that homeostatic cytokines such as IL-7 and IL-15, which are of low 
abundance and expressed in a wide variety of tissues, maybe sequestered on 
the surface of these tissues to stop cells consuming all available cytokine, as in 
the case of activated T cell production and consumption of IL-2 for reaction 
limiting purposes, and allow for maximum exposure for homeostatic survival of 
immune cells in peripheral and lymphoid tissues (539).
Most studies of IL-15 signal transduction to date have used soluble IL-15 and 
there has been no comparison of soluble IL-15 versus presented (bound) IL-15 
signalling. Presentation of IL-15 in Trans to antigen activated T cells could be 
achieved using an epithelial or bone marrow stromal cells as a feeder cell line,
where cells would be stably transfected with cDNA of IL-15 protein (secreted 
form); IL-15 + IL-15Ra chain; and IL-15Ra only. These cells could then be co­
cultured with P14 LCMV antigen activated CD8+ T cells, which would then be 
analysed for changes in cell morphology and compared to those seen in the 
soluble IL-15 system. This would be a very complicated system for biochemical 
analysis.
Although there might be concerns about the physiological relevance of soluble 
IL-15 there is a need to be pragmatic. It should also be noted that the framework 
for antigen receptor signal transduction has been based on the use of soluble 
TCR antibodies, yet has provided invaluable data that has been subsequently 
verified in physiological models. Moreover, although there may be some 
concerns about studying the effects of soluble IL-15 in terms of the physiology of 
T cell immune responses it should be noted that affects of soluble IL-15 is used 
clinically for immunotherapy.
Numerous T cell cytokines have now been used in the clinic to expand or 
activate immune cells or their progenitors, including IL-2 which was approved by 
the FDA in 1992 and has been used in the clinic regularly in the treatment of 
cancers, graft rejection/tolerance and immunosuppressive diseases. IL-2 has 
not really fulfilled its promise as an immunotherapeutic agent mostly due to 
problems with toxicity and unpleasant side effects. IL-15 appears to be less 
toxic and is increasingly being considered for clinical use as an alternative to IL- 
2, because of its shared functions with IL-2, and is now being considered to 
have a promising future in the treatment of cancer (203). IL-15 remains in pre- 
clinical trials but seems a likely candidate for exogenous cytokine therapy 
potentially expanding NK cells, memory CD8+ T cells and some non-classical T
cell lineages. Its value resides in its ability to drive T cell proliferative expansion 
but not differentiation. Thus IL-15 is being pursued for use in pathogen-targeted 
vaccination and against cancer antigens (reviewed in (540, 541)) and in the 
treatment of HIV (542, 543). Hence, comparisons of how soluble/exogenous IL- 
2 and IL-15 effect T cell physiology and biochemistry will be extremely useful in 
understanding how these cytokines might be used in the clinic.
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Chapter 4
IL-2 and IL-15 differentially regulate T cell growth
4.1 Introduction
One unexplored area of cytokine signal transduction is how cytokines compare 
in their effects on basic processes of cell growth. The question of how T cell 
cytokines regulate T cell growth is important because even if different cytokines 
can induce a common genetic program, differences in how they modify protein 
synthesis and cellular energy metabolism will influence how this genetic 
program is executed. The morphology of T cells cultured in IL-2 versus IL-15 
shown in the previous chapter indicates that IL-2 and IL-15 may not be 
equivalent growth factors for T cells. This possibility deserves further 
investigation because understanding the biochemistry of cell growth control in 
lymphocytes is essential to understanding the unique actions of different 
members of the yc cytokine family. It is usually assumed that mitogens are 
growth factors. The basic fact that cell division or proliferation is intrinsically 
linked to cell growth seems inevitable, as dividing cells need to generate new 
membrane. However, it is not clear how cells co-ordinate growth and division to 
maintain cell size (526, 544-546). There are two basic camps of thought 1. Cell 
division and growth are intrinsically linked where cell growth is rate limiting for 
cell division and driven by intersecting and common signalling pathways (547- 
549). 2. Cell growth can be regulated independently to division by initiating
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independent signalling cascades in response to common or independent factors 
growth (526-528). It is clear that cell size at division may be variable and seems 
to depend on the type of extracellular signals present to whether cell cycle or 
cell growth or both are maintained, also supported by data in this thesis. 
Although, a cell needs to reach a minimum size before it can divide. The 
threshold of size required for division may vary between cell types and rely on 
quantity and quality of external stimuli. Data from Martin Raff and Sally Leevers 
support this theory of cell division independent cell growth (526-528). The term 
cell growth has been used broadly to describe processes of cell division, 
development and differentiation. However, in this thesis T cell growth is 
describing the function of T cell volume, mass or size and is aimed at 
addressing links between this phenomenon and metabolic processes triggered 
within the cell as a consequence of yc cytokine signal transduction. Accordingly, 
in the present chapter the actions of IL-2 and IL-15 on protein synthesis and cell 
growth of antigen activated CD8+ T cells are compared.
4.2 Results
4.2.1 Cytokines IL-2 and IL-15 differentially regulate cell size 
and protein content.
To measure the change in cell size from naive T cell to antigen activated T cell 
we made use of the flow cytometer where light is passed through a single cell 
suspension and diffracted in response to the size and density, granularity, of a 
cell passing through the light. This gives a relative measurement of cell size. 
These measurements are expressed as forward light scatter and side light 
scatter (FSC, SSC) which can be shown in the form of a two dimensional dot
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plot or one dimensional histogram. The data in Fig 4.2.1a & 4.2.1b show both 
dot plots and histograms of the FSC and SSC of ex vivo CD8+ naive P14 TCR 
transgenic T cells and antigen activated P14 CD8+ T cells which have been 
stimulated for two days with the gp33 LCMV specific peptide in the presence of 
resident splenic antigen presenting cells. Data shows naive T cells have a low 
FSC and SSC indicating that they are very small. In contrast, CD8+ T cells 
activated with specific antigen have both a high FSC and SSC indicating that 
these cells are dramatically larger and more granular. Flow cytometric analysis 
of forward and side scatter profiles is a method to estimate cell size and 
granularity but cannot distinguish whether cells have changed cell volume due 
to osmotic swelling or whether cells have changed protein content. The size 
difference between quiescent CD8+ T cells and antigen activated T cells is 
further defined in Fig 4.2.1c where naive and activated T cells were analysed 
for cellular protein content. These data clearly show that antigen activation of 
naive T cells leads to a dramatic increase in the cellular protein content, 
approximately 4-fold, and cell size. Images of antigen activated T cells cultured 
in IL-2 indicate that they are large granular cells whereas cells cultured in IL-15 
appear much smaller and more similar in size to naive T cells.
To further examine the impact of IL-2 and IL-15 on T cell size, ex vivo P14 CD8+ 
T cells were activated with gp33 peptide for 2 days washed and cultured in the 
presence of 20ng/mL of IL-2 (CD8IL'2) or IL-15 (CD8IL'15), after 5 days in culture 
cell size and protein content was assessed. Data in Fig 4.2.2a shows cytometric 
dot plots of FSC/SSC analysis of CD8IL_2and CD8IL'15at day 5 in culture. The 
FSC/SSC profile of CD8IL"2 effector T cells is indicative of large granular cells, 
comparable to the initial population of antigen activated T lymphoblasts.
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Figure 4.2.1: Antigen stimulation of naive CD8+ T cells 
dramatically increases cell size and protein synthesis, a, b)
FACS dot plots and histograms (FSC/SSC) of naive P14 LCMV 
CD8+ T cells or gp33 antigen activated P14 LCMV CD8+ T 
cells.c) Cellular protein content (mg) of 106 naive P14 CD8+ T 
cells or antigen activated P14 CD8+ T cells.
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Figure 4.2.2: Cytokines IL-2 and IL-15 
differentially regulate cell size and protein 
content. Naive CD8+ P14 T cells were activated with 
gp33 peptide for 2 days, washed and cultured in the 
presence of 20ng/mL of IL-2 (CD8 IL'2) or IL-15 (CD8 
IL'15). a) Representative FACS dot plots show 
FSC/SSC and b) protein concentration of CD8 IL_2 
and CD8 IL'15 cells after 5 days in culture.
However, the FSC/SSC profile of activated T cells maintained over the same 
time period with IL-15 is consistent with these cells being markedly smaller (Fig 
4.2.2a). The differences in cell size indicated by flow cytometric analysis is also 
reflected in the protein content of these two populations: antigen primed cells 
cultured in IL-2 have a higher protein content than cells cultured in IL-15 (Fig 
4.2.2b). Thus IL-2 is more efficient at maintaining cell size and protein content 
than IL-15. Data for cells cultured in medium alone was not included as these 
cells are all dead after 5 days in culture.
Data in Fig 4.2.3 show the kinetics with which antigen primed T cells cultured in 
IL-15 reduce in size. The first point to note is that antigen activated T 
lymphoblasts cultured in medium alone, in the absence of exogenous antigen or 
cytokine stimuli, rapidly reduce cell size as judged by reductions in their flow 
cytometric forward and side light scatter (FSC, SSC) profiles (Fig 4.2.3a). These 
changes are seen within 24-48 hours of antigen deprivation. After 48 hours 
these cells are mostly dead or dying and hence are eliminated from the 72hour 
time point (Fig 4.2.3a). When antigen activated T cells are cultured with IL-2 
they maintain cell size (Fig 4.2.3a). In contrast, antigen activated T cells cultured 
in IL-15 decrease in size however, this is not an immediate response as with 
complete withdrawal of cytokine but occurs over a period of 48-72 hours (Fig 
4.2.3a). Data in Fig 4.2.3b show the protein content of CD8IL'2and CD8IL'15over 
24-72hrs and reveal that T cells cultured without exogenous cytokine rapidly 
reduce their protein content over a 48hour period. It is not possible to look at the 
72 hour time point as the cells are all dead by this time (Fig 4.2.3b). The first 
indication that IL-15 cannot maintain the morphology of antigen activated T cells
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Figure 4.2.3: Kinetics of the change in ceil size of antigen 
activated CD8+ T cells cultured with IL-2 or IL-15. a) FACS 
histograms of FSC/SSC. b) Protein content of antigen activated 
P14 LCMV CD8+ T cells cultured for 24, 48 and 72 hours in 
medium alone, 20ng/mL of IL-2 (CD8IL_2) or IL-15 (CD8IL'15).
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can be judged initially by comparing the side scatter profiles of T cells 
maintained in IL-2 or IL-15 for 24hours; at this point the cells have similar protein 
content. Differences in the protein content of antigen pulsed T cells cultured with 
IL-2 versus IL-15 are slower to emerge but T cells exposed to IL-15 for 48-72 
hours have both reduced forward and side light scatter and approximately 1.5-2- 
fold lower protein content than T cells maintained for an equivalent time in IL-2 
(Fig 4.2.3a & 4.2.3b).
The changes to the morphology and cell size of antigen activated T cells 
cultured in IL-15 are not permanent but reversible: IL-15 maintained T cells 
switched to a culture containing IL-2 rapidly increase in cell size (Fig 4.2.4). 
Suggesting IL-2 as a dominant cytokine in controlling and promoting high rates 
of T cell growth.
4.2.2 IL-2 and IL-15 differentially regulate protein synthesis.
The ability of IL-2 but not IL-15 to maintain the protein content of antigen 
activated T cells could be explained if these two cytokines could differentially 
regulate endogenous amino acid levels and the de novo synthesis of protein. 
Initially, the ability of cytokine treated T cells to incorporate a tritium labelled 
amino acid mixture was used to quantify rates of amino acid uptake. The data in 
Fig 4.2.5a show that an antigen activated T cell cannot autonomously maintain 
amino acid uptake when cultured in medium alone, indicated at the zero 
cytokine point which coincides with a very low level of tritiated (3H) amino acid 
incorporation. Both IL-2 and IL-15 are able to induce a dose dependent increase 
in amino acid uptake in antigen activated T cells but strikingly, amino acid 
uptake in IL-2 activated cells is approximately double that of cells stimulated
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Figure 4.2.4: CD8 IL'15 cultured T cells increase size in response 
to IL-2. FACS dot plots (FSC,SSC) profiles of antigen activated P14 
CD8+ T cells cultured in 20ng/mL of IL-15 (CD8IL_15) for 3 days. After 
3 days CD81L"15 cells were washed and re-cultured in 20ng/mL of IL- 
2 (CD8IL'15 + IL-2) or 20ng/mL IL-15 (CD8IL'15) for a further 48 hours. 
As a comparison, FSC/SSC profiles of activated T cells maintained 
in IL-2 (CD8,L_2) for the entire 5 days is shown.
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Figure 4.2.5: IL-2 and IL-15 regulate amino acid uptake into 
cells and incorporation into cellular proteins, a) Tritiated amino 
acid (3H-aa) uptake by 1 x 105 antigen activated P14 CD8+ T cells 
cultured for 24hours with the indicated concentrations of IL-2 or IL- 
15. b) Incorporation of tritiated amino acid (3H-aa) into cellular 
protein of 5 x 106 antigen activated P14 CD8+ T cells cultured for 
24hours in 20ng/mL IL-2, 20ng/mL IL-15 or medium alone, c) 
FACS histograms of Hoescht stained cellular DNA content of 
activated P14 CD8+ T cells cultured for 24hours with medium, 
20ng/mL IL-2 or 20ng/mL IL-15.
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with IL-15 (Fig 4.2.5a). The differences between IL-2 and IL-15 in amino acid 
uptake translated into differences in protein synthesis. Hence, when the ability of 
these two cytokines to induce incorporation of tritiated (3H) amino acids into 
cellular proteins was compared, the IL-2 response markedly exceeded the IL-15 
response (Fig 4.2.5b).
The regulation of cell size is thought to be tightly coordinated to the regulation of 
cell cycle progression in mammalian cells. However, differences between IL-2 
and IL-15 in their ability to regulate cell size of antigen primed T cells is not due 
to differences in their abilities to initiate DNA synthesis and cell cycle 
progression. Hence, IL-2 and IL-15 are equivalent mitogens and the frequency 
of cells in the proliferative (S and G2) phases of the cell cycle is comparable in 
IL-2 and IL-15 cultured antigen primed T cells (23% and 11% versus 23% and 
14% respectively) (Fig 4.2.5c).
4.2.3 IL-2 and IL-15 differentially regulate expression of 
transferrin receptors and amino acid transporters.
Mammalian cells have a broad range of mechanisms for the trans-membrane
transport of amino acids. In haematopoietic cell systems, CD98, a marker of
activated lymphocytes, is the common heavy chain subunit, which is thought to
support the formation of key amino acid transporters in these cells (432). The
data in Fig 4.2.6a show that antigen activated CD8+ T cells maintained in IL-2
have high levels of surface CD98 compared to cells cultured with no cytokine.
These data show that antigen activated T cells cannot autonomously maintain
surface levels of CD98. IL-15 is able to maintain some expression of CD98
when compared to the control cells cultured in medium alone. However, IL-15 is
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Figure 4.2.6: Expression levels of amino acid transporter 
CD98 (42F) and transferrin receptor CD71 on T cells 
cultured in IL-2 or IL-15. FACS histograms of the 
expression of a) an amino acid transporter subunit CD98 and 
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not as potent as IL-2 and the data in Fig 4.2.6a show that within 24hours of 
exposure to IL-15, CD98 levels are almost twofold lower than the levels seen in 
IL-2 maintained cells.
The uptake of amino acids is an energy dependent process and optimal growth 
responses in cytokine stimulated lymphocytes are associated with up regulation 
of transferrin receptors which deliver iron, a necessary cofactor for a number of 
critical metabolic reactions, to the cell interior. Antigen activated T cells 
maintained in IL-2 express high levels of transferrin receptor (CD71) but these 
decline rapidly if cells are cultured in medium alone (Fig 4.2.6b). The data show 
that levels of transferrin receptors in T cells maintained in IL-15 are markedly 
reduced compared to T cells cultured with IL-2 (Fig 4.2.6b). The level of 
transferrin receptor expression in a T cell cultured with IL-15 for 24 or 48hours is 
higher than in cells cultured with no exogenous cytokine but lower than in T cells 
cultured in the presence of IL-2 (Fig 4.2.6b). T cells cultured in IL-15 do not 
globally down regulate all surface receptors: levels of the common yc chain 
cytokine receptor subunit are higher in the presence of IL-15 or medium alone 
when compared to CD8+ T cells grown in the presence of IL-2 (Fig 4.2.6c).
4.3 Discussion
The object of the present study was to compare the role of cytokines as growth 
factors for T cells. IL-2 and IL-15 are equivalent mitogens for antigen stimulated 
CD8+ T cells but the present data show they are not equivalent growth factors 
and are strikingly distinct in their ability to control protein synthesis and T cell 
size. Antigen activated CD8+ T cells are stimulated by TCR and co stimulatory 
signals such as CD28 to become large blastoid cells approximately twice as big
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as naive T cells. Herein we show that such antigen induced blasts cannot 
autonomously maintain their size and are unable to maintain amino acid 
incorporation or de novo protein synthesis without exogenous cytokine 
stimulation. Both IL-2 and IL-15 are able to induce protein synthesis in antigen 
activated T cells, but protein synthesis rates in IL-2 activated cells are 
approximately two fold of those in IL-15 stimulated cells. The differential action 
of IL-2 and IL-15 on amino acid uptake and protein synthesis is associated with 
differences in the ability of these two cytokines to maintain surface levels of the 
transferrin receptor CD71 or the amino acid transporter subunit CD98. The 
difference in the ability of IL-2 and IL-15 to induce protein synthesis is 
approximately 2 fold, which may not seem like a huge difference, but IL-2 and 
IL-15 are potent and equivalent mitogens and a two fold difference in protein 
synthesis in rapidly dividing cells will quickly translate into a significant 
difference in the size of daughter cells and subsequent progeny.
Thus IL-2 is a strong stimulus for T cell growth whereas IL-15 is much weaker. 
The ability of IL-2 to induce cell growth was thought to be associated with its role 
as a mitogen. However the level of cell growth induced by IL-2 exceeds that 
required for mitosis, as judged by the ability of IL-15 to sustain mitosis and T cell 
clonal expansion without maintaining T cells at the same size as IL-2. Hence the 
potency of IL-2 as a growth factor may be more relevant to its ability to sustain 
synthesis and production of effector molecules in cytotoxic T cells. The 
differential effect of IL-2 and IL-15 on general protein synthesis may resolve the 
puzzle of how IL-2 and IL-15 differentially direct CD8+ T cell fate (51, 229), even 
though they initially activate common signal transduction pathways and induce 
very similar patterns of gene transcription (205, 206). The differentiation of
effector CTL takes several days and to sustain the production of cytokines or 
cytotoxic mediators, effector lymphocytes will need to maintain high rates of cell 
metabolism for a prolonged period. A sustained two fold difference in protein 
synthesis over a period of many hours or days would considerably diminish the 
ability of activated T cells to produce and secrete effector cytokines and 
chemokines with profound consequences for T cell differentiation. The power of 
IL-2 in terms of it's ability to induce protein synthesis could thus explain why it is 
required to sustain T cell expansion in vivo even though it is not essential to 
initiate T cell cycle progression (129, 529). Moreover, it also gives some insight 
as to why this cytokine may have a unique role in vivo as a regulator of 
peripheral immune homeostasis (132). In particular, the potency of IL-2 in terms 
of its ability to drive protein synthesis could explain why antigen stimulated T 
cells fail to secrete effector cytokines in the absence of IL-2 function even 
though they appear to undergo normal cell divisions (133).
In the immune system the adaptive CD8+ T cell response specifically seeks and 
destroys virally infected cells, this response if not controlled can continue and 
may eventually cause unwanted collateral damage, which can lead to the 
development of autoimmunity. IL-2 is associated with increased susceptibility of 
effector T cells to programmed cell death or apoptosis and this may be part of 
the key immunoregulatory role of IL-2 in vivo. The present results showing the 
potent growth stimulating ability of IL-2 compared to IL-15 may explain why this 
cytokine is associated with increased susceptibility of effector T cells to 
apoptosis. T cells exposed to IL-2 would thus expend high amounts of energy to 
maintain their effector status and this may lead to a state of metabolic 
exhaustion that promotes susceptibility to cell death. When comparing the
effects of IL-15 on CD8+ T cells it was surprising to find that even though this 
cytokine is an equivalent mitogen for T cells it is not as potent a growth factor as 
IL-2 in the fact that it cannot support massive cell size and protein synthesis. 
However, cells grown in IL-15 are able to divide at a similar rate to cells grown in 
IL-2 whilst maintaining a lower rate of protein synthesis. Proliferative expansion 
with IL-15 would thus be much less energy demanding than proliferative 
expansion with IL-2 and could explain why IL-15 does not promote T cell 
apoptosis in the same way that IL-2 does.
The object of the present study was to compare the role of cytokines as growth 
factors for T cells. IL-2 and IL-15 are equivalent mitogens for antigen stimulated 
CD8+ T cells but the present data show they are not equivalent growth factors 
and are strikingly distinct in their ability to control protein synthesis and T cell 
size. Antigen activated CD8+ T cells are stimulated by TCR and co stimulatory 
signals such as CD28 to become large blastoid cells approximately twice as big 
as naive T cells. The data show that such antigen induced blasts cannot 
autonomously maintain their size and are unable to maintain amino acid 
incorporation or de novo protein synthesis without exogenous cytokine 
stimulation (shown in medium only data). Both IL-2 and IL-15 are able to induce 
protein synthesis in antigen activated T cells, however, protein synthesis rates in 
IL-2 stimulated cells are approximately two fold of those in IL-15 stimulated 
cells. Hence even though the difference is small between the abilities of IL-2 and 
IL-15 to sustain protein synthesis, when taken into consideration with the fact 
that both IL-2 and IL-15 are equivalent mitogens, a two fold difference in protein 
synthesis in rapidly dividing cells will quickly translate into a significant 
difference in the size of subsequent daughter cells.
The initial differences in cell size, protein synthesis and amino acid uptake 
between antigen activated cells cultured in IL-2 and IL-15 within over 24-72 
hours could be associated with differences in the ability of these two cytokines 
to maintain surface levels of the transferrin receptor CD71 and the amino acid 
transporter subunit CD98. Transferrin receptors transport iron into the cell, which 
is an essential molecule in mediating cellular reactions.
Thus IL-2 seems to be a potent stimulus for T cell growth whereas IL-15 is much 
weaker in the context of regulating the availability of amino acids and iron to the 
cell. The ability of IL-2 to induce cell growth was thought to be associated with 
its role as a mitogen. However the level of cell growth induced by IL-2 seems to 
be in excess of that required for mitosis, as judged by the ability of IL-15 to 
sustain mitosis and T cell clonal expansion without maintaining T cells at the 
same size as IL-2. Hence the potency of IL-2 as a growth factor may be more 
relevant to its ability to sustain synthesis and production of effector molecules in 
cytotoxic T cells. The differential effect of IL-2 and IL-15 on general protein 
synthesis may resolve the puzzle of how IL-2 and IL-15 differentially direct CD8+ 
T cell fate (51, 229), even though they initially activate common signal 
transduction pathways and induce very similar patterns of gene transcription 
(205, 206).
The differentiation of effector CTL takes several days and to sustain the 
production of cytokines or cytotoxic mediators, effector lymphocytes will need to 
maintain high rates of cell metabolism for a prolonged period. A sustained two 
fold difference in protein synthesis over a period of many hours or days would 
considerably diminish the ability of activated T cells to produce and secrete 
effector cytokines and chemokines with profound consequences for T cell
differentiation. Hence, the essential need for IL-2 signalling in T cells may relate 
to it’s potent ability to induce protein synthesis, which is intrinsically required to 
sustain T cell expansion in vivo even though it is not essential to initiate T cell 
cycle progression (129, 529). Moreover, it also gives some insight as to why this 
cytokine may have a unique role in vivo as a regulator of peripheral immune 
homeostasis (132). In particular, the potent ability of IL-2 to drive protein 
synthesis could explain why antigen stimulated T cells fail to secrete effector 
cytokines in the absence of IL-2 function even though they appear to undergo 
normal cell divisions (132).
In summary, the present study demonstrates that cytokines that are equivalent 
mitogens can have different potency in terms of regulating T cell growth or 
protein synthesis. IL-2 and IL-15 have very different actions as inducers of 
protein synthesis and T cell growth although they are equivalent in their ability to 
drive T cell cycle progression.
The maximal level of protein synthesis induced by IL-2 is in excess of what is 
needed for T cell mitosis and may explain the unique non-redundant role for this 
cytokine in the mammalian immune response.
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Chapter 5
A mechanism of regulating T cell growth: 
PI3K inhibitor LY294002 effects cell size and 
protein synthesis in antigen activated T cells 
cultured with IL-2 and IL-15 by regulating nutrient
uptake.
5.1 Introduction
T cell growth is intrinsically linked to the ability of a cell to produce or synthesise 
protein, and it’s capacity to access sources of energy essential to cellular 
process from extracellular stores.
Previous data in this thesis suggests that antigen activated T cells can modulate 
their cell size or volume in response to growth factors IL-2 and IL-15 and that 
these processes are independently regulated from the cells ability to divide or 
proliferate. This distinction between T cell ‘growth’ and ‘proliferation’ challenges 
the current understanding of cell size regulation and presents the possibility that 
this process can be regulated independent from cell cycle and division in 
activated T cells. Thus, the aim of the present chapter was to explore signalling 
pathways involved in growth regulation mediated by IL-2 and IL-15.
One evolutionarily controlled pathway involved in cell growth regulation is 
mediated by the lipid product of class I phosphoinositide 3-kinases (PI3Ks),
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Phosphatidylinositol (3,4,5) triphosphate (PI(3,4,5)P3). For example, the 
activation of naive murine CD8+ T cells by antigen/MHC complexes on APC 
causes a sustained accumulation of PI(3,4,5)P3 and an increase in T cell size 
(32, 550). An inhibitor LY294002, which binds the ATP binding pocket of PI3K to 
block its catalytic activity prevents this accumulation of PI(3,4,5)P3 and prevents 
antigen induced blastogenesis (32).
Similarly, the ability of CD28 to induce glucose metabolism and an increase in 
growth of human T cells is blocked by PI3K inhibitors (437). There is also 
genetic evidence that PI3K effector pathways are important for the regulation of 
T cell mass: the deletion of PDK1 in T cell progenitors in the thymus causes a 
reduction in size (410). As well, the expression of a constitutively active mutant 
of PKB in T cell transgenic mice causes a modest increase in cell size of naive T 
cells (436). In this respect, it has been shown in pre B cells that a PI3K/PKB 
pathway regulates expression of CD98, an important subunit of amino acid 
transporters (432). In the previous chapter, we have shown that IL-2 and IL-15 
differ in their ability to regulate surface expression of CD98 in T cells. If PI3K 
regulation of CD98 expression also occurs in T cells then it would be predicted 
that PI3K would be an important regulator of cell growth in IL-2 or IL-15 
stimulated T cells.
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5.2 Results
5.2.1 Antigen activated T cells cultured with cytokines IL-2 and 
IL-15 can proliferate and are viable in the presence of PI3K 
inhibitor LY294002 for an extended period of time.
To dissect the role of PI3K in the regulation of cellular growth responses in 
antigen activated T cells responding to IL-2 and IL-15, experiments were 
conducted using the PI3K inhibitor LY294002. IL-2 and IL-15 are potent survival 
factors for antigen primed CD8+ T cells. PI3K has been shown to be important 
for IL-2 regulation of T cell cycle progression (505) and in many cell lineages, 
PI3K signals are known to be crucial in mediating cell survival responses. Thus, 
prior to looking at the effect of PI3K inhibitors on T cell size it was important to 
establish the effects of the PI3K inhibitor LY294002 on T cell proliferation, 
survival and viability.
Naive P14 LCMV splenic T cells were activated in the presence of 1 i^M gp33 
specific peptide for two days, washed free of exogenous antigen and 
subsequently cultured in medium only, 20ng/mL IL-2 or IL-15 plus or minus 
1CVM LY294002 for extended periods of time.
To assess effects of LY294002 on T cell proliferation, cell counts were taken at 
72hours of culture, using trypan blue viable dye (Fig 5.2.1a, 1c). These results 
show that LY294002 inhibits but does not abrogate IL-2 or IL-15 induced 
proliferation. T cells cultured in the presence of IL-2 and IL-15 proliferated at an 
approximate 2 fold higher rate than cells in the presence of LY294002, however, 
even though cells cultured in the presence LY294002 did have a reduced cell 
numbers the remaining cells were proliferating at a rate approximately five times
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Figure 5.2.1: Antigen activated T cells cultured in the presence 
of 20ng/mL IL-2 or IL-15 plus and minus 10pM LY294002 are 
viable and proliferate, a, c) Cell count of antigen activated P14 
CD8+ T cells cultured for 72hrs in medium only, 20ng/mL IL-2/IL- 
15 or IL-2/IL-15 + 10pM LY294002. b, d) Histograms indicating 
percentages of live and dead cells determined by 7AAD staining at 
48hours of these cultures.
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that of cells cultured without stimuli, or medium alone (Fig 5.2.1a, 1c). In further 
experiments flow cytometry was used to analyse cell death or viability of T cells 
cultured in the presence of the PI3K inhibitor. In these experiments the dye 
7AAD was used to quantify cell death, this dye is excluded from viable cells but 
absorbed by dead or dying cells. Fig 5.2.1b shows activated T cells cultured in 
the presence of 20ng/mL IL-2, 20ng/mL IL-2 plus 10^M LY294002 or in medium 
alone for 48hours. Cells cultured in IL-2 are 99% viable as compared to only 40- 
50% viability of cells cultured without cytokine. T cells cultured in the presence 
of IL-2 plus LY294002 were 87% viable. LY294002 thus has an impact on T cell 
viability but this is minor compared to the effects of removing IL-2 (Fig 5.2.1b). 
The data in Fig 5.2.1d show cell viability of activated T cells cultured in 20ng/mL 
IL-15, 20ng/mL IL-15 plus 10fiM LY294002 or in medium alone. CD8IL'15 cells 
were 94% viable whereas CD8IL'15 + LY294002 cultured cells were 75% viable 
compared to 54% viability in cells cultured in medium alone (Fig 5.2.1d). The 
inhibition of PI3K thus seems to have an impact on the viability of T cells 
cultured in IL-15 than IL-2 however, both IL-2 and IL-15 are able to induce 
substantial cell survival and some proliferation in the absence of PI3K activity.
5.2.2 PI3K inhibitor LY294002 mediates a reduction of cell size 
in antigen activated T cells cultured in either IL-2 or IL-15.
Flow cytometry was used to assess the effects of PI3K inhibitor LY294002 on 
activated T cell size. Forward and side scatter (FSC/SSC) dot plots and 
histograms indicate the relative size of gp33 peptide activated CD8+ P14 LCMV 
T cells cultured in IL-2 (Fig 5.2.2) or IL-15 (Fig 5.2.3) in the presence or 
absence of LY294002. The data in Fig 5.2.2 shows that the ability of IL-2 to
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Figure 5.2.2: Antigen activated T cells cultured in the 
presence of IL-2 + 10|xM LY294002 are smaller than T 
cells cultured in IL-2 alone. FACS dot plots and histograms 
show FSC/SSC profiles of antigen primed P14 CD8+ T cells 
maintained for 48 hours in medium, 20ng/mL IL-2 (CD8IL_2) or 
20ng/mL IL-2 (CD8IL-2) plus 10jiM LY294002 a PI3K inhibitor.
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Figure 5.2.3: Antigen activated T cells cultured in the 
presence of IL-15 + 10jiM LY294002 are slightly smaller 
than T cells cultured in IL-15 alone. FACS dot plots and 
histograms show FSC/SSC profiles of antigen primed P14 
CD8+ T cells maintained for 48 hours in medium, 20ng/mL 
IL-15 (CD8IL_15) or 20ng/mL IL-15 (CD8IL15) plus 10^iM 
LY294002 a PI3K inhibitor.
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regulate T cell size is LY294002 sensitive: IL-2 activated T cells treated with 
LY294002 are smaller than cells exposed to IL-2 alone. Fig 5.2.3 shows the 
same effect on cells cultured in IL-15 with or without LY294002 present, again 
suggesting CD8IL'15 cultured cells are also LY294002 sensitive in the context of 
cell size. These data suggest that PI3K may play a dominant role in the 
regulation of T cell size.
5.2.3 IL-2 and IL-15 regulation of protein synthesis and T cell 
growth is disrupted in the presence of LY294002.
T cell growth or T cell size is directly linked to the rate at which a cell can 
produce protein. To assess the role of PI3K in the ability of IL-2 and IL-15 to 
regulate protein synthesis, the impact of the PI3K inhibitor LY294002 on the 
ability of IL-2 and IL-15 to regulate protein synthesis was examined.
Data in Fig 5.2.4 show that LY294002 inhibited IL-2 induced amino acid 
incorporation into cellular protein and amino acid uptake into cells. Congruently, 
measuring cellular protein content also indicated that treatment with LY294002 
reduced the cells ability to synthesize protein by 1.5-2 fold (Fig 5.2.5).
Data in Fig 5.2.6 and Fig 5.2.7 show the effects of LY294002 on IL-15 induced 
amino acid uptake and protein content in activated T cells. Like IL-2, IL-15 
driven protein synthesis is restricted by inhibiting PI3K activity with LY294002 
(Fig 5.2.6, 7). Even though it is obvious that PI3K plays a role in mediating 
protein synthesis down stream of IL-2 and IL-15 in antigen activated T cells, it 
should also be noted that these cytokines still have a limited capacity to induce 
protein synthesis and cell growth in the presence of PI3K inhibitors. Where, 
amino acid uptake, incorporation into cellular protein and overall protein content
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Figure 5.2.4: Culturing antigen activated T cells in the 
presence of IL-2 + 10|xM LY294002 impedes the cells ability 
to synthesize protein when compared to cells cultured in IL- 
2 alone, a) Incorporation of tritiated amino acids (3H-aa) into 
precipitated cellular protein of antigen primed P14 CD8+T cells 
maintained for 48 hours in medium, 20ng/mL IL-2 or 20ng/mL 
IL-2 plus 10pM LY294002 a PI3K inhibitor (c.p.m x 106 cells), b) 
Percent maximum values of tritiated amino acid (3H-aa) uptake 
by antigen primed P14 LCMV CD8+ T cells maintained for 48 
hours in medium or the indicated concentration of IL-2 plus or 
minus 10fxM LY294002.
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LY294002 contain less protein. Antigen 
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Figure 5.2.6: Culturing antigen activated T cells in 
the presence of IL-15 + 10pM LY294002 effects 
protein synthesis when compared to cells 
cultured in IL-15 alone. Percent maximum values of 
tritiated amino acid (3H-aa) uptake by antigen primed 
P14 LCMV CD8+ T cells maintained for 48hours in 
medium or the indicated concentration of IL-15 plus 
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Figure 5.2.7: Antigen activated CD8+ T cells cultured 
with IL-15 in the presence of PI3K inhibitor 10^M 
LY294002 contain less protein. Antigen activated T cells 
cultured with 20ng/mL IL-15, 20ng/mL IL-15 + 10jaM 
LY294002, or cultured in medium alone were lysed and 
protein concentrations read in triplicate after 24 and 
48hours in culture.
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levels are reduced but not to that of medium only control cells (Fig 5.2.4, 5, 6, 
7).
5.2.4 IL-2 and IL-15 induced regulation of transferrin receptor 
and amino acid transporter expression is LY294002 sensitive.
The PI3K effector PKB/Akt regulates surface expression of CD98, a component 
of a key amino acid transporter complex in haematopoietic cell (432). We 
therefore addressed the role of PI3K signalling in expression patterns of CD98 
in the context of LY294002 inhibitory effects on antigen activated cells 
responding to IL-2 and IL-15 over 24 and 48hours.
The data in Fig 5.2.8a show that antigen activated CD8+ T cells maintained in 
IL-2 have high levels of surface CD98 compared to cells cultured with no 
cytokine. However, these levels are reduced when cells are cultured in the 
presence of LY294002. Antigen activated CD8+ T cells cultured with IL-15 are 
also shown to have high levels of CD98 when compared with medium controls, 
and again decreased CD98 levels in the presence of LY294002 (Fig 5.2.9a). 
The decrease in CD98 levels on treatment with LY294002 in CD8IL'15 T cells is 
not as pronounced when compared to IL-2 cultured cells, most likely due to the 
reduced overall concentration of CD98 receptors on the surface of CD8IL'15 cells 
when compared with CD8IL'2 (Fig 5.2.9a).
The uptake of amino acids is an energy dependent process and optimal growth 
responses in cytokine stimulated lymphocytes are associated with up regulation 
of transferrin receptors which deliver transferrin loaded with iron, a necessary 
cofactor for a number of crucial metabolic reactions, to the cell interior. Antigen
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Figure 5.2.8: IL-2 regulation of amino acid transporter 
subunit CD98 (4F2) and transferrin receptor CD71 is 
LY294002 sensitive. FACS histograms of a) the amino 
acid transporter subunit (CD98) and b) transferrin 
receptor (CD71) expression on the surface of antigen 
primed P14 CD8+ T cells cultured in medium alone or 
20ng/mL IL-2 (CD8IL_2) plus or minus 10p,M LY294002 a 
PI3K inhibitor for 24-48hours.
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Figure 5.2.9: IL-15 regulation of amino acid transporter 
subunit CD98 (4F2) and the transferrin receptor CD71 is 
sensitive to LY294002. FACS histograms of a) amino acid 
transporter subunit (CD98) and b) transferrin receptor 
(CD71) expression on the surface of antigen primed P14 
CD8+ T cells cultured in medium alone or 20ng/mL IL-15 
(CD8IL'15) plus or minus 10^iM LY294002 after 24 and 
48hours in culture.
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activated T cells maintained in IL-2 express high levels of transferrin receptor 
(CD71) over 24-48hours in culture, but these levels decline rapidly if cells are 
cultured-in medium alone (Fig 5.2.8b). Transferrin receptor expression is also 
reduced on activated T cells cultured with IL-2 and PI3K inhibitor LY2494002 
(Fig 5.2.8b). Antigen activated T cells cultured in IL-15 express 
high/intermediate levels of CD71 over the 24/48hour time period, respectively, 
and these levels decrease rapidly when these cells are cultured in medium 
alone (Fig 5.2.9b). Levels of CD71 in IL-15 cultured cells are also reduced 
rapidly in the presence of LY294002 (Fig 5.2.9b).
Hence, data suggests that cytokine induced protein synthesis and amino acid 
uptake in activated T cells is sensitive to treatment with LY294002, a PI3K 
inhibitor, suggesting these processes are partly dependent on PI3K activity. 
Also, cytokine regulation of an amino acid transporter CD98 and transferrin 
receptor CD71 is LY294002 sensitive, suggesting that IL-2 and IL-15 regulate T 
cell growth processes via a PI3K driven mechanism controlling the uptake of 
nutrients.
5.2.5 IL-2 regulation of T cell size is sensitive to wortmannin.
PI3K activity can also be inhibited by a compound wortmannin. This compound 
physically binds PI3K differently than binding to LY294002 and is known to have 
a very short half-life in culture, approximately 20 minutes, making it difficult to 
use in a long-term culture system. Experiments were initially undertaken using 
LY294002 as it was thought to be the best and most suitable inhibitor at that 
point. However, after this data was collected crystal log rap hie evidence that
125
LY294002 sterically binds and inhibits the PIM kinase family of proteins in a 
similar way to the PI3K inhibition was published (551).
Because recent data from Craig Thompson’s lab and others show the 
involvement of PIM kinases in the regulation of cell size (508, 512, 513) we had 
to consider the possibility that the effect of LY294002 on T cell size was 
mediated via its effects on PIM kinases. We therefore did some additional 
experiments using a second PI3K inhibitor wortmannin to measure the 
involvement of PI3K in this in vitro system. Initial experiments deducing effects 
on size were completed, however, not all experiments were repeated due to 
time restrictions.
Thus, relative cell size of antigen activated CD8+ T cells cultured in medium 
alone, 20ng/mL IL-2, 20ng/mL IL-2 plus 10pM LY294002 or 100nM wortmannin 
for 48hours was measured by flow cytometry. FACS dot plots and histograms 
show FSC and SSC, where cells cultured in the presence of LY294002 and 
wortmannin both have reduced FSC and SSC (Fig 5.2.10). These data show 
that LY294002 and wortmannin have similar effects on T cell size suggesting 
PI3K plays a role in regulating T cell size.
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5.3 Discussion
The present data show that the PI3K inhibitor LY294002 inhibited the ability of 
IL-2 and IL-15 to regulate T cell size. The effect of LY294002 on size was most 
obvious in the context of IL-2 responses. Data also show that LY294002 inhibits 
the capacity of IL-2 and IL-15 to drive amino acid uptake and protein synthesis 
in CD8+ T cells. Protein synthesis and amino acid uptake is dependent on the 
availability of amino acids transported into cells by specific amino acid 
transporters. The results in chapter 4 showed that IL-2 and IL-15 regulate cell 
surface expression of CD98 a common subunit of amino acid transporters 
known to mediate transport of neutral and dibasic amino acids across the 
membrane (552-555), (556). Protein synthesis is also very energetically 
demanding and accordingly IL-2 and IL-15 up regulate surface expression of 
CD71 the transferrin receptor, important for iron transport. Data in this chapter 
shows that IL-2 and IL-15 regulation of CD71 and CD98 is LY294002 sensitive, 
suggesting that PI3K plays a role in nutrient availability for antigen experienced 
CD8+ T cells.
The requirement for PI3K activity for protein synthesis in T cells correlates with a 
PI3K requirement for amino acid uptake. It is however very likely that PI3K has 
other relevant targets that are important for protein synthesis. Firstly, protein 
synthesis is energetically demanding and it has been described that PI3K and 
its effector PKB regulate glucose uptake and hence control ATP generation. 
Reports have indicated that PI3K/Akt regulates Glutl glucose transporter in 
lymphoblastic and naive T cells in response to yc cytokines and TCR
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stimulation. For example Barata et al showed IL-7 mediated Glutl up-regulation, 
cell size and iron transport increases as a direct result of PI3K activity in 
lymphoblastic T cells (363). Craig Thompson’s group has also shown Glutl up- 
regulation as a consequence of CD28 co-stimulation in naive T cells and clearly 
showed the requirement of PI3K in this process via the use of inhibitors (437). 
Evidence out side the immune system in the context of insulin signalling also 
support a role for PI3K in controlling glucose transporters Glutl and Glut4 (557). 
Thus it seems clear that PI3K/PKB plays a role in modulating T cell glucose 
metabolism in response to both TCR/CD28 stimulation and yc cytokines.
Little is known of the processes directly regulating glucose transporter 
expression in T cells although it might be possible to draw conclusions from 
what is known about insulin regulation of glucose transport. It is thus thought 
that Glutl and Glut4 expression is modulated by insulin via the rapamycin 
sensitive pathway PI3K/PKB/mTOR/4EBP1. Insulin has been shown to up- 
regulate Glutl translation via activation the mammalian target of rapamycin 
(mTOR) and inactivation of its primary substrate 4EBP1, a translation repressor 
(557).
PI3K activation is required and sufficient for activation of the serine kinase PKB 
(391). In the IL-3 dependent cell line FL5.12 expression of a constitutively active 
mutant of PKB can substitute for IL-3 induced expression of CD98 and is also a 
potent stimulus for cell growth (432).
What is the evidence that PKB is the key mediator for IL-2 and IL-15 induced 
cell growth? Firstly, it has been noted that pre-T cells lacking the expression of 
PDK1, a key upstream kinase for PKB, are smaller than normal (410). Secondly,
transgenic mice expressing an active mutant of PKB in naive T are larger than 
normal indicating a role for PKB in the control of T cell size (436). However, 
because the loss of PDK1 blocks T cell development in the thymus we know 
nothing about the role of PDK1 in IL-2 and IL-15 responses in the periphery 
(410). Moreover, PDK1 is required for activation of a number of serine kinases 
not just PKB (396) so it cannot be excluded that any role for PDK1 in the 
regulation of T cell size is mediated by PDK1 substrates such as the PKCs or 
RSK and is nothing to do with PKB. Naive T cells that express an active PKB 
mutant may be slightly larger that normal but they are nowhere near the size of 
an IL-2 or IL-15 lymphoblast which indicates that PKB is probably not sufficient 
for IL-2 or IL-15 regulation of T cell growth.
One evolutionarily conserved nutrient-sensing molecule involved in PI3K control 
of cell growth in a number of cellular systems is mTOR (mammalian target of 
rapamycin (reviewed in (455, 558)). mTOR is a serine threonine kinase 
specifically inhibited by the immunosuppressant rapamycin (456, 559) and is 
known to play a central role in integrating signals from nutrients (amino acids 
and energy) and growth factors (in higher eukaryotes) to regulate cell growth 
and cell cycle progression. TOR senses cellular amino acid (560) and energy or 
ATP levels (471) and is considered a ‘gatekeeper’ coupling nutrient availability 
with cell growth (559) (456).
The nutrient sensing mechanism of TOR remains poorly understood but 
appears to involve a protein complex containing Raptor (496), mediating 
rapamycin sensitive TOR functions including phosphorylation of S6K and 4E- 
BP1. Rictor is a new binding partner for TOR thought to mediate rapamycin 
insensitive functions (561) although upstream kinases and substrates of TOR-
rictor are still being discovered. Although recent data suggests that the TOR- 
rictor complex phosphorylates PKB at ser473 facilitating subsequent Thr308 
phosphorylation by PDK1 and thus full activation status (400, 503). It has also 
been implicated in regulation of cellular cytoskeleton (503, 562).
The role of TOR in cell growth has recently been shown in Drosophila where the 
inactivation of TOR or its substrate S6 kinase results in reduced cell size and 
embryonic lethality, illustrating the critical role for TOR in cell growth control 
(563). The functions of mammalian TOR (mTOR) have also recently been dealt 
with in mice by the disruption of the kinase domain in mTOR. Heterozygote mice 
were normal and fertile, homozygote embryos died shortly after implantation due 
to impaired cell proliferation (563). Furthermore, embryonic stem cells deleted 
for mTOR kinase activity were reduced in size and proliferation arrested (563). 
These data suggest a central role for TOR in cell growth in mammalian cells. 
However, we have compared the effect of LY294002 and rapamycin on IL-2 and 
IL-15 regulation of T cell growth and found very little effect of rapamycin on T 
cell size compared to the effects of LY294002 although rapamycin did effect T 
cell proliferation (data not shown). Hence the rapamycin sensitive TOR pathway 
is necessary for IL-2 induced T cell proliferation but not for T cell growth. It has 
recently been shown that mTOR is also part of a distinct complex defined by the 
novel protein rictor (rapamycin-insensitive companion of TOR) (503). The role of 
the TOR/rictor complex as a regulator of T cell growth is not known. 
Nevertheless, the failure of rapamycin to block IL-2 and IL-15 induction of 
protein synthesis argues that the ribosomal S6 kinases (S6K) are not absolutely 
necessary for cytokine regulation of protein synthesis. Hence PI3K activation is
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required and sufficient for S6K1 activation (389) yet rapamycin treatment has 
very little effect on protein synthesis and cell size of IL-2 or IL-15 stimulated 
effector CD8+ T cells (data not shown).
Interestingly, the early studies of rapamycin action that showed this drug was 
good at blocking the induction of T cell proliferation in primary T cells but could 
not down regulate an ongoing proliferative response (506). One explanation for 
the selective role of rapamycin in T cell proliferation is that it blocks the initiation 
of ribosomal biogenesis, induced by activation of naive T cells, but it does not 
have a major impact on sustaining ribosome function once the first phase of 
ribosome biogenesis is complete (564). Ribosome biogenesis must be essential 
during the initial activation of T cells by antigen/APC because it is hard to 
imagine that the huge increase in protein synthesis that occurs following 
immune stimulation of naive T cells could be achieved without massive 
ribosomal biogenesis. In this respect there is evidence that the co-stimulatory 
molecule CD28 regulates T cell activation via rapamycin sensitive mechanisms 
(565). This is however quite a controversial point with other experiments arguing 
that rapamycin does not always block CD28 responses (566)
One interesting set of molecules to explore in the context of IL-2 and IL-15 
regulation of cell growth are the Pirn kinases which have recently been identified 
by Craig Thompson’s lab as important regulators of T cell metabolism (513). Pirn 
kinases are serine/threonine kinases expressed in haematopoietic cells. Their 
expression is rapidly induced in T cells following stimulation through the TCR or 
with cytokines like IL-2 and most likely IL-15 although this has not been formally
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shown as yet. There are three members of the Pirn family Pim1, 2, and 3. Pirns 
were first discovered as a frequent site for proviral insertion in the lymphomas 
that arise following infection with Murine Maloney Leukemia virus (567, 568). 
These proteins have a well-documented role in oncogenesis (reviewed in (569, 
570)) as deregulation of these genes has been found in many lymphoid 
tumours. Pirns are thought to be transcriptionally and post-transcriptionally 
regulated in response to T cell activation (571). IL-2 has been shown to induce 
Pim1 mRNA expression, detected in microarray analysis of immediate early 
genes (572).
The essential role of Pirn kinases in T cells has only recently been recognised. It 
is now known that constitutive expression of Pim1 reconstitutes thymic cellularity 
in yc -/- and Rag-/- mice (511) but gene deletion of the single isoforms of PIM 
kinases has no discernable impact on T cell responses. However, the recent 
production of mice deficient in Pim1, 2 and Pim3 has yielded important new 
insights about the relevance of the Pirn kinases in T cells. Pim1, 2, 3 triple 
knockout mice are viable and fertile but with a much reduced body size 
compared to normal (508). T cell differentiation and export from the thymus was 
normal in Pirn deficient mice although peripheral T cells showed a reduced 
proliferative response to suboptimal anti-CD3 activation in the presence of IL-2 
due to a reduced capacity to undergo cell division. No enhanced apoptosis was 
observed. Pirn-deficient T cells also expressed lower levels of IL-2Ryc chain but 
did not show reduction in STAT5 signalling. The B cell compartment of these 
mice showed a more severe phenotype with reduced numbers in the spleen,
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increased pre-pro-B cell progenitors in the marrow and a decreased proliferaitve 
capacity in the presence of IL-7 (508).
T cells deficient in Pimland Pim2 have been studied by Craig Thompson’s lab. 
These studies have revealed a very interesting ability of Pirn kinases to 
substitute for rapamycin/TOR signals in the regulation of T cell survival, size, 
blastogenesis (predominantly Pim2 mediated) and proliferation in vitro and vivo 
(513). The key fact to emerge from the work by Thompson is that in normal T 
cells the regulation of cell survival and growth or size is rapamycin independent 
whereas in Pim2 deficient T cells these response become rapamycin sensitive 
(513).
In view of these recent results it would be very interesting to explore the role of 
PI3K in the regulation of the expression of Pim1 and Pim2. Is it possible that 
PI3K pathways regulate Pirn kinase expression. Little is known about the 
transcriptional mechanisms that induce expression of Pirn kinases. Although 
STATs have been proposed as important transcription factors for induction of 
the genes encoding the Pirn kinases (310). It would thus have been interesting 
to study the regulation of Pirn kinases in CD8+ T cells using the system 
described in this thesis although time constraints limited this possibility and 
other difficulties may have occurred because of limited access to reliable 
antibodies, inhibitors and transgenic mice. However, further biochemical and 
translational studies are needed to define expression patterns of Pirn kinases in 
naive and antigen stimulated T cells, especially in response to yc cytokines. For 
example are the Pirn kinases true down stream targets of IL-2/15 receptors?
Further experiments with Pim knockout mice in an infection model may also 
highlight whether these mice can mount normal immune responses, focusing on 
homing patterns and generation of effector memory CTL. This analysis maybe 
informative as to whether the Pim kinases play an important role in the 
functional differentiation of peripheral CD8+ T cells.
One other issue that would have been interesting to explore is the identity of the 
PI3K isoforms relevant for IL-2 and IL-15 signalling. In particular there is always 
a concern about making conclusions about signalling pathways based solely on 
the use of pharmacological inhibitors. As discussed in the introduction, T cells 
express multiple isoforms of PI3K and which ones involved in yc signal 
transduction is not known. Okkenhaug and colleagues generated mice 
expressing a catalytically inactive form of the p1106 subunit (p1106D910A/D910A) 
referred to as p1106 knock-in mice (81). In the last few weeks of the thesis we 
were able to carry out one experiment on T cells isolated from these mice. We 
observed that the ability of p1106 D910A/D910A j  cells to proliferate and grow in 
response to TCR triggering was impaired but these defects could be overcome 
by addition of IL-2 or IL-15. These results argue that p1106 is important for TCR 
but not IL-2/IL-15 signalling. However, one intriguing observation was that IL-2 
induced proliferation of p1106D910A/D910A T cells was much more sensitive to 
rapamycin than normal in the same way that Pim kinase deficient T cells show 
enhanced rapamycin sensitivity. These studies need much more work and were 
not completed due to time constraints.
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Chapter 6
IL-2 and IL-15 differentially regulate PDK1 signal 
transduction.
6.1 Introduction
Previous data indicated that IL-2 and IL-15 are equal mitogens but are not equal 
in their ability to regulate cell growth, or protein synthesis. There was also an 
indication that PI3K may play an important role in IL-2 and IL-15 regulation of 
cell size. Hence the aim of this chapter was to explore if differences in the 
effects of IL-2 and IL-15 on PI3K signals could explain the differential effects of 
these two cytokines on T cell growth. Key PI3K effectors for the regulation of cell 
growth: are the serine/threonine kinases Phospholipid Dependent Kinase 1 
(PDK1) and Protein Kinase B/Akt (389, 410, 436, 573). PDK1 (phosphoinositide 
dependent kinase-1), was first identified in the context of PI3K-PKB signalling 
and acts downstream of PI3K to activate PKB (393). Deletion of the PDK1 gene 
by homologous recombination technology in mice causes embryo lethality (409). 
Moreover, conditional gene deletion of PDK1 blocks T cell differentiation in the 
thymus, and reduced PDK1 expression was shown to allow T cell differentiation 
but block thymocyte proliferation and expansion. Of relevance to the present 
study is that pre-T cells lacking expression of PDK1 are reduced in cell size
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compared to normal pre-T cells revealing for the first time, that PDK1 plays a 
regulating T cell size and growth (410).
In studies of PDK1 deficient mice a method for the assessment of PI3K/PDK1 
signalling in T cells was described. This method quantifies the phosphorylation 
of the ribosomal S6 subunit on serine235/236 by using flow cytometric analysis 
of intracellular staining with specific phospho-S6 antisera (410). S6 
phosphorylation on ser235/236 is mediated by S6K1 (p70S6K) and occurs down 
stream of PDK1 via two pathways. Firstly, PDK1 directly phosphorylates 
p70S6K in its active site or T  loop’ site (574). Secondly, p70S6K is also 
regulated by the PDK1 substrate PKB via a TSC1/TSC2/mTOR pathway (Fig 
6.2.1). Importantly, previous studies have indicated that the activation of PI3K is 
both necessary and sufficient for the activation of PKB and p70S6K in T cells 
(389) indicating that quantification of S6 phosphorylation will report PI3K activity 
in T cells. As well, the ability of S6 phosphorylation to monitor PDK1 function 
has been verified by analysis of PDK1 null T cells (410).
The aim of this chapter was to use S6 phosphorylation as a sensitive and 
quantitative assay capable of measuring PDK1 signalling pathway activity to 
look at physiological regulation of these signals in antigen activated T cells 
responding to cytokines IL-2 and IL-15. Flow cytometric analysis of 
phosphorylated S6 ribosomal protein allows analysis at a single cell level of the 
phosphorylation of a downstream target of PI3K/PDK1/PKB/p70S6K (Fig 6.2.2). 
This is a sensitive assay for PDK1 function because it looks at phosphorylation 
of a downstream target of the enzyme at a point where there has been 
considerable signal amplification. Moreover, the specificity of the assay can be 
readily verified as treatment of cells with rapamycin, which inhibits the activity of
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Figure 6.2.1: Signalling pathways contributing to T cell 
growth. PI3K activity generates PI(3,4,5)P3 which signals to 
effector molecules PKB , mTOR, p70S6K and regulates glucose 
metabolism and protein synthesis. PI3K and mTOR activity is 
inhibited by LY294002 and rapamycin respectively.
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Figure 6.2.2: Measuring PI3K/PDK1 activity by monitoring 
phosphorylation of effector molecule S6 ribosomal protein.
S6 phosphorylation is amplified down stream of PI3K/PDK1 
signalling. Biochemical analysis of phosphorylated S6 using flow 
cytometry allows for the detection of phosphoylation events at a 
single cell level and proves to be a sensitive and quantitative assay 
of PI3K/PDK1 activity.
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mTOR, rapidly reverses S6 phosphorylation (78, 575). This makes it possible to 
provide an internal negative control as a standard for each sample. It is also 
possible to use a pharmacological stimulant, phorbol ester phorbol 12.13 
dibutyrate (PdBu) as a positive control to assess the maximum potential for S6 
phosphorylation in each cell.
6.2 Results
6.2.1 Antigen activation of naive T cells dramatically increases 
phosphorylation of S6 ribosomal protein.
Lymph nodes were taken from P14 LCMV mice and labelled for CD8, Thy1.2 
and intracellular phospho-S6 protein. Histograms show naive CD8+ T cells have 
very low concentrations of phospho-S6 protein (black filled area), comparable to 
the rapamycin treated cells (thick grey line) indicating basal levels of phospho- 
S6 (Fig 6.2.3a). Data also show that triggering of the antigen receptor complex 
with CD3 antibodies (light grey line) or a pharmacological stimulant, phorbol 
ester phorbol 12.13 dibutyrate (PdBu) (thin grey line) for 30mins induces S6 
phosphorylation. The data in Fig 6.2.3b compares S6 phosphorylation in naive 
T cells to P14 TCR transgenic T cells activated with gp33 specific peptide in the 
context of MHC I molecules for48hours. Antigen activation also induces high 
levels of phospho-S6 protein (black filled), which is comparable to levels 
induced by phorbol ester stimulation (thin grey line) suggesting antigen 
stimulation induces the phosphorylation of nearly all S6 protein present in the T 
cell (Fig 6.2.3b).
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Figure 6.2.3: Phosphorylated S6 protein levels 
are low in naive ex vivo CD8+ T cells but rapidly 
increase when stimulated with antigen in the 
context of MHC class I. FACS histograms 
indicating relative levels of phosphorylated S6 
ribosomal protein, a) Ex vivo lymph node P14 naive 
CD8+ T cells, b) Antigen activated P14 splenic T 
cells. Controls: phorbol ester phorbol 12.13 
dibutyrate (PdBu), anti-CD3 (2c11) (positive 
control), 20nM rapamyicn (negative control) for 
30mins (30’). All histograms represent CD8a+, 
Thy1.2+ T cells.
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6.2.2 In the absence of exogenous stimuli, antigen activated T 
cells rapidly lose phosphorylation of S6 protein.
Spleens were taken from P14 LCMV mice and antigen stimulated for two days 
with gp33 LCMV specific peptide. Fig 6.2.4a shows FACS histograms of antigen 
stimulated CD8+ T cells, which were washed free of exogenous antigen and 
cultured in medium only without cytokines. A kinetic analysis of these cells was 
undertaken over 6, 12, 24hours in culture. These data show that antigen 
activated T cells rapidly lose S6 phosphorylation when cultured without 
cytokines. This loss of S6 phosphorylation is seen after as little as 6hours 
without external stimuli (Fig 6.2.4a). Data in Fig 6.2.4b compares S6 
phosphorylation in antigen activated T cells cultured in medium alone or IL-2 
over a 24hour period. T cells lose S6 phosphorylation when cultured in medium 
but are capable of maintaining high levels of S6 phosphorylation when cultured 
in the presence of IL-2 for the same time period (Fig 6.2.4b). These data show 
that antigen activated CD8+ T cells cannot autonomously maintain the 
phosphorylation of S6 protein without the constant presence of external stimuli, 
be it antigen or cytokine growth factor.
6.2.3 PI3K plays a role in regulating IL-2 induction of S6 
phosphorylation
Previous studies have shown that the activation of PI3K is both necessary and 
sufficient for the activation of PKB and p70S6K in T cells (389). To explore 
whether S6 phosphorylation is an assay for PI3K signalling in T cells we 
examined the impact of a PI3K inhibitor LY294002 on S6 phosphorylation.
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Figure 6.2.4: Activated T cells down regulate S6 
phosphorylation when antigen is removed, but maintain 
phospho-S6 levels in the presence of IL-2. FACS histograms 
show levels of phosho-S6 in antigen activated P14 LCMV CD8+ T 
cells a) washed and cultured without exogenous growth factors for 
6, 12 and 24 hours, b) Antigen activated CD8+ T cells cultured in 
medium alone or 20ng/mL IL-2 for 24hours. Controls include 30 
minute treatment with phorbol ester (thin grey line) or rapamycin 
(thick grey line). All histograms represent CD8a+, Thy1.2+ T cells.
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Histograms in Fig 6.2.5 show antigen activated T cells cultured in medium alone 
(left column), 20ng/ml_ IL-2 plus or minus 10 i^M LY294002 (the PI3K inhibitor) 
for 48hours in total. A kinetic analysis of S6 phosphorylation was undertaken 
where T cells were stained for intracellular phospho-S6 after 6, 24 and 48hours 
of cytokine/inhibitor treatment. Fig 6.2.5 shows phospho-S6 levels rapidly 
decrease when cells were cultured in medium alone, but cells cultured in IL-2 
maintained high levels of phospho-S6 for the entire 48hours. This IL-2 response 
was lost when cells were co-cultured with IL-2 and the PI3K inhibitor LY294002. 
Thus the ability of IL-2 to induce phosphorylation of S6 ribosomal protein 
requires PI3K activity.
6.2.4 A comparison of IL-2 and IL-15 induced S6 
phosphorylation
The previous data show that antigen activated CD8+ T cells have high levels of 
phospho-S6 that is lost if cells are removed from antigen and cultured in 
medium alone. Phospho-S6 levels are maintained when antigen activated T 
cells are cultured with IL-2 and this response is dependent on activation of PI3K 
as co-culture of T cells with IL-2 and the PI3K inhibitor LY294002 abrogates S6 
phosphorylation.
Next we compared the ability of IL-2 and IL-15 to regulate the phospho-S6 
pathway. At early time points, up to 6hours, the ability of IL-2 and IL-15 to 
sustain S6 phosphorylation was very similar (Fig 6.2.6). However, during 
prolonged exposure to cytokine only IL-2 could maintain high levels of phospho- 
S6 whereas the IL-15 response was much lower (Fig 6.2.6). Hence T cells 
maintained in IL-15 for 12-24 hours have markedly lower levels of phospho-S6
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Figure 6.2.5: PI3K plays a role in regulating 
phospho-S6 levels in CD8IL~2 T cells. FACS 
histograms of antigen activated P14 CD8+ T cells 
cultured in 20ng/mL IL-2 with or without 10(iM 
LY294002 a PI3K inhibitor for 6, 24 and 48hrs. 
Controls: 30min (30’) treatment with PdBu or 20nM 
rapamycin previous to staining. All histograms 
represent CD8a+, Thy1.2+ T cells.
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Figure 6.2.6: Antigen activated CD8+ T cells cultured in IL- 
2 or IL-15 regulate S6 phosphorylation with different 
kinetics. IL-2 sustains S6 phosphorylation where IL-15 
provides a more transient regulation. FACS histograms 
show expression levels of phosphorylated S6 protein in naive 
T cells, antigen activated CD8+ T cells cultured with 20ng/mL 
IL-2, IL-15 or medium only. Controls: 30min (30’) treatment 
with PdBu or 20nM rapamycin previous to staining. All 
histograms represent CD8a+, Thy1.2+ T cells.
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than cells maintained in IL-2. It should be emphasized that phospho-S6 levels in 
T cells cultured in IL-15 are higher than those seen in cells cultured in medium 
lone but considerably lower than cells cultured in IL-2 (Fig 6.2.6). It was possible 
that the difference between IL-2 and IL-15 in terms of their ability to regulate 
phosphorylation of S6 was due to the fact that CD8+ T cells maintained in IL-15 
had lower levels of the substrate S6 protein than cells grown in IL-2. However, 
phorbol ester (PdBu) treated controls show comparable levels of phospho-S6 
protein (Fig 6.2.6). Hence T cells maintained in IL-15 or IL-2 have the potential 
to activate similar levels of S6 phosphorylation if activated pharmacologically but 
IL-15 is unable to maximise this potential and can only transiently maintain high 
levels of S6 phosphorylation. In contrast, IL-2 can sustain high levels of S6 
phosphorylation for a prolonged period.
The ability of IL-2 to regulate S6 phosphorylation is dependent on PI3K. The 
experiment in Fig 6.2.7 assesses the role of PI3K in IL-15 induction of S6 
phosphorylation. At early time points S6 phosphorylation is high in the presence 
of 20ng/mL of IL-15. These levels are reduced over the same 6hour time period 
by the presence of lO^M LY294002, which are comparable to levels seen in 
medium only control cells. The data show that T cells co-cultured with IL-15 and 
LY294002 cannot sustain S6 phosphorylation compared to cells cultured in 
cytokine alone. IL-15 phosphorylation of S6 is thus mediated by PI3K. 
Accordingly, differences between IL-2 and IL-15 in terms of the kinetics of their 
S6 response is an indication that there are quantitative and kinetic differences in 
the activation of PI3K by these two cytokines.
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Figure 6.2.7: PI3K plays a role in regulating 
phospho-S6 levels in CD8IL~15 T cells. FACS 
histograms of antigen activated P14 CD8+ T cells 
cultured in 20ng/mL IL-15 with or without 10pM 
LY294002 a PI3K inhibitor for 6, 24 and 48hrs. 
Controls: 30min (30’) treatment with PdBu or 20nM 
rapamycin previous to staining. All histograms 
represent CD8a+, Thy1.2+ T cells.
6.2.5Regulation of IL-2 and IL-15 receptors
Differences in the kinetics of IL-2 and IL-15 induction of phospho-S6 reveals that 
IL-15 initiates more transient signalling pathways in CD8+ T cells than IL-2. A 
predominant mechanism used by T cells to terminate cytokine signalling is to 
regulate surface expression of cytokine receptors (106, 124, 539). The high 
affinity binding of IL-2 is mediated by a complex of; the common cytokine 
receptor y chain (yc), CD122 (the IL-2 receptor p chain) and CD25 (the unique 
IL-2 receptor a  chain). IL-15 interacts with cells via binding to the unique IL-15 
receptor a subunit (IL-15Ra), which presents IL-15 in trans to yc and p (CD122)
subunits present on nearby cells (207, 210). IL-2 binding to its receptor triggers 
receptor internalisation and ligand degradation but simultaneously up regulates 
expression of CD25 (576), thereby preventing receptor down regulation and
allowing activated T cells to sustain proliferative and growth responses to IL-2.
In contrast, exposure to IL-15 is reported to down regulate expression of high 
affinity IL-15 receptors with a resultant loss of IL-15 responsiveness (577).
To examine the possibility that IL-15 down regulates expression of the IL-15 
receptor a subunit in antigen primed CD8+ mouse T cells, flow cytometry was 
used to quantify IL-15 and IL-2 receptor subunits on the surface of antigen 
activated T cells maintained in medium alone or in the presence of 20ng/mL IL-2 
or IL-15 (Fig 6.2.8a & b). Surface levels of CD25, the unique IL-2 receptor a 
chain, are markedly up regulated when antigen activated CD8+ T cells are 
grown in IL-2 versus media alone (Fig 6.2.8a). IL-15 is not as potent as IL-2 at 
maintaining CD25 levels but still stimulates CD25 expression when compared to 
media alone. Activated CD8+ T cells also express IL-15Ra but surface levels of
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Figure 6.2.8: Transient signalling through PI3K 
pathways maybe a result of cytokine receptor down 
regulation. FACS histograms showing expression levels of 
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this receptor are not maintained in the presence of IL-15 (Fig 6.2.8b). IL-15Ra 
chain expression is relatively high in antigen activated T cells cultured in media 
alone or in IL-2 but relatively low in cells stimulated with IL-15. Hence, IL-2 and 
IL-15 differ in the way they regulate expression of their receptors: IL-2 triggers a 
positive feedback mechanism that up regulates expression of the IL-2 receptor a 
subunit: the key receptor subunit for high affinity IL-2 receptor expression. 
Conversely, levels of IL-15 receptor a chain decline in CD8+ T cells cultured 
with IL-15.
6.3 Discussion
Data in this chapter shows that antigen activation of ex vivo CD8+ T cells is a 
very strong stimulus for the induction of S6 phosphorylation. When the antigen 
stimulus is taken away and the cells cultured in medium alone the ability of the 
cell to phosphorylate S6 protein is compromised and levels of phospho-S6 are 
rapidly down regulated. Thus, antigen activated T cells cannot autonomously 
maintain S6 phosphorylation. Further analysis showed that antigen activated T 
cells exposed to growth factors IL-2 and IL-15 are able to maintain S6 
phosphorylation via a PI3K mediated pathway, although with different kinetics 
and magnitude. Initially the IL-2 and IL-15 response are equivalent in magnitude 
but there is a significant difference in the prolonged response to these two 
cytokines. IL-2 has the capacity to sustain S6 phosphorylation at high levels for 
several days whereas IL-15 only transiently induces high levels of S6 
phosphorylation and very low levels during a prolonged response. The major 
difference between IL-2 and IL-15 signalling is thus temporal and quantitative: 
IL-15 signalling is relatively transient whereas IL-2 signalling is sustained.
The phosphorylation of S6 ribosomal protein is a result of signalling through the 
PI3K/PDK1/PKB/p70S6K pathways (78, 389, 410, 517, 578, 579). Differences 
between IL-2 and IL-15 are thus consistent with differences in the ability of these 
cytokines to sustain PI3K activity. To test this hypothesis directly would require 
quantitative analysis of cellular levels of Ptdlns(3,4,5)P3(PIP3) in antigen 
activated T cells cultured in IL-2 or IL-15. Measuring PIP3 levels can be 
achieved by labelling cells with [3H]inositol or [32P]orthophosphate followed by 
lipid extraction and analysis by HPLC. However, cell labelling with inositol is not 
very efficient, where labelling to isotopic equilibrium can take days and can be 
inconvenient, requiring large amounts of radioactivity. Both labelling procedures 
also suffer from the drawback of elaborate and time-consuming HPLC analysis 
and require very large numbers of cells. Another method for the measurement of 
PIP3 mass in cells uses a radio-ligand displacement assay that does not require 
cells to be metabolically labeled but does require large numbers of cells (580). 
Another approach for measuring PI3K activity is to measure phosphorylation 
events known to be down stream of PI(3,4,5)P3 such as the phosphorylation of 
Akt/PKB or the activation/phosphorylation of p70S6K. Conventional western 
blotting using phospho-specific antibodies and ECL technology is the most 
common approach to look at signalling pathways and can be a very sensitive 
assay. However, from the present data it is shown by flow cytometric analysis 
that there is only a two-fold difference in signalling between IL-2 and IL-15 and 
ECL detection is insufficiently quantitative in this range. Hence, the use of 
phospho-specific antibodies in intracellular staining for flow cytometry is an 
attractive option, as this method is fast and provides strong quantitative data. 
However, the use of phospho-specific antibodies in flow cytometry can be
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difficult and relies on the integrity and specificity of the antibodies used. We 
would have liked to have used flow cytometry to quantify the phosphorylation of 
signalling molecules in the IL-2/IL-15 receptor signalling cascade including 
PKB/Akt, the MAP kinases p42/44 ERK1//2 and the STATs, STAT3 and STAT5. 
MAP kinase phosphorylation by cytokines is very weak and transient and 
difficult to quantify accurately when relying on western blotting. As well, our 
attempts to use flow cytometric analysis to look at MAP kinase phosphorylation 
failed, probably due to the low stoichiometry of MAP kinase phosphorylation per 
cell. We also failed to get any convincing data with phosphoSTAT5 antibodies. A 
sensitive and quantitative method of measuring STAT activity involves DNA pull 
down experiments where active STATs would be sequestered by target 
promoter oligonucleotide sequences and assayed by western blot analysis with 
STAT5 antibodies. These experiments were not performed due to time 
constraints of the thesis. Even though we didn’t directly measure STAT5 
activation, it is known that STAT5 mediates IL-2 up regulation of CD25 (581). 
Data from previous chapters indicate that antigen activated cells cultured in IL-2 
or IL-15 differentially regulate expression levels of CD25 over a 24hour period 
which would be consistent with temporal and quantitative differential regulation 
of STAT5 phosphorylation in response to IL-2 and IL-15 in antigen activated 
CD8+ T cells.
So, why is IL-15 activation of S6 phosphorylation transient whereas the IL-2 
response is sustained? The possibility of IL-15 up regulating a global negative 
regulator pathway that antagonizes PI3K signals (e.g. an inositol lipid 
phosphatases such as PTEN or SHIP) can be excluded mainly because of the 
fact that T cells maintained in IL-15 can immediately up regulate PI3K pathways
and increase cell size if re-exposed to IL-2. However there are other regulators 
of cytokine signalling namely the SOCS proteins that have recently been 
suggested to elicit a more specified inhibitory function for IL-15 versus IL-2 
signalling. The SOCS family are cytokine induced adaptor proteins that function 
as negative feedback inhibitors of cytokine receptor signalling by inhibiting the 
JAK-STAT signal transduction pathway. Over the past few years it has become 
obvious that the 7 members of the SOCS family all play important and specific 
roles in many different cell types (582, 583). Specifically SOCS1 has been found 
to play an important role in T cell homeostatic proliferation and is constitutively 
expressed in CD8+ T cells. Rottapel and colleagues have argued that loss of 
SOCS1 preferentially regulates IL-15 versus IL-2 responses where they show 
that SOSC1-/- T cells with a memory phenotype (CD44+ T cells) were hyper 
responsive to IL-15 (584). Further more, llangumaran et al have suggest that 
SOCS1 is an indispensable attenuator of IL-15 receptor signalling in 
thymocytes, where IL-15/IL-15R signalling induced sustained STAT5 
phosphorylation and maintained massive cell proliferation of SOCS1-/- CD8+ 
thymocytes (585). However, Alexander and colleagues have shown that SOCS1 
also regulates IL-2 signaling such that SOCS1 null mice lose tolerance and 
develop autoimmune disease (586).
Thus, it is unclear that IL-2 and IL-15 differ in their ability to regulate expression 
of SOCS proteins but in this context it is noteworthy that SOCS proteins have 
recently been found to interact with ubiquitin ligase complexes, and have been 
shown to target cytokine receptors and associated tyrosine kinases for 
proteosomal degradation (587, 588). Thus we might speculate that SOCS1 
could target IL-15Ra chain for degradation limiting the signalling capacity of IL-
15 down stream to PI3K and other effectors. However, there are other 
mechanisms by which SOCS proteins can be inhibitory including direct inhibitory 
effects on JAK-STAT signalling.
One option we did consider was that the different kinetics of IL-2 and IL15 
signalling results from differences in the way these cytokines are presented to T 
cells. IL-2 binds as a soluble ligand whereas IL-15 is thought to be presented in 
trans by the IL-15 receptor a subunit to p/y subunits on neighbouring cells (207, 
210). The signal strength delivered by IL-15 presented in trans may be lower 
than that delivered by de novo binding of IL-2 to its trimeric receptor complex. 
This possibility cannot be excluded but the simplest explanation for the relative 
transience of the IL-15/PI3K response compared to the IL-2 sustained response 
resides in differences in the way these two cytokines can modulate expression 
of their own receptors. IL-2 thus binds to its high affinity receptor, is internalised 
and degraded. However, IL-2 signalling is sustained because IL-2 up regulates 
expression of its a subunit, which replenishes surface levels of high affinity IL-2 
receptors that are then available for occupancy by additional IL-2 molecules. 
Hence during the sustained response to IL-2 there is constant formation of new 
IL-2/IL-2 receptor complexes. In contrast, IL-15 receptor levels decline during 
continued exposure to IL-15 thus reducing the number of available IL-15 
receptors during sustained exposure to cytokine. In this respect IL-15 receptor 
regulation is reminiscent of the IL-7 receptor, where IL-7 exposure results in 
down regulation of IL-7 receptor expression as a mechanism to prevent T cells 
competing for limiting quantities of cytokine once the appropriate cell response 
has been stimulated (539).
155
Could temporal differences in PDK1 signalling translate into differences in 
protein synthesis? In particular, would the ability of IL-2 to sustain PI3K signal 
transduction pathways over several days allow this cytokine to sustain T cell 
protein synthesis at high levels for a prolonged period? The answer is yes as 
data from the present and previous chapters show that the ability of T cells to 
maintain protein synthesis is driven by constant signal input as removal of 
cytokine or inhibition of PI3Kwith LY294002 almost immediately abrogates 
amino acid uptake and amino acid incorporation into proteins. The differential 
actions of IL-2 and IL-15 on T cell growth responses thus correlates well with the 
differential kinetics of the PI3K signalling patterns stimulated by these two 
cytokines.
As discussed, PI3K has been shown to regulate glucose metabolism and it is 
quite likely that IL-2 and IL-15 differentially regulate glucose metabolism. In fact, 
when activated T cells are grown in the presence of IL-2 and fully complimented 
medium containing the pH indicator phenol red, the media rapidly changes 
colour reflecting a lowering of its pH as a consequence of lactic acid production 
by the T cells. In contrast, T cells maintained in IL-15 do not have this effect on 
the media indicating that their rate of lactic acid production is not as high. 
However over this time these cells are still undergoing mitosis at a similar rate 
illustrating the fact that these cytokines are equivalent mitogens but not 
equivalent growth factor in context of metabolic capacity.
IL-2 promotes differentiation of effector CTL and IL-15 promotes memory T cell 
development (40, 524). Could the different biological actions of IL-2 and IL-15 
on CD8+ T cell function explain temporally quantitative differences in PI3K
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activation by these cytokines? Data that support this theory includes the fact that 
PI3K signalling is necessary for CTL differentiation (589). As well, low doses of 
IL-2 mimic IL-15 and induce the differentiation of memory T cells rather than 
effector CTL (48). The significance of these data are that low doses of IL-2 
result in transient signalling because activated T cells consume (i.e. internalise 
and degrade) IL-2 and at low doses the cytokine is rapidly depleted from the 
culture medium and hence only transiently available to the T cell population. It is 
also noteworthy that IL-7 transiently signals to T cells because it down regulates 
expression of its receptor (539). IL-7 does not mimic the effect of IL-2 on antigen 
primed T cell mass, and like IL-15 is associated with the development of 
memory T cells rather than cytolytic effectors (262, 266).
In summary, the present data demonstrates that cytokines that are equivalent 
mitogens and can have different potency in terms of regulating PDK1 signalling 
pathways. We predict that the ability of IL-2 to sustain PDK1 signal transduction 
pathways over several days allows this cytokine to sustain T cell protein 
synthesis at high levels for a prolonged period.
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Chapter 7
yc cytokines differentially regulate cell growth in 
antigen and anti-CD3 activated T cells.
7.1 Introduction
The common gamma cytokine receptor chain (yc) is a component of the 
receptors for interleukin 2 (IL-2), IL-4, IL-7, IL-9, IL-15 and IL-21. Mutation in the 
gene that encodes yc results in X-linked severe combined immunodeficiency 
(XSCID) in humans and in mice (87, 119, 274, 521). Signals dependent on yc 
have been shown to be important in the lymphoid compartment particularly for T 
cells, where they have been shown to play a crucial part in peripheral T cell 
homeostasis and thymocyte development (87, 119, 274, 521, 590). Data in 
previous chapters suggests that IL-2 and IL-15 confer differential actions as 
growth factors whilst maintaining equal potency for mitogenesis. These data 
presented the possibility that different members of this cytokine family may act 
in different ways to control the growth and metabolic status of antigen activated 
T cells.
In the following chapter we compare the effects of IL-2, IL-15, IL-7 and IL-4 on T 
cell growth.
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7.2 Results
7.2.1 Common gamma chain cytokines differentially regulate 
the size and protein content of activated CD8+ T cells.
Lymph nodes and spleens were taken from P14 LCMV transgenic and C57BL6J 
wild type mice, mashed, pooled and activated in vitro. The P14 CD8+ T cells 
were activated with gp33 specific peptide (VM ) and wild type T cells activated 
by cross-linking of the TCR using an anti-CD3 monoclonal antibody 2C11 
(l^ig/mL), both stimuli were carried out for 48hours in culture. Populations of 
activated T blasts were washed and cultured in the presence of 20ng/mL IL-2, 
IL-15, IL-7, IL-4 or medium alone. Analysis of T cell growth and proliferation was 
taken over the first three days of culture and show IL-2, IL-15, IL-7 and IL-4 are 
similar mitogens for antigen activated T cells (Figure 7.2.1).
FACS analysis of T cell size was shown as a measure of forward and side light 
scatter (FSC/SSC) and undertaken on CD3+ gated T cells, where P14 LCMV 
cultures were additionally gated for CD8+ co-receptor. Figures 7.2.2 & 7.2.3 
show FACS dot plots and histograms of antigen activated P14 CD8+ and wild 
type T blasts cultured in the presence of yc cytokines as indicated. After 48hours 
in culture it was clear that IL-2 is the only cytokine capable of maintaining the 
large granular size indicative of effector T cells in both T blast cultures. T blasts 
cultured in IL-4 are slightly smaller than IL-2 cultured blasts but larger than cells 
cultured in either IL-15 or IL-7. Hence, it is clear that IL-4 is more potent than IL- 
15 and IL-7 at maintaining activated T cell size, however, IL-2 far exceeds all 
three in it’s potential too maintain T cell size.
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7.2.1: Cell count of antigen activated T cells 
cultured in the presence of cytokines IL-2, 
IL-15, IL-4 and IL-7. Graph shows a cell count 
taken of antigen activated P14 CD8+ T cells 
cultured in 20ng/mL of IL-2, IL-4, IL-15, IL-7 
and medium alone for 3 days.
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7.2.2: Size of antigen activated T cells cultured in the 
presence of cytokines IL-2, IL-15, IL-4 and IL-7.
FACS dot plots and histograms of P14 CD8+ T cells stimulated 
with specific antigen for two days, washed and cultured in 
20ng/mL of IL-2, IL-4, IL-15, or IL-7 for 48hours.
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7.2.3: Size of anti-CD3 stimulated splenic T cells cultured in the 
presence of IL-2, IL-15, IL-4 and IL-7. C57BL6J splenic T cells were 
stimulated with 1|xg/mL anti-CD3 antibody (2C11) for 48hours, 
washed and cultured in 20ng/mL of IL-2, IL-4, IL-15, IL-7 and medium 
only. FACS dot plots and histograms show FSC/SSC analysis of 
these cells after 48hours in culture.
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Protein concentration of anti-CD3 stimulated T cells cultured in IL-2, IL-15, IL-4 
and IL-7 was determined. Figure 7.2.4 shows that cells cultured in IL-2 maintain 
higher concentrations of protein after 3 days in culture than cells growing in the 
presence of IL-4, IL-15 or IL-7. This data corroborates with the flow cytometric 
analysis of T cell size in response to these cytokines and suggests that IL-2 is 
the only member of the gamma chain cytokine family capable of maintaining a 
high rate of protein synthesis and large cell size, which contrasts with the fact 
that all cultures were proliferating or dividing at similar rates, see Figure 7.2.1.
7.2.2 Common gamma chain cytokines differentially regulate 
the phosphorylation of S6 ribosomal protein.
The differential effect of IL-2 and IL-15 on T cell growth correlated with 
differences in their ability to activate PDK1 mediated signalling pathways as 
judged by measurements of S6 phosphorylation. Accordingly, we compared the 
effect of IL-2, IL-4, IL-7 and IL-15 on S6 phosphorylation.
Lymph node and spleen were taken from P14 LCMV and wild type mice, 
mashed, pooled and stimulated in vitro with 1(iM of gp33 specific peptide or 
Vg/mL of anti-CD3 antibody, respectively. Activated T blasts were washed and 
cultured in 20ng/mL of cytokines IL-2, IL-4, IL-15, IL-7 or medium only for 
negative control. Figure 7.2.5 and 7.2.6 show FACS histograms indicating 
phosphorylation levels of S6 ribosomal protein in antigen activated P14 CD8+ T 
cells and wild type T cell blasts in response to yc cytokines. Antigen activated T 
cells cannot maintain S6 phosphorylation when cultured in medium alone.
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the indicated cytokine
Figure 7.2.4: Concentration of protein maintained by 
anti-CD3 activated T cells cultured in the presence of 
cytokines IL-2, IL-15, IL-4 and IL-7 for 72hours.Graph
shows C57BL6J splenic T cells stimulated with anti-CD3 
antibody (2C11) for 48hours, washed and cultured in 
20ng/mL of IL-2, IL-4, IL-15, and IL-7 for 3 days after which 
cells were lysed and protein concentration determined. 
Medium control concentrations are not shown due to death 
of the culture after 48hours.
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7.2.5: Phosphorylation of S6 ribosomal protein in antigen activated 
CD8+ T cells responding to cytokines IL-2, IL-15, IL-4 and IL-
7.FACS histograms show antigen activated P14 CD8+ T cells cultured 
in the presence of 20ng/mL IL-2 , IL-4, IL-7, IL-15 and medium only 
control. Samples were fixed and stained after 2, 4, 6, 8, 24 and 48hours 
in culture. Controls: 30min treatment with PdBu and 20nM Rapamycin. 
All histograms represent CD3+T cells.
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7.2.6: Phosphorylated S6 protein in anti-CD3 activated wild type 
T cells cultured in the presence of cytokines IL-2, IL-15, IL-4, IL-
7. FACS histograms show levels of phospho-S6 in anti-CD3 
stimulated C57BL6J splenic T cells cultured in 20ng/mL of IL-2, IL-4, 
IL-15, IL-7 and medium only for 24, 48 and 72 hours. Cells cultured 
in medium died after 24hours. All histograms represent CD3+ T cells.
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Here it is most striking that even after 2hours the antigen activated T cells had 
lower levels of phospho-S6. When comparing the effects of IL-2, IL-15, IL-4 and 
IL-7, it is clear that IL-2 is the only cytokine capable of maintaining high 
phospho-S6 levels in activated T cells. IL-4 can maintain some level of phospho- 
S6 higher than that of IL-15 and IL-7, although not the equivalent of IL-2. IL-7 
and IL-15 rapidly lose phospho-S6 levels over a very short period of time, 
although, the level maintained is higher than T blasts cultured in medium alone.
7.3 Discussion
The data in this chapter suggests that IL-2 is the most potent T cell growth factor 
when compared to other yc cytokine family members IL-7, IL-15 and IL-4. 
Moreover IL-2>IL-4>IL-15s IL-7»>medium (no stimulus) in a scale of the most 
potent growth factor for activated T cells. The importance of this group of 
cytokines to T cell homeostasis, proliferation and differentiation is well known 
and there have been many comparative studies of their actions as mitogens, 
survival factors and differentiation factors. However, little is known about the 
growth or cell size promoting capacity of the yc cytokines even though an 
understanding of how these cytokines control cell size and protein synthesis 
may prove advantageous for predicting their immunotherapeutic value.
The fact that such diversity in the ability to regulate growth occurs may act in 
defining cytokine function in the immune system. For example, IL-7 and IL-15, 
that has limited growth factor potential, function as naive and memory T cell 
survival factors (40, 591). Hence, these cytokines act to sustain small non­
effector cells, which have a low metabolic capacity and maintain very low
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bioenergetic levels. Thus, IL-15 and IL-7 do not need to induce high rates of 
metabolism and protein synthesis to fulfil their role. They just need to sustain T 
cell survival by the maintenance of mitochondrial potential through the regulation 
of anti- and pro- apoptotic proteins (434).
The present results also indicated that IL-4 was not as potent a growth factor as 
IL-2 but was more potent than IL-7 and IL-15. The present results analysed IL-4 
responses in a population with a high percentage of CD8+ effector T cells and it 
would be very interesting to extend analysis of IL-4 growth effects to CD4+ T 
cells where IL-4 is known to play a central role in the differentiation of antigen- 
activated CD4+ T helper cells. IL-4 polarizes the differentiation of T cells to the 
Th2 population that secrete IL-4, IL-5, IL-9, IL-6, and IL-13. Thus one would 
imagine that Th2 cells would need to maintain relatively high levels of protein 
synthesis to fulfil their function. In this respect, recent data has shown that IL-4 
is not sufficient for CD4+ T helper 2 differentiation rather there is an additional 
requirement for IL-2 (592). This might reflect that only IL-2 can maintain 
sufficiently high rates of cell growth in CD4 T cells and that the role of IL-4 is to 
regulate differentiation of the cells. We performed a pilot experiment to probe 
this possibility. Thus OT-1 CD4+ splenic T cells were stimulated with cognate 
ova peptide and maintained in culture in the presence of 20ng/mL IL-2 (CD4IL'2) 
or IL-4 (CD4il*15). Both cultures proliferated equally, but, CD4IL'2 T cells were 
larger than CD4IL'4 when analysed for FSC/SSC on the flow cytometer (data not 
shown). We would thus predict that IL-2 is the superior growth factor for antigen 
activated CD4+ T cells. The basis for this differential effect of IL-2 versus IL-4 for 
T cell growth needs further analysis but may reflect quantitative and kinetic 
differences in signal transduction as shown herein for IL-2 versus IL-15.
In summary we have compared a number of different yc cytokines for their ability 
to regulate T cell growth. Our studies indicate that IL-2 may be unique. This 
comparison of different yc cytokines was limited to studies of CD8+ T cells. 
Clearly it will be important to examine the role of these cytokines as growth 
regulators in other T cell populations including Th1/Th2 cells, regulatory T cells 
and NK/NKT cells. As well, these studies could be extended to other yc 
cytokines such as IL-21, which has been shown recently to synergise with IL-15 
for CD8+ T cell activation (194). It would also be valuable to comprehensively 
analyse and compare the effects of different yc cytokines on amino acid 
transporter expression, amino acid uptake and incorporation into protein, 
glucose receptor expression, glucose uptake and importantly PI(3,4,5)P3 levels 
in these different lymphocyte populations.
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Final Discussion
The data in this thesis highlights differences between yc cytokines, specifically 
IL-2 and IL-15, in their role as T cell growth factors. The comparison of IL-2 and 
IL-15 came about because of data presented by Von Andrian’s lab showing that 
either cytokine drove terminal differentiation of phenotypically divergent cell 
types, CD8+ effector ( T e m ) and central ( T c m ) memory T cells respectively (48, 
51). This data was particularly interesting as IL-2 and IL-15 share two common 
receptor subunits (IL-2R(3, IL-2Ryc) and have been shown to drive very similar 
transcriptional programs (205, 206). Thus the aim of the thesis was to conduct a 
kinetic analysis of IL-2 and IL-15 signalling in peptide activated CD8+ T cells to 
define divergence in signalling that could possibly be driving differentiation.
The present data shows that IL-2 and IL-15 are equivalent mitogens for antigen 
stimulated CD8+ T cells but they are not equivalent growth factors and are 
strikingly distinct in their ability to control protein synthesis and T cell size. IL-2 
and IL-15 were shown to induce protein synthesis in antigen activated T cells 
although protein synthesis driven by IL-2 is approximately two fold greater than 
that induced by IL-15. The ability of IL-2 to induce cell growth was thought to be 
associated with its role as a mitogen. However the level of cell growth induced 
by IL-2 seems to exceed that required for mitosis, as judged by the ability of IL- 
15 to sustain mitosis and T cell clonal expansion without maintaining T cells at 
the same size as IL-2. Hence the role of IL-2 as an effector CD8+ T cell growth 
factor may be relevant to its ability to sustain synthesis and production of 
effector molecules. The differential effect of IL-2 and IL-15 on general protein 
synthesis may help resolve the puzzle of how IL-2 and IL-15 differentially direct
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CD8+ T cell fate (48, 51, 229), even though they initially activate common signal 
transduction pathways and induce very similar patterns of gene transcription 
(205, 206).
These data may help to understand the full power of IL-2 on T cell protein 
synthesis and may help explain why IL-2 can sustain T cell expansion in vivo 
even though it is not essential to initiate T cell cycle progression (129, 529).
Also, this data may give some insight as to why IL-2 has a unique role in vivo as 
a regulator of peripheral immune homeostasis (132). In particular, it may help to 
explain why antigen stimulated T cells fail to secrete effector cytokines in the 
absence of IL-2 function even though they appear to undergo normal cell 
divisions (133).
In the present study we also compared the IL-2 growth responses of T cells to 
other members of the yc cytokine family, namely IL-4 and IL-7. It was clear that 
IL-2 was more potent than IL-4 and IL-7. The differential effects of yc cytokines 
on T cell size correlated with differences in their ability to maintain surface levels 
of the transferrin receptor CD71 and the amino acid transporter subunit CD98. 
Hence yc cytokines have different potentials for regulating protein synthesis and 
cell growth.
The present data show that the ability of T cells to maintain protein synthesis is 
driven by constant signal input and constant activation of PI3K, as removal of 
cytokine or inhibition of PI3K almost immediately abrogates amino acid uptake 
and amino acid incorporation into proteins. In particular the differential effects on 
T cell growth by IL-2 and IL-15 seems to correlate with differential kinetics of
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PI3K signalling stimulated by these two cytokines. Thus IL-2 has the capacity to 
sustain PI3K signalling at high levels for several days whereas IL-15 only 
transiently induces high levels of PI3K signalling and very low levels during a 
sustained response. The major difference between IL-2 signalling is thus 
temporal and quantitative: IL-15 signalling is relatively transient whereas IL-2 
signalling is sustained. These data reveal the importance of understanding the 
kinetics of signalling responses induced by different cytokines. Moreover, as the 
different cytokines exert their biological functions over several days it is 
necessary to examine signalling over long time courses rather than just focusing 
on immediate events.
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